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2ABSTRACT
Background
The rate at which the prevalence of allergic disease is increasing in many
countries suggests that environmental exposures may be important aetiological
factors. Epidemiological evidence indicates that infection with helminth parasites
may be one such factor: in particular, in a systematic review and meta-analysis,
current hookworm (Necator americanus) infection at an intensity of 50 eggs/g
faeces was shown to be associated with a halving of risk of asthma. The relation
between parasite infection and atopy has not been subjected to the same rigorous
and comprehensive review. Based on the results of the studies in asthma, it is
possible that hookworm infection may have potential in the treatment of this
disease, but to date, no clinical trials have been carried out to test this hypothesis.
For ethical and safety reasons, before embarking on a clinical trial in asthma it is
necessary to establish the dose of larvae required to produce at least 50 eggs/g
faeces, and to determine whether experimental hookworm infection might
exacerbate bronchial hyper-responsiveness during larval lung migration.
Aims and objectives
The first aim of this thesis was to establish whether experimental hookworm
infection improves asthma by carrying out a series of three intervention studies.
The second aim was to determine the association between intestinal parasite
infection and atopy (defined as positive allergen skin sensitisation or the presence
of specific IgE) and to establish whether the association was species-specific.
3This thesis therefore consists of two main components: a series of three clinical
trials of experimental hookworm infection; and a systematic review and meta-
analysis of the association between intestinal parasite infection and atopy.
Methods and Results
Dose-ranging study of experimental hookworm infection
Aim: To identify the dose of hookworm larvae necessary to achieve 50 eggs/g
faeces and to monitor any adverse effects of infection.
Methods: Ten healthy volunteers, without asthma or bronchial responsiveness to
inhaled methacholine, received 10, 25, 50, or 100 Necator americanus larvae
administered double-blind to an area of skin on the arm and were monitored
weekly for 12 weeks.
Results: All doses resulted in the production of at least 50 eggs/g faeces in the
eight subjects who completed the study. Skin itching at the entry site and
gastrointestinal symptoms were common at higher doses.
Study of experimental hookworm infection in allergic rhinoconjunctivitis
Aim: To determine whether hookworm larval migration through the lungs
increases bronchial responsiveness in allergic individuals with measurable
bronchial responsiveness but not clinical asthma, and to investigate the general
tolerability of infection and its effect on allergic symptoms.
Methods: Thirty individuals with allergic rhinoconjunctivitis and measurable
bronchial responsiveness to adenosine monophosphate (AMP) but not clinically
diagnosed asthma were randomised, double-blind, to cutaneous administration of
either ten Necator americanus larvae or histamine placebo, and followed for 12
weeks. The primary outcome was the maximum fall from baseline in provocative
4dose of inhaled AMP required to reduce one-second forced expiratory volume by
10% (PD10AMP) measured at any time over the four weeks after active or placebo
infection. Secondary outcomes included peak flow variability in the four weeks
after infection, adverse effect diary scores and rhinoconjunctivitis symptom
severity over the 12-week study period, and change in allergen skin sensitisation
between baseline and 12 weeks.
Results: Mean maximum change in PD10AMP from baseline was slightly but not
significantly greater in the hookworm than the placebo group (-1.67 and -1.16
doubling doses; mean difference -0.51, 95% confidence interval: -1.80 to 0.78;
p=0.42). There were no significant differences in peak flow variability,
rhinoconjunctivitis symptoms or allergen skin sensitisation between groups.
Symptom scores of potential adverse effects were more commonly reported in the
hookworm group, but infection was generally well tolerated.
Study of experimental hookworm infection in asthma
Aim: To determine the effects of experimental hookworm infection on asthma.
Methods: Thirty-two individuals with asthma and measurable bronchial hyper-
responsiveness to adenosine monophosphate (AMP) were randomised, double-
blind, to cutaneous administration of either ten Necator americanus larvae or
histamine placebo, and followed for 16 weeks. The primary outcome was the
change in provocation dose of inhaled AMP required to reduce one-second forced
expiratory volume by 20% (PD20AMP) from baseline to week 16. Secondary
outcomes included change in several measures of asthma control and allergen
skin sensitisation and the occurrence of adverse effects.
Results: Mean PD20AMP improved in both groups, more in the hookworm (1.49
doubling doses (DD)) than the placebo group (0.98 DD), but the difference
5between groups was not significant (0.51 DD, 95% confidence interval: -1.79 to
2.80; p=0.65). There were no significant differences between the two groups for
other measures of asthma control or allergen skin sensitisation. Infection was
generally well tolerated.
Systematic review and meta-analysis of the association between intestinal
parasite infection and atopy
Aim: To quantify the association between current intestinal parasite infection and
the presence of atopy in a systematic review and meta-analysis of
epidemiological studies, and to determine whether, as with asthma, this relation is
species-specific.
Methods: MEDLINE, EMBASE, LILIACS and CAB Abstracts (to March 2009);
reviews; and reference lists from publications were searched. No language
restrictions were applied. Studies that measured current parasite infection using
direct faecal microscopy and defined atopy as allergen skin sensitisation or
presence of specific IgE were included. Pooled odds ratios (OR) and 95%
confidence intervals (95% CI) using data extracted from published papers using
random effect models were calculated.
Results: 20 studies met the inclusion criteria. Current parasite infection was
associated with a reduced risk of allergen skin sensitisation (OR 0.69, 95% CI:
0.60 to 0.79; p<0.01). When analyses were restricted to current geohelminth
infection, the size of effect remained similar (OR 0.68, 95% CI: 0.60 to 0.76;
p<0.01). In species-specific analysis, a consistent protective effect was found for
infection with Ascaris lumbricoides, Trichuris trichiura and hookworm. There were
insufficient data to pool results for Schistosomiasis or atopy defined by presence
of specific IgE.
6Conclusions
Experimental infection with ten Necator americanus larvae produces at least 50
eggs/g faeces, the intensity of infection seen to protect against asthma in
observational studies. This dose is safe, well tolerated, feasible to use in clinical
trials and does not cause clinically significant exacerbation of bronchial
responsiveness during larval pulmonary migration. In clinical trials, it did not result
in significant improvement in symptoms of allergic rhinoconjunctivitis, or in
bronchial hyper-responsiveness or other measures of asthma control. However, a
non-significant improvement in bronchial hyper-responsiveness was seen,
indicating that further studies incorporating revised dosing regimens that more
closely mimic natural infection are feasible, and should be undertaken, with the
aim of identifying novel treatments for asthma. As with asthma, there appears to
be an inverse association between intestinal parasite infection and atopy. Work
should continue to identify the mechanisms of this effect and means of harnessing
these to reduce the global burden of allergic disease.
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1 INTRODUCTION
1.1 Overview of thesis
Asthma, allergic rhinoconjunctivitis and eczema all belong to the spectrum of
atopic or allergic disease and are some of the most common causes of chronic
morbidity worldwide. Allergic disease affects around one in five children in high
income countries and whilst the prevalence has increased over the last 30 years,
it appears to have now reached a plateau 1-4. The prevalence of allergic disease
in low and middle income countries is generally lower than that in high income
countries, but has increased rapidly over the last 30 years 5. In the UK alone,
asthma affects over 5 million people and causes around 1400 deaths each year 6.
Allergic rhinoconjunctivitis is estimated to affect around 15% of adults in the UK 7
and overall prevalence continues to increase 8. Eczema affects around 5.8 million
people in the UK, with the greatest burden of disease in young children 9-11.
Allergic disease occurs as a result of a complex interaction of genetic and
environmental exposures 12, but marked changes in prevalence over recent
decades, particularly in economically-rich countries, indicate that environmental
factors play a key role. Many environmental factors have been posited to
influence the development of allergic disease. One such factor is infection with
parasites, particularly the soil-transmitted helminths (or geohelminths), which may
be protective, and the association between parasite infection and allergic disease
forms the basis of the work in this thesis. The finding of an inverse relation
between hookworm infection and asthma 13 has prompted scientific interest in the
possibility of a therapeutic role for hookworm infection in the management of
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asthma and other allergic disease. This possibility has led to design and
execution of a series of three intervention studies of intentional hookworm
infection, carried out in the UK and presented in this thesis, to test the hypothesis
that hookworm infection improves clinical control of asthma, and also to
investigate the feasibility of using hookworm infection as a therapeutic agent for
asthma. The first two studies comprised a dose-ranging study, described in
Chapter 2, and a safety and feasibility study in people with allergic
rhinoconjunctivitis and bronchial responsiveness, described in Chapter 3. These
studies were primarily designed to determine the safety and tolerability of
intentional hookworm infection in people. A third study was conducted to
determine the efficacy of experimental hookworm infection on asthma and is
described in Chapter 4. Chapter 5 contains the results of a systematic review of
the literature and meta-analysis of the association between parasite infection and
atopy. The thesis concludes with a summary and discussion of the clinical
implications of the findings of these studies, and identifies areas for further
research.
1.2 Definition of asthma
The benchmark definition of asthma was proposed by the 1958 Ciba Guest
Symposium as the condition of subjects with widespread narrowing of the
bronchial airways, which changes its severity over short periods of time either
spontaneously or under treatment. This variable bronchoconstriction, and
subsequent airflow obstruction, results in the clinical features of asthma - which
are abnormal breathlessness (paroxysmal or persistent), wheezing and cough 14 -
and is caused by several underlying processes. These include inflammation, due
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to inflammatory mediators release during mast cell and basophil degranulation;
abnormal contraction of bronchial smooth muscle, in response to a variety of
stimuli; thickening of the airway wall, due to oedema, smooth muscle thickening
and fibrosis formation; and mucus production in the airways. Asthma is
characterised by bronchial hyper-responsiveness to triggers that would not
normally cause bronchoconstriction, probably as a result of the underlying airway
inflammation. These triggers vary between individuals and range from cold air and
exercise, to stimuli such as histamine. The gold standard for measuring bronchial
hyper-responsiveness is bronchial challenge testing which can be measured both
by direct and indirect tests depending on the mode of action by the agent on
airway smooth muscle contraction 15;16. A variety of stimuli can be used, the most
common in clinical assessment and trials being histamine and methacholine
which act directly on smooth muscle contraction, and adenosine monophosphate
which acts indirectly. This test involves the sequential inhalation of increasing
doses of the stimulant whilst monitoring lung function, with the aim of establishing
the provocation dose (or concentration) of stimulant required to reduce one-
second forced expiratory volume by 20% 17. Alternative methods for diagnosing
asthma used in clinical practice and epidemiology studies include other objective
measures of airflow obstruction such as the occurrence of exercise-induced
bronchoconstriction and peak expiratory flow rate variability, and subjective
assessment of the presence of symptoms.
1.3 Definition of atopy and allergy
Atopy is the capacity to produce IgE antibodies specific for common
environmental allergens, and is a term also used to describe a predisposition to
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develop allergic diseases. Allergy is a symptomatic response to normally
innocuous environmental antigens. It should be noted that not all atopic
responses will be associated with an allergic reaction: around a quarter of atopic
individuals will develop clinically relevant allergic disease 18 and it has been
suggested that around 40% of asthma is attributable to atopy at the population
level 19. Worldwide studies have suggested the relation between atopy and
allergic disease may be linked to the economy of the country 20. Atopy is
diagnosed by testing for allergen skin sensitisation (a form of IgE-mediated
immediate hypersensitivity reaction), most commonly using skin prick testing;
other methods include intra-dermal and skin patch tests 21. In skin prick testing, an
allergen is introduced just under the surface of the skin where it encounters
subcutaneous mast cells. If these are coated with IgE specific to that particular
allergen (or sensitised), binding between the allergen and IgE will occur.
Adjacent IgE molecules directed against the allergen then cross-link on the cell
surface and initiate intracellular signalling, with mast cell activation and
degranulation releasing vasoactive mediators and triggering de novo generation
of inflammatory mediators. This results in a visible and measurable "wheal-and-
flare" reaction characterised by a central area of superficial skin oedema (wheal)
surrounded by erythema (flare).
1.4 The immune system and allergy
A brief description of the normal function of the immune system is necessary to
place in context the changes, described later in this thesis, that occur in allergy,
and with parasite infection. When potential pathogens are recognised by the
immune system (identified by pathogen associated molecular patterns (PAMP) or
27
pattern recognition receptors such as Toll-like receptors and C-type lectin
receptors), a cascade of events is triggered. First, the innate immune system is
stimulated with activation of macrophages, neutrophils, Natural Killer cells and
dendritic cells resulting in release of pro-inflammatory cytokines such as IL-1, IL-6
and TNF-Į. These cytokines stimulate the phagocytic actions of neutrophils and
monocytes-macrophages and activate dendritic cells. In addition to their
involvement in the innate immune response, these dendritic cells also have a
crucial role as antigen presenting cells in the specific immune response which
ensues. Once activated, dendritic cells degrade antigen peptides and present
them on their cell surface to naïve T-helper (TH0) cells; in turn, the TH0 cells
recognise the antigen via specific receptors triggering their transformation into
type 1 T-helper (TH1) cells, type 2 T-helper (TH2) cells and T-regulatory
lymphocytes 22;23. If exposed to IL-12 from dendritic cells, macrophages and other
cells, TH0 cells develop into TH1 cells and trigger cell-mediated immunity via
SURGXFWLRQ RI ,)1Ȗ ZKLFK DFWLYDWHV PDFURSKDJHV HQDEOLQJ WKHP WR GHVWUR\
intracellular parasites (such as viruses, fungi and Mycobacteria). In addition,
Natural Killer cells are activated to destroy viruses and tumour cells and cytotoxic
T-cells develop and to provide further immunity specific to the peptide presented
by the dendritic cells. If, instead, the TH0 cells are exposed to IL-4, TH0 cells
transform into TH2 cells and produce several cytokines (specifically IL-4, -5, -6, -
10 and -13), which trigger antibody formation by B-lymphocytes. The antibodies
themselves are pro-inflammatory and cause activation of the complement
cascade, which results in a further neutrophil-dominated immune response. It
should also be noted that some cytokines also have a down-regulatory effect on
parts of the immune system (Figure 1.1).
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IgE is the principal antibody involved in the allergic response and is formed by the
action of IL-4 and IL-13 after an allergen is encountered. If IgE directed against a
specific allergen then binds to a mast cell, a type 1 hypersensitivity reaction
follows characterised by mast cell degranulation and release of vasoactive
mediator release (such as histamine, tryptase and chymase), which are
chemotactic predominantly for eosinophils, but also for neutrophils. IgE also
provides protection against extracellular parasites such as Ascaris lumbricoides
and hookworm.
If an immune response is potentially harmful or inappropriate, for example,
against self-tissues, food and pollen, it should be blocked or down-regulated
through the development of tolerance. This involves formation of antigen-specific
T-regulatory cells which produce the immunosuppressive cytokines TGF-ȕ and IL-
10 and which then block local immune reactions by other cells. In allergic disease,
there is an inappropriate immune response to innocuous antigens driven by the
TH2 cells. In the past, it was thought that this might develop as a result of an
immune system imbalance, with insufficient stimulation of the TH1 arm resulting in
an exaggerated TH2 response. It is now thought that it occurs as a result of a
failure in development of fully functioning T-regulatory cells leading to problems
with both TH2 driven reactions (causing allergic disease) and TH1 driven reactions
(resulting in autoimmune disease such as inflammatory bowel disease and
multiple sclerosis) 23.
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1.5 Prevalence of asthma
Accurate assessment of the prevalence of asthma is hampered by varying
definitions of asthma and by different methods of data collection, making
comparison of data across studies and globally difficult. Epidemiology studies
commonly define disease using question-based criteria, for simplicity, to reduce
costs and to increase participation. Where possible, questionnaires are used in
combination with objective clinical measures of lung function and bronchial hyper-
responsiveness such as peak flow variability, exercise testing and bronchial
challenge testing. There are inherent problems with each method used and the
biases vary with different approaches. For example, if asthma is diagnosed after
clinical assessment, physician criteria will not be standardised and there will be a
bias by access to healthcare. Questions pertaining to a history of symptoms will
be biased towards more severe cases and influenced by recall bias. Presence of
symptoms may not be specific to asthma. For example, wheeze in young children
is a poor predictor of asthma 24, is often due to isolated viral respiratory tract
infections 25 causing a degree of bronchospasm in narrow immature airways and
may lead to an overestimation of asthma prevalence in these age groups.
Meanwhile, bronchial challenge testing in the setting of an epidemiology study
has a low positive predictive value for asthma 26.
Despite these challenges, two large ongoing international population studies to
determine allergic disease prevalence using standardised methods have
successfully collected a wealth of data from where much of our knowledge of the
epidemiology of these conditions is derived. These are the European Community
Respiratory Health Survey (ECRHS), which looked at young adults 27, and the
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International Study of Asthma and Allergy in Childhood (ISAAC) 3. The studies
both use well validated standardised questionnaires (based on self-reported
asthma symptoms in the preceding 12 months), which have been shown to have
good specificity and sensitivity for both bronchial hyper-responsiveness and a
diagnosis of asthma 28.
1.5.1 International Study of Asthma and Allergy in Childhood
ISAAC was established with the aims of identifying prevalence and trends in
allergic disease in children worldwide, and providing a baseline framework to be
used in investigating possible aetiological factors for these diseases. ISAAC
Phase One, carried out between 1992 and 1998, involved the participation of
700,000 children from 1565 centres in 56 countries using written, and in some
cases video, questionnaires 29. In ISAAC Phase Two, which began in 1998,
detailed questionnaires were carried out and objective measurements of indoor
exposure and physiological variables were made in 30 centres in 22 countries 30.
Between 1999 and 2004, ISAAC Phase Three repeated the original cross-
sectional survey on around 193,000 6-7 year olds and over 300,000 13-14 year
olds to investigate trends in disease prevalence 1;3. Baseline data were collected
on 463,801 13-14 year olds and showed a marked variation between countries in
prevalence of self-reported asthma symptoms, with the highest prevalence being
about 20 times higher than in the centre with the lowest prevalence (range 1·6
36·8%) and an eight-fold variation seen between the 10th and 90th percentiles
(3·930·6%). Prevalence of symptoms was greatest in the United Kingdom (UK),
Ireland and Australasia (29.4-32.2%) and lowest in Indonesia, Albania and parts
of Ethiopia and India (2.1-2.6%). Most countries had similar reported prevalence
of symptoms, though large within-country variations were seen in India (1.6-
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17.8%), Ethiopia (1.9-10.7%) and Spain (2.7-13.5%) 2;3. ISAAC Phase III found
that, in the (on average) seven year interval between the two studies, the
prevalence of asthma had changed by one standard error or more in most of the
centres. In 6-7 year olds, 59% of centres showed a change, with two-thirds of
these having had an increase in prevalence. In 13-14 year olds, the prevalence
changed in 77% of centres, evenly divided between increased and decreased
prevalence. Generally asthma prevalence tended to increase in centres where
mean asthma prevalence had been low, whereas in centres with already high
mean prevalence, decreases were more common for both age groups 1.
1.5.2 European Community Respiratory Health Survey
The ECHRS is a survey of the prevalence, determinants and management of
asthma in 20-44 year olds from 48 centres 31, the majority in Western Europe. It
was first carried out in 1990 (ECRHS I) with follow-up studies of 11,168
participants in 1998-2002 (ECRHS II). As in ISAAC, significant variation both
between countries and within countries was found in ECRHS I and,
unsurprisingly, the prevalence of reported wheeze was greater than that of
diagnosed asthma. In general, a similar geographical pattern was seen, with a
higher prevalence of respiratory symptoms and asthma in centres in English-
speaking countries and a lower prevalence in Mediterranean countries 27. Wheeze
prevalence ranged from 25-32% in Australasia, the United States, Ireland and the
UK and parts of Spain, compared with prevalence of around 4% in India and
Algeria. Diagnosed asthma was reported in 7-11% of those surveyed in the US,
the UK and Australasia, and was as low as 2-4% in India, Algeria, Greece,
Estonia, Iceland, and parts of Spain, France and Germany 27. Again, there was
evidence of within-country variation: for example, in Belgium, a relatively small
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country geographically, prevalences were 21% and 5% for wheeze and asthma
respectively in Antwerp city, compared with 13% and 3% in South Antwerp.
Similarly, in Germany, asthma prevalence in Hamburg was over twice that in
Erfurt (4.4% as against 2.1%). Follow-up studies 5-11 years later in some of these
centres in ECRHS II found an overall increase of 0.8% in subjects reporting
asthma attacks (95% CI: 0.2 to 1.4) and of 2.1% in the proportion of subjects
using medication for asthma (95% CI: 1.6 to 2.6). Interestingly, there was no
significant change in reported symptoms 32, possibly reflecting better control of
disease. However, using data from ECRHS I and performing a retrospective
analysis in 17,613 individuals, Sunyer et al demonstrated a progressive increase
in yearly incidence of asthma between 1946 and 1971 by birth cohort, in 15 high-
income countries, with a relative risk of 2.33 (95% CI: 1.81 to 2.98) in those born
in 1966-1971 compared with those born in 1946-1950 33.
Whilst change in disease classification and increased clinical awareness are
probably responsible in part for observed changes in trends of disease, some of
the changes will be due to modifications in the risk factors that cause and worsen
asthma 34. Asthma, and indeed other allergic diseases, traditionally affects those
living in higher income countries. As described, they have increased in prevalence
particularly in the second half of the last century and have probably now reached
a peak 1. The worldwide data from ISAAC, ECRHS and other studies suggest that
it is in low and middle income countries where rapid increases in prevalence are
now being seen 26;28;35. In seeking to identify possible aetiological factors, studies
have often focussed on countries within which variations in asthma prevalence
have been noted. One such example is Ghana where the prevalence of exercise-
induced bronchospasm in schoolchildren appeared to double between 1993 and
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2003 and was much higher in urban rich schools (8.3%), compared with urban
poor (3.0%) and rural (3.9%) schools 36. Another example is Ethiopia, where
prevalence of wheeze was found to be 3.7% in urban areas and 1.2% in rural
areas 37. The finding of such an urban-rural gradient is not unique to these studies
and it has been observed that these changes in prevalence seem to occur as
communities move from a rural subsistence lifestyle to one which is more
urbanised 38;39. Possible reasons for this are discussed in the next section.
1.6 Aetiology of asthma
1.6.1 Genes and environment
Whilst the aetiology of asthma is not fully established, it is accepted to be multi-
factorial and to involve complex interactions between genetic susceptibility and
environmental factors. Genetic studies of asthma, which initially looked at areas of
broad linkage, have now identified several candidate genes and have revealed
complex associations with, for example, differences in the links between ethnic
groups 40. However, evidence for a key role of environmental factors in the
aetiology of asthma arises from two main observations. First, the increase over
the last 50 years in worldwide prevalence of asthma and allergic disease is too
rapid to be due to genetic factors alone. Secondly, as suggested above,
significant variation in prevalence of allergic disease exists in genetically similar
groups. For example, in a study of nearly 2000 Polynesian children, 11% of those
living in Tokelau had a diagnosis of asthma compared with 25.3% of those living
in New Zealand 41. In another study, reversible airflow obstruction (provoked using
exercise testing) was assessed in three different areas of Zimbabwe: positive
tests were found in 5.8% of children in Northern Harare (high socio-economic
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class urban children), 3.1% in southern Harare (low socio-economic class urban
children) and 0.1% in Wedza Communal Land (rural children from peasant
families) 38. After the reunification of Germany, 9-11 year olds were studied in
West Germany (n=5030) and East Germany (n=2623) and asthma was found to
be significantly higher in West compared with East Germany based on a self-
administered questionnaire (5.9% vs. 3.9%) and presence of bronchial hyper-
responsiveness (8.3% vs. 5.5) 42. Interestingly, within a few years, the prevalence
in the Eastern and Western German populations had become similar 43. Similarly,
studies have demonstrated an increase in risk of atopy, wheeze and eczema in
migrants as they move from areas of low allergy prevalence to areas of higher
prevalence 44 with this apparent loss of protection from allergic disease occurring
in a time-dependent manner 45.
These observations have resulted in a plethora of possible environmental factors
being implemented in the aetiology of asthma and allergic disease. Many of these
factors have been identified in studies from rural Europe and have the hygiene
hypothesis, which is discussed below in more detail, as a central theme.
1.6.2 The Hygiene Hypothesis
The development of the immune system is probably influenced both in utero and
during infancy by early environmental exposure to allergens and infections. In
1989, Strachan put forward the hygiene hypothesis to explain the observation
that hay fever was associated with number of siblings in the household, with lower
prevalences of hay fever in children with higher birth order, possibly as a result of
exposure to more infections early in life 46. Other studies - for example, where an
inverse relation between attendance at day care and prevalence of asthma 
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have supported this hypothesis 47-49. Exposure to a farming environment has been
shown in several studies to be protective against asthma in children 50;51, with
meta-analyses identifying contact with livestock and poultry as specific key factors
52. In addition, children exposed to stables and/or unpasteurised milk during the
first year of life, regardless of where they lived, had substantial protection against
the development of asthma and other atopic conditions. Prenatal exposure in this
group appeared to have an additional effect 53. These findings are not entirely
consistent, however, with other studies identifying a protective effect of
unpasteurised milk consumption on eczema and atopy, but not on asthma
symptoms 54. The role of infections has been looked at in detail. One retrospective
study in the United States found positive hepatitis A serology to be protective
against hay fever and asthma 55, a finding that was confirmed in other studies
56;57; but the evidence for this and for other viral infections remains inconclusive 58-
61. Support for the protective effect on allergy of the traditional lifestyle has also
come from studies on Steiner school children who follow an anthroposophic
lifestyle. This lifestyle involves the minimal use of medications, delayed
vaccinations, a lower use of antibiotics and paracetemol, and a diet consisting of
organic or fermented vegetables. Children following this lifestyle were shown to
have a much lower rate of IgE sensitisation, asthma, hay fever and eczema than
children attending non-Steiner schools in the same area 62. A systematic review
and meta-analysis of the literature found that antibiotic use in the first year of life
was associated with an increased risk of physician-diagnosed asthma in those
aged 1-18 years (OR 2.05, 95% CI: 1.41 to 2.99) and also demonstrated a dose-
response relation between numbers of antibiotic courses and risk of asthma or
wheeze 63. This association could of course be attributed to reverse causation.
However, in utero exposure to antibiotics has also been shown to be associated
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with wheeze and asthma in a dose-related response 64. Endotoxin exposure in
these environments may account for some of the reduction in allergic disease,
with the suggestion that microbes combine with dendritic cells to cause induction
of the TH1 response via IL-12
50. However, subsequent studies specifically
designed to test this hypothesis have been inconclusive 65. The relation between
parasite infection and asthma and other allergic disease is also closely linked to
the hygiene hypothesis and is explored in detail later in this chapter.
1.6.3 The role of diet and paracetemol
Evidence from Steiner schools and the urban-rural studies led to the hypothesis
that changes in diet as populations adopt less subsistence-based lifestyles affects
occurrence of allergic disease. Whilst this hypothesis is based on biologically
plausible mechanisms, the evidence for a causal relation between diet and
asthma is inconsistent: whilst the general trend in observational studies is for the
identification of positive associations, intervention studies have not confirmed
clinically significant effects 66-68. ISAAC identified an inverse relationship between
the intake of complex carbohydrates and vegetables and prevalence rates of
asthma, allergic rhinoconjunctivitis and eczema 69. It also found a statistically
significant positive relation between prevalence of the allergic diseases and intake
of trans-fatty acids 70. But whilst fish-oil supplements were found to reduce
exercise-induced bronchoconstriction in asthma 71, further studies showed no
evidence of an effect on asthma symptoms or medication usage 72. Dietary
deficiencies of antioxidants may contribute to the presence of asthma 73:
observational studies have shown Vitamin C intake to be associated with a
reduced risk of asthma 66;74-77; but this was not confirmed in longitudinal 78;78 or
large intervention studies 79;79. However, placebo-controlled studies of ozone-
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induced bronchoconstriction found a protective effect of Vitamin C and E
supplements in adults with asthma 80, and of a combination of Vitamin C, Vitamin
E and ȕ-carotene in a small study of Mexican street workers without asthma 81.
Longitudinal data suggested a protective effect of dietary vitamin E 78, but there is
less cross-sectional evidence for this relation 66;74;75, and an intervention study of
vitamin E supplements found no evidence of clinical benefit in asthma 82. Low
dietary intake of selenium has been identified in some patients with asthma 66;74;75,
but this finding is not consistent 83 and two intervention studies of selenium found
no objective improvement in disease 84;85. Several studies of sodium intake have
found conflicting results 86;87, but a recent large intervention study of a low-sodium
diet (compared with a normal diet) found no effect on asthma 88. Finally, it may not
be individual nutrients which are important, but food groups or diet as a whole; for
example, a recent systematic review and meta-analysis of observational studies
found that a Mediterranean diet was strongly protective for wheeze 89.
Again, in line with data from the urban-rural studies and Steiner schools, there is
increasing evidence that regular paracetemol use carries a dose-dependent risk
of developing asthma 90. Glutathione, an endogenous antioxidant, exists in high
concentrations in the airway epithelial lining fluid 91; local oxidant damage may
occur if levels fall 92;93. It is also involved in paracetemol metabolism 94, and high
doses of the drug can cause a reduction in lung tissue levels of glutathione 95;96. A
case-control study of 664 people with asthma and 910 people without asthma in
London found the risk of asthma to be related to paracetemol use, with a positive
dose response such that there was a more than doubling in risk for daily users
compared with never-users 97. Similar dose-related responses were found using
the Third National Health and Nutrition Examination Survey where daily use of
38
paracetemol was associated with almost a doubling in risk of diagnosis of asthma
compared with never use 98. This association is also seen in low income countries
99 which helps to exclude bias from medical contraindication to use of aspirin/non-
steroidal anti-inflammatory drugs in asthma as knowledge of aspirin avoidance
with asthma is rare in these countries. It also provides evidence against reverse
causation, because use of analgesia in these countries is uncommon. Stronger
evidence against reverse causation comes from longitudinal studies where
paracetemol use in infancy was associated with wheeze between 1 and 3 years of
age 100 and, in adulthood, where it was associated with an increase in new
diagnosis of asthma 101. Furthermore, the relation does not appear to be restricted
to adults, and studies have shown that paracetemol use in pregnancy increases
the risk of wheezing in the first year months of life 102-104 and persists in children of
school age 104-106.
1.6.4 Other environmental factors
Other environmental factors have been identified in relation to the aetiology of
asthma and allergic disease and studies continue to try and elucidate which of
these factors are the most important 107;108. Prenatal factors have been
extensively researched. Prenatal maternal smoking is consistently associated with
early childhood wheezing, and probably occurs (at least in part) because of
decreased airway calibre in early life 109. Indeed, a meta-analysis of studies of
parental smoking prenatally and immediately after birth excluded an increased
risk of allergic sensitisation in exposed children 110. Mode of delivery may also be
important, with development of atopy more common in children delivered by
emergency Caesarean section (although not by elective Caesarean section)
111;112; the evidence for this, however, is not consistent 113. The relationship
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between breastfeeding and allergy remains controversial, with some studies
showing a protective effect 114;115 and others reporting a higher incidence of
allergy and asthma amongst breastfed babies 116. A meta-analysis of prospective
studies in 2001 found a protective effect of exclusive breastfeeding during the first
3 months after birth on asthma between the ages of 2-6 years (OR 0.70, 95% CI:
0.60 to 0.81) 117. The impact of maternal dietary manipulation during lactation on
risk of childhood allergy has been explored, but a longitudinal study showed no
association with atopic disease at 4 years of age 118.
Finally, exposure to air pollution may be important. Indoor air pollution, which
includes smoke emitted from combustion of biomass fuels and coal, and
environmental tobacco smoke, is associated with an increased risk of
exacerbation of asthma in addition to other adverse health outcomes 119.
Exposure to outdoor air pollution in epidemiological studies is evaluated in
different ways including measuring individual pollutants levels, or using surrogate
markers for exposure to traffic-related pollution such as proximity of home to main
roads and use of different modes of transport. There is reasonable evidence that
air pollutants such as particulate matter and ozone trigger exacerbations of
asthma 120 but whilst some studies have shown an effect of transport-related
pollution on asthma and wheeze, the evidence is inconsistent 26;121. Much of this
evidence on air pollution arises from cross-sectional studies in people with pre-
existing asthma. However, there is also evidence from longitudinal studies to
suggest an association with new diagnoses of asthma; for example, one study
from California found a greater risk of developing asthma in children who spent
significant amounts of time exercising in areas of high ozone, compared with
children who did not exercise 122. Similarly, a large birth cohort study in the
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Netherlands found an increased incidence of wheeze and physician-diagnosed
asthma in children at 2 and 4 years of age exposed to greater levels of traffic-
related air pollution 123;124. There is also longitudinal evidence suggesting a
detrimental effect on lung development with one study reporting that adolescents
living within 500m of a motorway in the United States had lower increases in lung
function over an eight year period compared with those who lived beyond 1500m
125;126.
1.7 Helminth infection
1.7.1 Classification of helminth infection
The evidence for an association between helminth infection (in particular
hookworm infection) and allergic disease, and the relative influence of different
species, is discussed in detail in sections 1.9 and 1.10. The helminth family
includes the nematodes (roundworms), trematodes (flukes) and cesatodes
(tapeworms) classes. Most of the evidence is for geohelminths, namely
hookworm, Ascaris lumbricoides, Trichuris trichiura and Enterobius vermicularis
(Figure 1.2). The two main hookworm species causing significant disease in
humans are Necator americanus and Ancylostoma duodenale. In addition, three
zoonotic hookworm species can infect humans but cause less serious pathology:
A. caninum (dog hookworm), which can cause human eosinophilic enteritis; A.
braziliense, which may cause cutaneous larva migrans, a self-limiting pruritic
eruption (usually on the feet) with burrows up to 5cm in length; and A. ceylanicum,
which may infect cats, dogs and humans but is generally asymptomatic 127.
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Schistosoma species, belonging to the trematode class, have also been found to
be associated with allergic disease and are also discussed in this thesis. Those
infecting humans include Schistosoma mansoni and S. intercalatum (causing
intestinal Schistosomiasis), S. japonicum and S. mekon (causing Asian intestinal
Schistosomiasis) and S. haematobium (causing urinary Schistosomiasis). Their
lifecycle is very different from that of the geohelminths in that it includes a snail as
an intermediate host.
1.7.2 Epidemiology of helminth infection
Between one and two billion people worldwide, or a quarter of the global
population, are estimated to be chronically infected with geohelminth infections
128;129. Estimates for individual species range from 800 to 1500 million for A.
lumbricoides, 600 to 1100 million for T. trichiura and 575 to 1300 million for
hookworm 129;130. Geohelminths require warm wet climates in which to thrive and
be transmitted and this is reflected in their geographical distribution. Infection is
associated with poor sanitation, poverty and lack of access to clean water 131. The
areas of highest prevalence of infection are sub-Saharan Africa and Papua New
Guinea, followed by China, India, east Asia and the Americas 132. Of the two main
hookworms, N. americanus tends to predominate in the countries listed above
(other than India), whereas A. duodenale predominates in India, North Africa and
the Middle East. Schistosoma infection is also very common, with S. mansoni
and S. haematobium affecting 170 million people in sub-Saharan Africa alone and
many more being at risk 130. The intensity of infection for A. lumbricoides and
Schistosoma species peaks during childhood and adolescence. With hookworm,
however, there is more variation: in so far as there is a general pattern, it is for a
steady increase during childhood, followed by a peak or plateau in adulthood 133.
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These trends are reflected in the literature, where the majority of studies have
been performed in children.
1.8 Hookworm infection
1.8.1 Lifecycles of helminth infection
N. americanus, the species on which much of this thesis is focused, infects its
human host via the cutaneous route by stage 3 (L3) larvae 134. These larvae,
measuring 600 microns in length, burrow through the skin and probably then enter
the blood circulation, passing via the right side of the heart to the pulmonary
vasculature. Here, usually around ten days after cutaneous infection, larvae
rupture into the alveoli, migrate up the bronchial tree into the proximal airways
and are expectorated and swallowed. Once in the duodenum, they remain and
undergo two molts, maturing into adult male or female hookworm measuring 5-
13mm in length at around weeks 6 to 8 135. Sexual reproduction occurs, and
females lay thousands of eggs every day, which pass out in the hosts faeces. In
an optimal warm moist environment, the eggs then hatch into stage 1 larvae
within 48 hours. These stage 1 larvae molt twice to develop into L3 larvae which
can survive on their lipid metabolic reserves for several weeks. The optimal
conditions for them to be transmitted to humans, usually through the feet, are in
areas with high moisture and silted sand; worldwide rates of infection therefore
tend to coincide with countries where walking barefoot, particularly in rural areas,
is normal practice 136;137. Adult hookworms typically live in the host for about five
years, although survival has been reported for up to 18 years 138. The lifecycle of
A. duodenale is similar to that of N. americanus, but infection may occur both
cutaneously or after ingestion of eggs.
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Humans are also the only major definitive host for the other geohelminth
infections A. lumbricoides and T. trichiura. However, in contrast with N.
americanus, people become infected with these parasites after ingesting the fully
mature eggs 129. A. lumbricoides has a similar lifecycle to N. americanus; after
ingestion, the larvae penetrate the intestinal mucosa and are carried via the portal
and then systemic system into the lungs. Here they mature further before moving
through the alveoli walls, ascending the bronchial tree into the proximal airways
and are expectorated and swallowed, re-entering the gastrointestinal tract.
Approximately ten weeks after egg ingestion, they develop into adult worms and
reside throughout the small intestine. Conversely, T. trichiura has no pulmonary or
systemic phase in its lifecycle and following ingestion, the eggs enter the small
intestine where they hatch into larvae develop into adult worms in the large
intestine around 12 weeks after egg ingestion.
The lifecycle of Schistosoma species are somewhat different from the
geohelminth in that they requires a fresh-water source and an intermediate snail
host. Eggs are released from the host via faeces or, in the case of S.
haematobium, in the urine. On contact with water, the egg releases a miracidium
which swim and penetrates the snail host 139. Here the miracidium multiple
asexually into sporocysts and then develop into cercarial larvae which are
released by the snails into the water. These microscopic cercariae then seek out
and penetrate the skin of the definitive human host. Once through the skin, they
migrate in the vasculature through the lungs and into the liver where they
transform into young worms or schistosomulae. They mature in the portal vein
and migrate to the venous system of the gastrointestinal tract (S. mansoni) or the
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bladder (S. haematobium). Here, the females lay eggs which move from the
venules into the lumen of intestine (or bladder) and are expelled.
1.8.2 Immune modulation in helminth infection
Helminth infections induce polarised TH2 responses
140, elevated serum IgE titres
and eosinophilic-rich tissue inflammation. Yet helminth infections also appear to
be inversely associated with allergic disease where as described in section 1.4, a
similar TH2 response to allergens is seen. Extensive research, much of which has
been undertaken using murine models, is slowly elucidating the reasons behind
this apparent paradox, and a number of possible mechanisms involved in this
immune modulation have been postulated. Helminths have developed defences
against host immunity which are necessary for their survival. These defences
centre on modulation of the immune system and specifically include suppression
of antigen-specific immune responses, modulation of the host immune response
from protective to non-protective response and inactivation of immune effector
mechanisms 133;138;141. There is now epidemiological evidence that these effects
may be particularly pronounced when exposure to infection occurs in early life 142.
It is thought that a consequence of these effects on the host immune system is a
suppressed response to other environmental allergens, conferring a degree of
protection in the host against allergic disease. There is also evidence that this
decline in host immune responsiveness during infection reverses following
parasite eradication 133. A full discussion of research to date and possible
mechanisms explaining the underlying immune modulation is beyond the scope of
this thesis; however a brief overview follows, by way of a background to the
epidemiology discussed and the intervention studies presented in this thesis.
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One early suggestion was the IgE blocking hypothesis 143;144: this posited that
polyclonal total IgE production induced by the helminths saturates the IgE
receptor binding sites, stopping binding of allergen-specific IgE and subsequent
mast cell or basophil degranulation. There is now little evidence to support this as
a key mechanism 145;146. Over the last 15 years, several hookworm products have
been identified, predominantly in animal models, which may contribute to the
immune modulation either via a direct effect on the allergic response or through
effector mechanisms. These include inactivation of complement-mediated
haemolysis and subsequent inflammatory responses by a calcireticulin 147;148;
modulation of T-cell function by potassium channel blockage via a kaliseptine-like
molecule 149; digestion of eotaxin by metalloproteinase secretion controlling tissue
eosinophilia 150; and tissue damage from superoxide dismutase secretion (in
response to host phagocytes) and production of hydrogen peroxide. Glutathione
S-transferase secretion also protects the hookworm against lipid peroxidation
from the host immune response and from the potential effects of its own
superoxide dismutase/hydrogen peroxide combination 151;152. Necator product ES-
62 has been shown to inhibit mast cell degranulation 153;154, and other Necator
secretory products have been shown to induce T-lymphocytes apoptosis 155.
It is likely, however, that the more important mechanism is induction of a
regulatory network by hookworm and other helminths, with T-cell hypo-
responsiveness, resulting in suppression of the host immune system. This
network involves activity of both T-regulatory and B-regulatory cells 156, and
modulation of innate immune cells such as macrophages, dendritic cells and local
stromal cells. In turn, this results in an anti-inflammatory environment
characterised by high levels of IL-10 (produced by both T and B cells) and TGF-ȕ
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141;157-159. A key role for IL-10 in this setting has been suggested by the
observations of several epidemiology studies 160-162 where, for example, an
inverse association between the degree of infection with Schistosomiasis and
atopy was associated with the amount of serum IL-10 present 163. IL-10 and/or
TGF-ȕ probably interfere with allergic effector mechanisms by inhibiting mast cell
degranulation or TH2 cell proliferation
141;164. A role for T-regulatory cells was
identified with the observations that forkhead box P3 (FoxP3), a gene expressed
on T-regulatory cells and a key regulator in development and function of the T-
regulatory cells, protects against allergic disease 165; and that patients with
mutations in the gene show immune-mediated pathologies, including allergy and
asthma 166. Further evidence in support of this hypothesis comes from the
observation of proliferation of T-regulatory cells and an increase in IL-10 in
successful allergen-specific immunotherapy (resulting in a decrease in allergic
symptoms) 167;168. The changes in T-cell functioning may also be directed towards
bystander antigens such as vaccine antigens, providing an explanation for the
reduced immune responses to Bacillus Calmette-Guérin and cholera vaccines
previously observed with chronic helminth infections 169. Despite the progress
made in this area, studies have not always identified changes in IL-10 levels with
helminth infection either in healthy individuals 170 or people with atopic disease,
indicating that further research is needed 171.
There is also consistent evidence that helminth products fail to induce
conventional dendritic cell maturation 172 and that they inhibit PAMP-induced
dendritic cell activation, which may impair TH1 development and bias the immune
response toward TH2 and regulatory responses
159. Airway epithelial cells and
their derived cytokines (in particular, IL-25 and IL-33 and thymic stromal
47
lymphopoietin), through their interactions with dendritic cells, may also have a role
in influencing the immune system in helminth-infected individuals 159. Induction of
alternatively activated macrophages by helminths may also directly suppress T-
cell effector functions and thus play a part in suppression of allergic disease 173.
1.8.3 Antibody response to hookworm infection
In natural hookworm infection, there is a strong immune response with elevated
levels of all five isotypes of serum antibodies occurring after weeks 2-8 174.
Specifically, there is marked up-regulation of polyclonal IgE 175;176, raised levels of
serum polyclonal IgG and intestinal IgG, IgM and IgE 177;178 and reduced total
intestinal IgA 178. Most types of anti-hookworm antibodies show cross-reactivity
with other helminth infection such as A. lumbricoides and S. mansoni 179-181, but
IgG4 or IgE responses are more species-specific 177;182;183. In primary intentional
infections, specific and total IgE responses are sometimes low 184, but with
repeated infection they increase progressively and, in such cases, antibody levels
reflect cumulative exposure rather than current parasite infection levels 185.
1.8.4 Adverse effects of hookworm infection
In addition to the possible relation between hookworm infection and allergic
disease, there are, of course, other symptoms and health consequences of
acquiring infection whether naturally, or as a result of iatrogenic intervention. The
majority of infections do not result in clinical disease; however, morbidity as a
result of infection is closely related to intensity of infection and tends to be most
apparent in young children and pregnant women 186. In response to these effects,
the World Health Organisation therefore now advocates anti-helminth treatment
for all at-risk school-aged children 187 although re-infection usually occurs within a
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few months, necessitating the use of frequent repeated treatments and giving rise
to concerns about drug resistance. Consequently, a collaborative initiative, the
Human Hookworm Vaccine Initiative (HHVI), has developed an anti-hookworm
vaccine (Na-ASP-2) and preparatory work and phase I studies and are currently
in progress 188;189.
1.8.4.1 Anaemia
Iron deficiency anaemia is the most important complication of naturally acquired
hookworm infection and results in significant morbidity and mortality worldwide 190.
For example, up to 38 million women of reproductive age may be infected with
hookworm in sub-Saharan Africa alone 191 and hookworm-related anaemia in
pregnancy can cause low birth weight, impaired milk production, and increased
risk of maternal and child mortality 192. Adult hookworm attach to the duodenal
mucosa using a cutting plate, contract their muscular oesophagus and use
negative pressure to pull a plug of tissue into their buccal mucosa. Capillaries and
arterioles rupture both mechanically and by the action of hydrolytic enzymes. The
hookworm then releases anti-coagulative agents, allowing ingestion of extra-
vasated blood amounting to around 0.3mls/ blood per N. americanus worm per
day (and probably more in A. duodenale) 136;193. Total blood loss will depend on
worm burden, and though probably negligible in well-nourished people who have
no other causes of anaemia, is likely to be much more significant in people with
poor nutrition, in children and in pregnant women.
1.8.4.2 Rash
A pruritic erythematous maculopapular rash (ground itch), often with visible tiny
blood speaks representing entry portals, occurs at the time of cutaneous infection
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with both N. americanus 194 and A. duodenale 195. This appears within minutes
and lasts approximately 48 hours before disappearing, but often reappears a few
weeks later 184;194. A skin biopsy taken from the penetration site five days after
infection showed a perivascular inflammatory lymphocytic infiltrate with occasional
presence of eosinophils, although in the same study a biopsy from another
infected individual was unremarkable 195.
1.8.4.3 Gastrointestinal
The peripheral blood eosinophilia which starts to occur around five weeks after
infection can cause an eosinophilic gastroenteritis associated with a range of
symptoms such as nausea, anorexia and abdominal pain 194;195. These symptoms
are generally self-limiting, abating with the reduction in eosinophilia at around
eight weeks after infection 194.
1.8.4.4 Respiratory
There is a theoretical chance of developing respiratory symptoms with parasite
infection due to a pulmonary eosinophilic syndrome, or local effects of larval
migration. These are rare, however, and tend to be associated with tissue
nematodes (particularly Onchocerca), A. lumbricoides or canine hookworm
species 196;197. One study performed bronchoscopy and bronchoalveolar lavage
on four normal volunteers eight to 21 days after being infected with 50 N.
americanus larvae and found bronchial mucosa erythema in all volunteers 195.
Lavage samples were no different from normal or pre-infection samples in all the
volunteers with the exception of one whose lavage contained 2% eosinophils.
Wright and Bickle described mild rawness in the lower respiratory tract in the
third week after intentional hookworm infection; however, they did not perform any
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objective clinical assessment of airway functioning, and the infected individual in
this study was fully aware of the potential side effects of infection, which may
have biased his reporting 170. There are no other reports in the literature of
respiratory symptoms occurring as a result of N. americanus infection.
1.8.4.5 Endomyocardial fibrosis
Helminth infection has been implicated as a causal agent in endomyocardial
fibrosis, a form of restrictive cardiomyopathy which occurs mainly in populations
living in the rainforests of Africa, South India, South America and Thailand 198. It is
thought to occur as the end-stage result of a sustained parasite-induced hyper-
eosinophilia 199, though a high eosinophil count may also be a risk factor
independent of parasite infection 200. Other aetiological hypotheses include the
effects of poor diet, poverty and geochemical exposures. Although hookworm
infection is often listed with other helminths as a potential cause of eosinophilia
leading to endomyocardial fibrosis, there are no reports in the literature of it
occurring in people infected with hookworm alone, and only two reported cases of
it occurring in individuals who were concurrently infected with A. lumbricoides
201;202. In fact, the tissue-based filarial nematodes are the most frequently
implicated helminth in inducing eosinophilia causing endomyocardial fibrosis
196;197;203, followed in frequency by Schistosoma species. Given that parasite
infection is endemic in the tropics, the risk of developing endomyocardial fibrosis
with hookworm infection is therefore minimal.
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1.9 Observational studies of helminth infection and allergy
There is now a growing body of epidemiological evidence suggesting that
intestinal parasite infection is associated with a reduced risk of allergy, and that
hookworm infection in particular may protect against wheeze 13, hay fever and
atopy 146. This association is likely to vary according to species, age of acquisition
of infection and burden of infection 13. A likely consequence of one or more of
these factors is that the results of studies in the literature are sometimes
contradictory. Other explanations for the conflicting nature of the results include
the heterogeneity of the study designs and study populations, and the fact that
multiple parasite infection is common in areas of endemic infection. Finally, there
is always the chance in observational studies that residual or unmeasured
confounders may explain any observed associations.
1.9.1 Helminths and asthma
A systematic review and meta-analysis of the relation between parasites and
asthma was reported in 2006 13. No significant association was found in pooled
analyses between infection with T. trichiura, E. vermicularis or Strongyloides
stercoralis, and asthma. However, the pooled results of nine studies of hookworm
showed a 50% reduction in the risk of asthma with infection (OR 0.50, 95% CI:
0.28 to 0.90; p=0.02) 13. In contrast, the pooled results of 20 studies of A.
lumbricoides identified a significant, increased risk of asthma with infection (OR
1.34, 95% CI: 1.05 to 1.71; p=0.02) 13.
Since this review was published, several further studies have been reported. The
first, in South Africa, found that isolated A. lumbricoides infection was associated
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with an increased risk of exercise-induced bronchospasm (adjusted OR 1.87,
95% CI: 1.19 to 2.95), whereas dual infection with A. lumbricoides and T. trichiura
showed no association 204. The second study was performed in Brazil: here nearly
20% of children had helminth infection, of which the most common were A.
lumbricoides (12%) and T. trichiura (5%). Wheeze and bronchial hyper-
responsiveness were significantly associated with A. lumbricoides infection at
higher loads (>100 eggs/g faeces), but no association was seen for diagnosed
asthma or when all helminth infections were considered together 205;206. The third
study, carried out in 1320 children in Cuba, found no relation between current
helminth infection (A. lumbricoides, E. vermicularis, T. trichiura, or hookworm) and
wheeze, although prevalence was below 5% for the last two of these infections
207. The fourth study was carried out in Ecuador in over 3500 children, of whom
75% had geohelminth infection. Heavy infection with T. trichiura was found to be
significantly associated with reduced risk of wheeze in those with positive allergen
skin sensitisation; in contrast, no relation was identified between A. lumbricoides
infection and presence of wheeze 208. The fifth study was undertaken in 682
school children in Brazil and found that current infection with T. trichiura, but not
A. lumbricoides, was significantly associated with a reported history of wheeze in
the last 12 months (adjusted OR 2.60, 95% CI: 1.54 to 4.38) 209. A sixth study
was carried out on over 1000 children in Thailand, and found that hookworm was
significantly associated with physician diagnosed wheeze, in contrast, no
association was seen for infection with A. lumbricoides or T. trichiura 210. The final
study was carried out in Uganda and comprised a small case-control study nested
within a trial of deworming in pregnancy. The authors found that infection with
hookworm was significantly less frequent in women with a history of asthma but
no such association was found with Schistosomiasis 211.
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1.9.2 Hookworm and asthma
In the meta-analysis described in the previous section, an inverse association
between hookworm infection and asthma was identified 13. The nine studies which
looked specifically at this relation are described here in more detail. The first five
studies were all case-control studies performed in the 1970s and showed no
association between hookworm and asthma in the analyses presented which
were all unadjusted for potential confounders. However, except in one study,
numbers of either cases or controls were small and the individual studies were
therefore unlikely to be adequately powered to show a significant effect (if one did
exist). Alshishtawy et al studied 68 cases with a clinical diagnosis of asthma and
37 non-asthmatic controls in Egypt. Three cases and just one control had
hookworm infection producing an OR of 1.66 (95% CI: 0.17 to 16.56) 212. Carswell
et al performed two studies, both with small numbers of cases, in Tanzanian
children. The first compared eight children with exercise-induced asthma with 97
non-asthmatic controls. Two of the seven children with asthma from whom stool
samples were obtained tested positive for hookworm (29%), compared with 25 of
the 97 controls (26%) (OR 1.15, 95% CI: 0.21 to 6.32) 213. In the second study, 18
children with exercise-induced asthma were compared with 224 normal controls,
with no significant difference found in hookworm infection between those with
asthma (21%) and normal controls (23%) (OR 0.92, 95% CI: 0.24 to 3.46) 214.
Tullis et al reported results from a study in Canada where stool samples from 201
hospital inpatients with asthma were examined. Just two of these patients were
found to have hookworm ova, compared with none of 20 non-asthmatic controls
(OR 0.51, 95% CI: 0.02 to 11.07) 215. Cheah and Kan examined stools from 108
cases of asthma and 300 controls of adults and children living in Singapore, and
reported 11 cases and 19 controls to have evidence of hookworm infection (OR
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1.68, 95% CI: 0.77 to 3.65) 216. Salako and Sofowora reported the results of a
study from Nigeria which was the only study presenting an unadjusted analysis to
find a protective effect of hookworm infection on asthma. Here, N. americanus
was found in 35 out of 250 cases of asthma (14%), compared with 44 out of 100
controls (44%) (OR 0.21, 95% CI: 0.12 to 0.35) 217.
Three larger studies in Ethiopia - two cross-sectional surveys and one case-
control study - have been carried out in the last ten years and have reported
adjusted analyses. Scrivener looked at 205 cases of self-reported wheeze and
399 adult controls. Hookworm was present in 24% individuals and was associated
with a significant reduction in the risk of wheeze (adjusted OR 0.48, 95% CI: 0.24
to 0.93; p=0.03) 58. Dagoye et al studied 7155 children and found the prevalence
of hookworm infection to be 10%. Wheezing in the preceding year was reported in
3.4% of children and was negatively associated, though not at a statistically
significant level, with hookworm infection (adjusted OR 0.6, 95% CI: 0.2 to 1.8)
218. Davey et al found similar results in 7649 children and adults 219, with a
prevalence of wheeze in the preceding year of 10.5% and asthma ever in 2% of
responders. Hookworm was found in 14.7% of these participants, with no
statistically significant relationship between the asthmatics and controls (adjusted
OR 0.89, 95% CI: 0.48 to 1.63) or wheezers and controls (adjusted OR 0.92,
95% CI: 0.73 to 1.14).
In addition to the studies in the meta-analysis, three further recent studies have
also investigated the association between hookworm infection and asthma. The
first was carried out in Thailand as part of the Prospective Cohort Study of Thai
Children, a birth cohort study of children from four rural areas born in 2001 and
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which includes over 1000 children 210. Data were available from 706 of these
children and in contrast to most of the previous studies, the authors found current
hookworm infection to be strongly related to physician-diagnosed wheeze in the
last six months (adjusted OR 4.20, 95% CI: 1.45 to 12.10). The second, a small
nested case-control study carried out in Uganda, found an significant inverse
relation between hookworm and asthma. The authors compared 20 women with a
history of asthma with 117 non-asthmatic controls; four of the cases and 62 of the
controls had had hookworm infection within the past two years (adjusted OR 0.24,
95% CI: 0.07 to 0.81) 211. Finally, another birth cohort study currently in progress
in Butajira, Ethiopia has looked at the association between infection and asthma
or wheeze. The first analysis was carried out on 899 children when they were
aged one year to look at risk factors for wheeze and eczema. Faecal samples
were collected for analysis, but the prevalence of infection with any helminth was
less than 4%, with hookworm being the most common, and whilst wheeze was
lower in the uninfected than the infected children, the numbers were too low to
derive a meaningful estimate of effect 100;220.
1.9.3 Relation between intensity of helminth infection and asthma
In the meta-analysis, five studies (three from Ethiopia 58;218;219 and two from
Central/South America 221;222) presented sufficient data to allow a pooled analysis
on effects of burden of infection. A significant dose-related reduction in risk of
both asthma and wheeze was seen with increasing hookworm infection, with the
risk of asthma in the highest tertile of infection being reduced by approximately
two-thirds compared with those with no infection (adjusted OR 0.34, 95% CI: 0.19
to 0.62) 13. Much of this effect was due to the study by Scrivener et al who
reported an adjusted OR for the lowest tertile of 0.54 (hookworm eggs 1.00-5.79
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per gram of faeces (/g faeces)), 0.60 for the middle tertile (5.80-48.87 eggs/g
faeces) and 0.30 for highest tertile (>48.88 eggs/g faeces), all compared to zero
eggs 58. No significant effects on asthma or wheeze were seen for different
intensities of infection with T. trichiura or A. lumbricoides in the studies from the
meta-analysis 58;218;219;221;222. Since then this was published, a study from Brazil
reported A. lumbricoides infection at higher loads (>100 eggs/g faeces) to be
significantly associated with wheeze and bronchial hyper-responsiveness (OR
1.8, 95% CI: 1.0 to 3.0) but not diagnosed asthma 205;206 and in a study from
Ecuador heavy infection with T. trichiura (>490 eggs/g faeces) was found to be
significantly associated with reduced risk of wheeze in participants with positive
allergen skin sensitisation (adjusted OR 0.24, 95% CI: 0.09 to 0.63) 208.
1.9.4 Helminths and allergic rhinoconjunctivitis
The first report of the observed association between parasites and allergic
rhinoconjunctivitis was by Preston, a naval officer, who in 1970 observed fewer
symptoms of hay fever amongst those on board his ship who were infected with
parasites 223. More recently, however, cross-sectional studies of the relation
between parasites and allergic rhinoconjunctivitis have been reported which
demonstrate little convincing evidence of a significant association. One
explanation for this might be that the studies have mainly been performed in
areas of endemic A. lumbricoides infection and different parasite species are
likely to exert different effects on allergic disease. Lynch et al found that allergic
rhinoconjunctivitis was significantly more common in Venezuelan children living in
urban areas than in those in rural areas; however, infection with A. lumbricoides
was equally prevalent in urban and rural areas, which suggests that other factors
were responsible 224. Two cross-sectional studies of children, one in rural Ecuador
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(n=1002) 225 and one in South Africa 226 (n=53), found no significant relation
between allergic rhinoconjunctivitis symptoms and current A. lumbricoides
infection. Similarly, a study of 1320 children in Cuba found no association with A.
lumbricoides, E. vermicularis, hookworm or T. trichiura and allergic
rhinoconjunctivitis 207. Finally, in contrast to this last study, Huang et al reported a
protective effect of E. vermicularis against rhinitis in 3107 children in Taiwan
(adjusted OR 0.61, 95% CI: 0.45 to 0.84) 227.
1.9.5 Helminths and eczema
Eczema is a complex disease, and a particular problem with large epidemiological
studies is the challenge of making a reliable diagnosis when using self-reported
questionnaires. Itchy rashes are common in children, and are often incorrectly
attributed to eczema, which can cause an overestimation of prevalence. Even
when using clinical examination to confirm a diagnosis, the relapsing-remitting
nature of the condition may lead to an underestimation of prevalence. This may,
in part, explain the mixed findings of the studies that have investigated the relation
between parasites and eczema. Some studies have shown an inverse relation
between eczema and any helminth infection (predominantly hookworm) 228;
current infection with A. lumbricoides 207;229 and a history of infection with A.
lumbricoides 230. In contrast, others have found a positive association between
eczema and T. trichiura infection 231; a history of infection with E. vermicularis 207
and a history of mixed parasite infection (predominantly A. lumbricoides) 232.
Moreover, no association between eczema and helminth infection was identified
in three other studies where E. vermicularis 227, geohelminths (T. trichiura, A.
lumbricoides and hookworm) 221 and any parasite (hookworm, Mansonella
perstans and S. mansoni 211 were the predominant infections.
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1.9.6 Helminths and atopy
The association between parasite infection and atopy is much less clear. In
almost all epidemiological studies atopy is defined as the presence of positive
allergen skin sensitisation and these terms are therefore used interchangeably in
this thesis. Where another definition of atopy has been used, such as the
presence of specific IgE, it will be explicitly stated. Studies have explored the
relation between atopy and parasites generally, and specifically between atopy
and helminths and individual species. These studies have found mixed results
163;209;211;221;225;230;232-238. In view of this, as part of the work forming this thesis, a
systematic literature review of the relation between atopy and parasite infection,
and meta-analysis of the identified studies, were performed. The results of this
review and meta-analysis are presented in Chapter 5.
1.10 Intervention studies of helminths and allergy
Most of the evidence for an association between parasites and allergy arises from
observational studies. The majority of these are cross-sectional in design and, as
such, can only demonstrate a relation between exposure and outcome, rather
than a temporal association or causality. Cohort studies are the only observational
study which can show a temporal association, but for several reasons, there are
limited numbers of these investigating the relation between parasites and allergy,
including the significant length of time the studies take to complete and the large
numbers of recruits into the cohort that are usually required. Alternatively,
intervention studies may also identify whether a temporal association between
parasites and allergic disease exists. These need to look at the effect on allergic
symptoms, either after infection of parasite-naïve individuals or after eradication of
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parasite infection from areas where it is endemic. Because of the apparently
strong inverse relation between hookworm infection and asthma, a series of
intervention studies using N. americanus was planned and carried out, and forms
part of this thesis.
1.10.1 Previous studies of deliberate helminth infection
Several previous intervention studies, with a variety of objectives, of intentional
infection with N. americanus have been described in the literature. There are two
early case reports in the literature describing intentional infection with N.
americanus and its longevity. In the first, reported in 1941 by Palmer 239, an
undetermined number of cultured N. americanus larvae were given in one dose to
a healthy male and faecal egg counts were measured at regular intervals during
the course of infection. A plateau of egg production was attained by the 11th
month and remained constant for six years, subsequently declining until egg
production ceased at 15 years 240. In the second case report, reported by Beaver
in 1951, a healthy volunteer was given three larvae and faecal egg counts were
monitored thereafter. Eggs counts were 1000/g faeces during the first year,
1500/g faeces over the next five years, reducing to less than 200/g faeces over
the last three years with egg production ceasing 18 years after infection 138.
Cline et al infected 30 healthy volunteers with 45 hookworm larvae to establish
efficacy of eradication of infection with a single dose of albendazole. Six days
after infection, volunteers were randomised to receive one of the following:
albendazole plus a meal, albendazole plus instructions to fast for 24 hours, or
placebo. Cutaneous reactions in all volunteers except one, and gastrointestinal
symptoms, were reported in those who developed sustained infection. The single
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dose of albendazole was unsuccessful in eradicating the infection given six days
earlier in 13 of the 21 volunteers (regardless of whether or not they had fasted)
who went on to develop established infection, although geometric mean egg
counts on day 56 post-exposure were significantly lower in the albendazole
groups as against the placebo group (72 vs. 268 eggs/g faeces) 194.
Turton described self-infection with 250 larvae on four occasions over 26 months,
(starting in October 1974,) with the two-fold purpose of examining the
haematological response to the infection and obtaining a supply of larvae for
antigen preparation 241. These hookworms produced between 3500 and 5000
eggs/g faeces and, interestingly, Turtons pre-existing symptoms of hay fever
abated and he remained symptom-free at the time of publication in 1976. This is
the only case report in the literature where self-infection caused remission of hay
fever symptoms. In 1978, Ogilvie et al reported the clinical and antibody
responses following Turtons self-infection. Gastrointestinal symptoms were
reported from days 25 to 70 after each infection and were most marked following
the first infection. A pronounced eosinophilic leucocytosis was also reported with
each infection and no significant changes were seen in red cell parameters. Total
IgE rose after the second infection and continued to increase after each
subsequent infection and over time to more than 500 U/ml. A rise in specific IgE
to hookworm antigen occurred after the third and fourth infections. Antibodies to
the adult worm secretions and to extract of L3 larvae were detected six weeks
after the first infection and rose again after subsequent infections. Antibodies to
Necator acetylcholinesterase were detected 12 weeks after the second infection
and also rose after subsequent infections 184.
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In 1987, Maxwell et al infected five healthy volunteers with 50 infective larvae of
N. americanus in order to observe the clinical and immunological responses over
60 days. All volunteers reported gastrointestinal symptoms of flatulence and
epigastric/abdominal pain between days 30 and 45, with some also describing
nausea, diarrhoea and vomiting. Three described these symptoms as mild to
moderate, one as moderate to severe and one had severe symptoms
necessitating eradication treatment on day 40. Faecal eggs were identified in
three of the volunteers between days 48 and 58 (500-1200 eggs/g faeces); one
volunteer temporarily lost to follow-up after day 45 had a count of 200 eggs/g
faeces on day 113. The fifth volunteer was treated on day 40 and had never had
eggs identified. Eosinophil counts increased after two to three weeks and peaked
between days 38 and 64 at between 1.35 and 3.83 x109/litre. No significant
change was seen in other blood leucocytes counts. IgG-specific antibody
responses to N. americanus antigen, measured by enzyme-linked immunosorbent
assay, rose by 1.5-3.0 fold titres, and peaked after around 21 days. A modest
increase in total serum IgE was seen by weeks five to eight in four of the five
volunteers; specific IgE rose in two volunteers in the period 28 to 38 days post-
infection 195.
Finally, in 2005, after the onset of the clinical intervention studies reported in this
thesis, Wright and Bickle published a study where a single healthy male was
infected with 50 N. americanus larvae, and then re-infected 27 months later, with
the aim of characterising the immune response. Following the first infection, and
in keeping with other reports, a pruritic cutaneous reaction was noted which, in
this case, persisted until day 47. Nausea and moderate abdominal pain was
experienced between days 26 and 45 post-infection. The infected individual also
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reported mild rawness in the lower respiratory tract during days 17 to 19 and
occasional peripheral oedema between days 27 and 42. Eggs were present from
week 7 post-infection, peaked at 1176 eggs/g faeces on day 145 and remained
between 600 and 900 thereafter. An eosinophilic leucocytosis was noted with
maximum eosinophil counts of 6.4 x109/litre on day 42 before declining to a
persistently elevated level of 1.6 x109/litre. A similar, though less marked
response was seen after the second infection. Antigen-specific IL-5 production
increased between days 13 and 27 after infection and then fell to baseline
between days 41 and 118. Hookworm specific IgG and IgE increased gradually
during the primary infection and peaked during the 20th and 27th month after
infection respectively. IL-13 response was noted between days 41 and 118. Little
FKDQJHLQOHYHOVRI,)1Ȗ,/RU&53ZDVGHWHFWHG170.
1.10.2 Eradication studies of helminth infection
Following on from the evidence for a relation between helminth infection and
allergy demonstrated in the observational studies, it might be expected that
eradication of naturally-occurring infection could result in an increase in allergic
symptoms. However, generally, the results from eradication studies of naturally-
occurring infection have failed to show an effect on allergic symptoms. Almost all
these studies have been carried out in children. Two large eradication studies
investigating a variety of different outcomes of allergic disease 242;243 and a
number of other studies looking at specific allergic outcomes have been reported.
The first large study was a cluster-randomised controlled trial in schoolchildren
based in 68 rural schools in Ecuador 242. Children were randomly assigned, by
school to treatment with albendazole (34 schools and 1164 children) every two
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months for 12 months (7 occasions) or to no treatment (34 schools and 1209
children). The primary outcome was atopy to various allergens using skin
sensitisation tests at 12 months. Secondary outcomes were presence of allergic
symptoms (namely wheeze, rhinitis with itchy eyes, or itchy flexural rash),
presence of flexural dermatitis on clinical examination and risk of exercise-
induced bronchospasm. In this study, 72% of children were infected with
geohelminths with 56% infected with A. lumbricoides and 56% infected with T.
trichiura. They found no evidence of any difference in any of the outcomes in
those children receiving albendazole compared with placebo.
The second large study was carried out in Vietnam and 1084 schoolchildren were
randomised to receive anti-helminth treatment or placebo at 0, 3, 6 and 12
months 243. Outcomes were changes in the prevalence of exercise-induced
bronchoconstriction, allergen skin sensitisation, flexural eczema on skin
examination and reported symptoms of wheeze and rhinitis using a questionnaire
between 0 and 12 months. 5% of children were lost to follow-up. The most
common helminth infections were hookworm (65%) and A. lumbricoides (7%).
Anti-helminth therapy was associated with a significantly higher allergen skin
sensitisation risk (adjusted OR 1.31, 95% CI: 1.02 to 1.67; p=0.03). This effect
was particularly strong for children infected with A. lumbricoides at baseline
(adjusted OR 4.90, 95% CI: 1.48 to 16.19; p=0.009). There was no effect of
mebendazole observed on any of the other outcomes. No other studies have
reported the effects of helminth eradication on symptoms of allergic
rhinoconjunctivitis or flexural dermatitis.
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One smaller study, carried out in Venezuela, looked specifically at the effects of
anti-helminth treatment in people with pre-existing asthma 244. 100 people with
asthma were randomised to receive monthly albendazole for 12 months or
placebo. At baseline, 41% of participants were infected with helminths, the
predominant ones being T. trichiura (26%) and A. lumbricoides (23%). The
primary outcome was asthma control as determined by number of exacerbations,
need for inhaled corticosteroids and use of reliever inhaler. Secondary outcomes
were allergen skin sensitisation to Dermatophagoides species and A.
lumbricoides. Although this study did report a temporary improvement in clinical
asthma control after albendazole therapy, the results are not convincing as they
were based on assessments before and after treatment in those in the treatment
group, and no statistical analysis comparing the treated and control groups was
reported.
Three studies, of varying quality, have looked specifically at the effects of anti-
helminth treatment on allergen skin sensitisation and have also found an increase
in risk of atopy after treatment. Two were performed in areas where A.
lumbricoides and T. trichiura were most prevalent and involved 375 children in
Venezuela 245 and 317 children in Gabon 246. In the study from Venezuela, 375
schoolchildren were offered anti-parasite treatment and followed for 22 months.
107 children took the treatment and 80 did not for various reasons and were
considered as an untreated control group. The authors noted that atopy increased
in those treated compared with those untreated at the end of study for a variety of
allergens. For example, to positivity to D. pteronyssinus changed from 26% to
16% in the untreated group and from 17% to 68% in the treated group. As this
study design was not randomised, limited inferences can be made from the
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results. In the study in Gabon, schoolchildren were randomised using an open-
label protocol to receive praziquantel and mebendazole or placebo every 3
months for the duration of the study. Skin sensitisation tests to D. pteronyssinus
were checked every 6 months. After 30 months of follow-up, they found a
significant increase in the rate of developing skin sensitivity to D. pteronyssinus
with treatment compared with placebo (adjusted hazard ratio 2.51, 95% CI: 1.85
to 3.41). The third study, also carried out in Ecuador, investigated the impact on
allergic disease of a control programme for onchocerciasis where ivermectin,
which is also active against helminth infection had been given on an annual or
semi-annual basis for the last 15 to 17 years 247. 3901 children were assessed
with similar numbers from treated and untreated areas. The prevalence of
helminth infection was greater in those from non-treated areas (86%) than those
in the treated areas (67%) with T. trichiura being the most prevalent of the
infections. Those children living in treated areas had higher odds of atopy after
adjusting for confounders (OR 2.10, 95% CI: 1.50 to 2.94). A further analysis was
then performed to assess whether this association might be explained by the
reduction in infection. They found this to be true for T. trichiura, but not for A.
lumbricoides or hookworm. There was no effect of infection or treatment on
prevalence of eczema symptoms. A further randomised controlled trial of the
effects of anti-helminth treatment on the prevalence of allergen skin sensitisation
and allergic disease is currently in progress in Indonesia and the results are
awaited 248.
In addition to these studies described above, a randomised controlled trial of the
effects of giving helminth treatment to pregnant women on incidence of eczema in
their infants has been carried out in Uganda 228. Women in the second trimester of
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pregnancy were randomised to receive a single dose of albendazole or placebo
and the incidence of infantile eczema, was confirmed by clinical examination up
until the age of 15 months. 53 participants received albendazole and 50 received
placebo; and complete follow-up data were available for 78%. 66% of participants
had helminth infection at enrolment into the study. The authors found the
incidence of infantile eczema was lower when the mother had helminth infection
both during pregnancy and at delivery (adjusted rate ratio 0.26, 95% CI: 0.08 to
0.83). Similarly, there was also an inverse association between presence of
helminth infection at delivery alone and the incidence of new eczema (8.6 per 100
person-years vs. 47.5 per 100 person-years; p=0.001) 228. Whilst incidence of
eczema was higher in infants whose mothers had received albendazole
compared with placebo, this was not statistically significant in the adjusted
analyses. The numbers in the study were small but the inverse association
between maternal infection at delivery and infantile eczema may demonstrate the
effect of maternal helminth infection priming the infants immune system in utero
against development of clinical allergic disease. Following on from the study
above, a trial is now in progress in Uganda to investigate the relation between
eradication of perinatal and postnatal infection and risk of atopy 249. 2507
pregnant women were randomised, double-blind to albendazole or placebo, and
praziquantel or placebo using a 2x2 factorial design. Primary outcome includes
incidence of atopic disease episodes in the children. Worm infection was detected
in 68% of women before treatment, of which hookworm infection was most
common (45%). Early results from this study have shown that there was an
increased risk of physician-diagnosed eczema in infants whose mothers had
received albendazole treatment compared with placebo (Hazard Ratio 1.82, 95%
CI: 1.26 to 2.64) 249. This effect was slightly stronger among infants whose
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mothers had no albendazole-susceptible worms (compared with infants whose
mothers had such worms), although this difference was not statistically significant.
Moreover, there was a significant trend of effect with the greatest effect being in
those with no worms and smallest effect in those with three or more worm
species. Treatment with albendazole was also strongly associated with reported
recurrent wheeze in the infants at one year compared with placebo (OR 1.58,
95% CI: 1.13 to 2.22). Similarly, maternal treatment with albendazole (compared
with placebo) was weakly associated with reported eczema at one year (OR 1.29,
95% CI: 0.96 to 1.72; p=0.09). In exploratory analyses, when stratified according
to maternal hookworm status at enrolment, albendazole showed no effect on
reported eczema if mothers had hookworm but a slight increase if mothers had no
hookworm (OR 1.46, 95% CI: 0.98 to 2.17; p-value for interaction = 0.10).
Reported recurrent wheeze showed a similar trend, with albendazole showing no
effect when a mother had hookworm but a significant effect if a mother had no
hookworm (OR 1.97, 95% CI: 1.27 to 3.05; p-value for interaction = 0.31).
1.11 Aims and objectives of thesis
Allergic diseases, and specifically asthma, are common and as described, the
prevalence of these conditions continues to increase in parts of the world. There
is an emerging body of epidemiological evidence supporting an association
between parasite infection and allergic disease, some of which is presented in this
introduction, but it is not known if this relation is causal. For causality, to be
established, a number of different criteria need to be fulfilled 250, one of which is
temporality and is best assessed in a cohort study or in a randomised controlled
trial. To date, no randomised controlled trials of experimental infection with
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parasites have been performed. If the relation is ultimately proven to be causal,
there is potential for parasites, or their products, to be used as treatments for
asthma and the efficacy of this would also need to be evaluated in an
appropriately designed trial.
There are three main advantages in the design of a randomised controlled trial.
The process of randomly allocating the exposure, (in this case, infection), should
ensure that each intervention group is similar with respect to all factors, including
known and unknown potential confounders. This therefore controls for
confounding providing the sample size is a sufficiently large. A trial which is
placebo-controlled and double-blinded, if successful, removes bias in
ascertainment of subjective outcome measures. For example, if study participants
are aware of the treatment allocation, this can result in bias in reporting of
symptoms experienced; and similarly, if the investigator is aware, there may be
bias in recording of outcome measures and interpretation of results. As discussed
in section 1.10, one of the problems of cross-sectional studies is that temporality
cannot be assessed, and so reverse causation may explain the observed relation
between parasite infection and asthma. In a randomised controlled trial
temporality is accounted for and the issue of reverse causation is overcome by
first giving the exposure (here, the parasite infection) and then following up the
effects on outcome.
The need for a randomised control trial prompted the design of a triad of
intervention studies with the overall aim to establish whether experimental
hookworm infection improves asthma and if so, whether it could potentially be
used as a treatment. The first two studies were designed primarily as safety
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studies in preparation for the third study in people with asthma. All were carried
out in the UK. Hookworm was chosen as the parasite to be used as the size of a
protective effect on asthma was the greatest from the meta-analysis 13 and the
side effects of a controlled low dose of infection were likely to be limited.
The epidemiological evidence suggests that protection against asthma is related
to the intensity of parasite infection, being most evident in the presence of
infections generating more than 50 eggs/g faeces 58. In light of this, experimental
studies of therapeutic effects of hookworm infection in asthma should aim to
establish infection at this level, while minimising any adverse effects. The first
study, reported in Chapter 2, was therefore designed as a dose-ranging study and
was carried out in healthy volunteers. The primary aim of this study was to
establish the dose of hookworm required to achieve an egg count of 50 eggs/g
faeces. Secondary aims were to establish the side effects of different doses of
larvae and to explore the effects of infection on the immune response. It also
aimed to assess the feasibility of infecting healthy volunteers with hookworm in a
clinical trial setting.
The second study, reported in Chapter 3, was carried out in people with allergic
rhinoconjunctivitis and again was designed as a safety study. As described in
section 1.8.4.4, it was necessary to establish whether there was any increase in
risk of bronchial hyper-responsiveness during the phase of larval pulmonary
migration with experimental infection. The study was designed to address this
question and was carried out in people who had measurable bronchial
responsiveness but not clinical asthma. The primary aim of the study was
therefore to determine the effects of experimental hookworm infection on
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bronchial responsiveness over the first four weeks after infection which
corresponds with this period of larval lung migration. Secondary aims were to
investigate the effects on symptoms of allergic rhinoconjunctivitis and on allergen
skin sensitisation over a 12 week period. The study also aimed to evaluate the
immune response and occurrence of adverse effects potentially due to the chosen
dose of ten larvae in a greater number of people.
The third and final intervention study was designed to evaluate the therapeutic
efficacy of experimental hookworm infection on asthma and is reported in Chapter
4. It was only possible to proceed with this study after favourable results from the
first two studies had been achieved. The primary aim of the study was to
determine the effects of experimental hookworm infection on bronchial hyper-
responsiveness over a 16 week period. Secondary aims were to investigate, over
the same time period, the effects on other indicators of asthma control and on
allergen skin sensitisation and as before, to monitor the occurrence of adverse
effects potentially due to the infection.
The epidemiological evidence for the association between parasite infection and
asthma has previously been subject to a systematic review and meta-analysis 13,
however, to date, this is not the case for the relation been parasite infection and
atopy. This would be particularly useful given the number of studies already
carried out with varying results. A meta-analysis of the literature would also
indicate whether the inverse association is unique to asthma or applies to allergic
disease more generally. Therefore the aims of the systematic review and meta-
analysis were to determine the association of infection with any parasite infection
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or species-specific infection, and allergen skin sensitisation. The aim was also to
determine the relation between parasite infection and allergen-specific IgE.
72
Figure 1-1: Overview of the immune system adapted from Hanson 251
Ab: antibody; CK: cytokines; DC: dendritic cells; ,)1ȖLQWHUIHURQȖIg: immunoglobin; IL: interleukin;
NK: natural killer; TH: T-helper leucocytes; TGF-ȕ: transforming growth factor-ȕ; TNF-Į: tumour necrosis factor;
T-reg: regulatory T cell
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Figure 1-2: Classification of helminth infection
Intestinal Nematodes
Necator americanus
Ancylostoma duodenale
(hookworms)
Ascaris lumbricoides
(roundworm)
Trichuris trichiura
(whipworm)
Enterobius vermicularis
Nematodes
(roundworms)
Tissue Nematodes
Loa Loa
Wucheria bancrofti
Helminths Trematodes
(Flukes)
Toxocara canis
Brugia malayi
Onchocerca volvulus
Cesatodes
(tapeworms)
Blood Flukes
Schistosomiasis spp.
Tissue Flukes
Liver, lung and intestinal
flukes
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2 DOSE-RANGING STUDY
2.1 Introduction
Evidence that the effect of hookworm infection on asthma is linked to intensity of
infection is described in section 1.9.3. In pooled analyses of the epidemiological
studies, a significant dose-related reduction in risk of both asthma, and wheeze,
was observed with hookworm infection, with the risk of asthma in the highest
tertile of infection being reduced by approximately two-thirds (adjusted OR 0.34,
95% CI: 0.19 to 0.62) 13. The main study to demonstrate this protective effect of
hookworm infection on asthma was a case-control study carried out in Ethiopia,
where 205 cases with asthma symptoms were compared with 399 controls 58.
After identifying that hookworm infection appeared to be protective against
wheeze the effect of intensity of infection was explored. Hookworm egg counts
were analysed in tertiles and the protective effect was found to be most marked
where counts were greater than 50 eggs/g faeces. After adjusting for age and
sex, the odds ratios for wheeze were 0.54 for the lowest tertile (hookworm eggs
<5.79/g faeces), OR 0.60 for the middle tertile (5.80 to 48.87 eggs/g faeces) and
OR 0.30 for the highest tertile (>48.88 eggs/g faeces) (Figure 2.1).
Whilst with natural infection female hookworm can produce over one thousand
eggs every day, a detailed study of the number of eggs produced with
experimental infection has not been previously reported. Before embarking on an
intervention study of the effect of experimental hookworm infection in asthma, it
was important to establish how many larvae would be needed to generate an
effect. A dose-ranging study in healthy volunteers, in preparation for a study in
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people with asthma was therefore designed with the aim of determining how
many larvae were needed to achieve the apparent protective threshold of at least
50 eggs/g faeces. The other aims of this study were to determine the feasibility of
giving experimental hookworm infection in the context of a trial and to establish
the side effects resulting from different doses of larvae as the morbidity from
natural helminth infection is strongly associated with intensity of infection 186;252.
The study was in part designed as a safety study to assess tolerability of infection
and was therefore carried out in healthy volunteers. People with bronchial
responsiveness were excluded in case this was exacerbated during the
pulmonary phase of larval migration. The primary outcome was the faecal egg
count at eight weeks with the different doses of larvae. Secondary outcomes were
the side effects reported of different doses of N. americanus infection and
changes in specific immunoglobulins, differential white cell counting, and
interleukin and TGF-ȕ levels over the 12 weeks of the study.
The dose-ranging study was started before I commenced work on this grant and
the projects. However, as stated earlier, I was involved with the data analyses and
production of the manuscript that reported the findings of the study. As such, for
completeness, the study is detailed here.
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2.2 Methods
2.2.1 Recruitment, eligibility criteria and screening of participants
Potential study participants were recruited by local advertisement and word of
mouth. Initial screening took place to exclude those with a diagnosis of asthma,
anaemia or any other significant medical disorder as judged by the study clinician
carrying out the visit. In addition, women were also excluded who were pregnant
or of child-bearing potential and not willing to use contraception for the duration of
the study. Those volunteers who met the initial eligibility criteria were then invited
to attend a baseline visit where further criteria were assessed as detailed in
section 2.2.2. There were no data available on which to base a sample size
calculation as this was the first study of its kind. Therefore, a pragmatic decision
was made to randomise five volunteers to each dose of larvae on the basis that
this should provide adequate egg count data to fulfil the objective of the study.
2.2.2 Baseline visit
At the baseline visit, the study was explained in detail and written informed
consent obtained. Several clinical measures were then taken as detailed below.
2.2.2.1 Lung function and bronchial challenge
Lung function was measured using a Micro Spiro (Micro Medical Limited, Kent,
UK) spirometer, taking the one-second forced expiratory volume (FEV1) as the
higher of two values within 100mls, and the higher of two measures of forced vital
capacity (FVC) according to international guidelines 17. Bronchial responsiveness
to methacholine was measured by the Yan method 253 to a maximum cumulative
dose of 24.5 ȝM, stopping the test if FEV1 fell by 20% or more from the post-
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saline baseline value. Individuals with a 20% or greater fall in FEV1 were deemed
to have bronchial hyper-responsiveness and were excluded from further
participation.
2.2.2.2 Allergen skin sensitisation
Allergen skin sensitisation to grass, cat fur and D. pteronyssinus plus positive
(histamine) and negative (0.9% saline) controls (Allergopharma, Diagenics Ltd,
Milton Keynes, UK) was measured by standard skin prick test methods 254. A drop
of the solution was placed on the ventral surface of the forearm and the skin was
broken using a lancet needle. After 15 minutes, the mean of two diameters at right
angles to each other (excluding pseudopods), one of which was the largest
measurable diameter, was measured for all five solutions.
2.2.2.3 Blood samples
Peripheral blood samples were taken for haemoglobin estimation and differential
cell counting (Full Blood Count) which was analysed in the pathology department
at Nottingham City Hospital. Total IgE and specific IgG to hookworm levels were
estimated using standard enzyme-linked immunosorbent assay techniques and
antigen recognition by postinfection sera was analysed by Western blot 183;255.
These immunology tests were performed by scientists in the University of
Nottingham School of Pharmacy and the methods used are not described in
further detail here.
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2.2.3 Randomisation visit
2.2.3.1 Randomisation
Individuals who met all eligibility criteria and who consented to participate in the
study were then seen for a second visit where infection was carried out.
Participants were randomised to receive a drop of water containing 10, 25, 50 or
100 N. americanus larvae, administered under gauze to an area of skin on the
ventral aspect of the non-dominant forearm. Randomisation was in blocks of four
according to a computer-generated random code, produced by the trial
statistician. N. americanus larvae were obtained by culture of faecal material 256
from a healthy human source using the method described in section 2.2.3.3, and
stored in water until required.
2.2.3.2 Blinding
The trial was carried out double-blind: both the participants and the study clinician
responsible for conducting the study visits and carrying out clinical measurements
were blind to randomisation code. The randomisation code was shared by the trial
statistician with the scientist responsible for larvae culture to allow him to infect
participants with the appropriate number of larvae.
2.2.3.3 Necator americanus L3 larval culture
Larval culture was performed by scientists based in the Department of
Immunoparasitology in the University of Nottingham School of Pharmacy. Faecal
material containing N. americanus eggs was obtained from a healthy human
source known to be Hepatitis B and C and Human Immunodeficiency Virus
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negative, mixed with activated charcoal, 1% (w/v) amphotericin B and water to
form a smooth paste and then applied to the upper half of a 5 x 30 cm strip of filter
paper. The strips were suspended in 750mls of distilled water in a sealed glass
chromatography tank and incubated at 28°C for 7 to 10 days. The water
containing the larvae was then transferred to a measuring cylinder and the larvae
allowed to settle for 2 hours. After aspirating off the water, the larvae were
washed twice to remove any contamination and then re-suspended in
approximately 20mls of storage buffer (50mM Na2HPO4, 70mM NaCl, 15mM
KH2PO4, pH7.4) 256.
2.2.4 Follow-up visits
After infection, study participants were seen weekly for twelve weeks. On each
occasion, FEV1 and FVC were measured, blood was taken for Full Blood Count
and immunoglobulin estimation, and a faecal sample was collected to quantify
egg production. Faecal egg counts were carried out by scientists in the University
of Nottingham School of Pharmacy by suspending a weighed sample of faeces in
one to two mls of saturated salt solution, counting eggs in a MacMaster egg
counting chamber under a pre-marked grid, and back-calculating to estimate
eggs/g faeces. Between visits, participants completed daily diaries of a variety of
adverse effects, scoring severity on an arbitrary scale of 0 (no symptoms) to 10
(maximum possible severity of symptoms) because no validated questionnaire to
assess the effects of infection existed. These adverse effects were selected
based on previous reports in the literature of past experimental infection and were
as follows: local skin reactions at the site of infection, gastrointestinal symptoms
(nausea, indigestion, abdominal pain, diarrhoea, wind) and respiratory symptoms
(cough, wheeze, breathlessness) 184;194;195. Participants were also encouraged to
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report the presence of any other symptoms (such as tiredness) that they were
experiencing and which they felt might be important.
2.2.5 Final visit
At the final visit, 12 weeks after randomisation, in addition to the other clinical
measures taken, allergen skin tests were repeated. The study clinician then
unblinded the participants and provided them with 100mg mebendazole tablets to
be taken twice daily for 3 days to eradicate the infection. A further faecal sample
was checked for presence of eggs two weeks later to ensure eradication of the
infection in all participants.
2.2.6 Trial monitoring
Data on adverse effects, blood results and faecal egg counts were monitored as
the trial progressed, blind to allocation, by the trial statistician.
2.2.7 Ethical approval
The study was approved by the Nottingham NHS and University Ethics
Committees.
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2.3 Data analysis
2.3.1 Data entry
Data analyses were carried out at the end of the study blind to randomisation
code. All data were double entered into Statistical Package for Social Sciences
version 13 (SPSS Inc, Illinois, Chicago) and cross-checked for discrepancies.
2.3.2 Primary outcome
2.3.2.1 Faecal egg counts
The primary outcome was the number of faecal eggs produced with different
doses of hookworm larvae 12 weeks after being infected. Faecal egg counts for
each dose of hookworm larvae were not normally distributed and could not be
transformed. The median faecal egg count was therefore calculated for each
week and plotted by dose of larvae for each of the 12 weeks of the study and
compared descriptively. The lowest maximum egg count for any individual was
identified.
2.3.3 Secondary outcomes
The secondary outcomes were the occurrence of adverse symptoms potentially
due to hookworm at different doses of larvae and the immune response to
infection, determined by changes in leucocyte counts, haemoglobin and various
cytokines over the course of the study. Exploratory analyses were also carried out
to investigate changes in lung function and allergen skin sensitisation between the
start and end of the study. Given the small sample size of the study, the intention
was to descriptively assess outcomes and so no statistical tests of significance
were therefore performed.
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2.3.3.1 Adverse symptoms
The occurrence of adverse symptoms potentially due to the hookworm larvae is
presented for each participant separately to demonstrate the range of
experiences at each infection dose. Scores for each symptom were plotted over
the 12 week study period and then compared between the different doses.
2.3.3.2 Lung function
The change in lung function between the start and end of the study (FEV1 and
FVC) was calculated for each individual. The mean change in FEV1 and FVC was
then calculated for all participants and also according to dose of larvae received.
In addition the maximum fall in lung function was determined for each dose and
compared between the groups.
2.3.3.3 Allergen skin sensitisation
To remove any effect on the size of the wheal from the saline solution or the act of
breaking the skin, a saline-adjusted mean wheal diameter was calculated by
subtracting the mean wheal diameter for the negative control from the mean
wheal diameter for each allergen. The change in allergen skin sensitisation test
(for any participants who had a positive response defined as a saline-adjusted
mean wheal diameter equal to or greater than 3mm 254) was compared for each
individual between the start and end of the study.
2.3.3.4 Blood results
Leucocyte (total white cell and eosinophil) counts and immunoglobulin levels were
not normally distributed but could be transformed by taking the natural log of each
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value. The geometric means were therefore calculated and plotted for each week
of the study according to dose of hookworm larvae and compared descriptively.
The change in haemoglobin level was calculated for each individual as the
difference between week 12 and screening visit values and the maximum fall
identified.
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2.4 Results
2.4.1 Participant flow
Ten people were randomised to the study (Figure 2.2). Three participants were
randomised to each of the lower doses of ten, 25 and 50 N. americanus larvae
and one to the dose of 100 larvae. Two participants withdrew from the study due
to experiencing gastrointestinal symptoms and were subsequently unblinded. The
first withdrew on day 35 after experiencing recurrent vomiting and diarrhoea.
Unblinding of this participant revealed they had been given 100 larvae; no other
volunteers had yet been randomised to this dose and the decision was made by
the study investigators not to randomise any further people to this dose in view of
the severity of the symptoms. The second, developed diarrhoea and abdominal
pain and withdrew on day 28. Unblinding of this participant revealed they had
received 50 larvae. Both these participants were treated with mebendazole to
eradicate the infection. The remaining eight participants went on to complete the
full twelve week study, attending a minimum of ten of the twelve weekly visits. The
initial intention had been to randomise five people to each dose of larvae
however, recruitment was stopped after three participants had been allocated to
each dose of the three lower doses since it became apparent from monitoring the
faecal egg count data that the number of larvae required to generate an egg count
of more than 50 eggs/g faeces had been established.
2.4.2 Faecal egg counts
Hookworm eggs were not seen in faecal samples at any time in the two
participants who withdrew from the study prematurely, but appeared at between
four and six weeks after infection in all participants who completed the study. The
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highest egg counts occurred in the people who received 50 larvae; median egg
counts were similar in participants allocated to the two lower doses. The lowest
maximum egg count in an individual was 66 eggs/g faeces (Figure 2.3). Egg
counts for individual participants were variable and two participants had one or
two weeks in which eggs were not seen, having previously been detected. Two
weeks after treatment with mebendazole at the end of the study, faecal eggs were
undetectable in all participants.
2.4.3 Adverse symptoms
2.4.3.1 Local skin reactions
Nine of the ten participants reported immediate local skin itching and developed a
localised maculopapular rash at the skin entry site that typically lasted for two to
five days (maximum score 8/10) but persisted beyond this time in two participants,
who had been infected with 50 and 100 larvae (Figure 2.4). In the person who
received 100 larvae the eruption was severe and lasted a total of 21 days
(maximum score 8/10 on days 4 and 5 after infection). The participant who did not
experience skin symptoms received ten larvae. The rash recurred at lower
intensity (maximum score 5/10) for a few days at two to three weeks after
infection in five participants, of whom two had received 25 larvae, two had
received 50 larvae and one had received 100 larvae.
2.4.3.2 Gastrointestinal symptoms
Gastrointestinal symptoms appeared to be dose-related with symptoms generally
occurring earlier (within the first two weeks following infection) in those who
received 50 or 100 larvae compared with those who received lower doses where
symptoms did not occur until after at least three weeks. In addition, severity
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scores were tended to be lower in those infected with fewer larvae. Abdominal
discomfort was the most commonly experienced symptom and was reported by
nine out of ten participants. It tended to be intermittent and in some cases, was
related to meals. The maximum score for abdominal discomfort in those who
received ten larvae was 4/10; the highest score at any time for abdominal
discomfort was 6/10 and was reported by participants who had received 50 and
100 larvae (Figure 2.5).
Most participants also reported occasional episodes of diarrhoea but these were
mild, scoring a maximum of 2/10 on the severity scale for all but three
participants. Of these three who recorded higher scores, the first had received ten
larvae reported diarrhoea on day 56 only (score 6/10), the second who received
25 larvae had two isolated days with diarrhoea on days 2 and 95 (score 6/10).
The third of these participants had received 100 larvae and had symptoms which
started at day 20 and lasted several days at a time (scores of 5/10 and 6/10).
Occasional nausea was reported by five participants, of whom two had received
ten larvae (maximum score 2/10), one had received 25 larvae (maximum score
2/10), one had received 50 larvae (maximum score 5/10) and one who had
received 100 larvae (maximum score 8/10). Two reported early satiety, and six
reported increased flatulence (maximum score 4/10). As described in section
2.4.1, the two participants who withdrew from the study as a result of their
gastrointestinal symptoms, had received the two higher doses of larvae.
2.4.3.3 Respiratory symptoms
With the exception of one participant who reported a cough productive of a small
amount of phlegm during week seven, no respiratory symptoms were reported by
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the three participants who received ten larvae. One participant who received 25
larvae reported mild wheeze (score 2/10) on the second day of infection. The
participant who received 50 larvae and withdrew after four weeks reported cough
on days 5, 15 and 16 post-infection and mild wheeze (score 3/10) during the third
week. The participant who received 100 larvae reported mild breathlessness
(score 2/10) on day 11. No respiratory symptoms were reported by any of the
other participants.
2.4.3.4 Other reported symptoms
Symptoms of malaise or fatigue were reported by four of the ten participants.
Symptoms were mild to moderate (maximum score 5/10) and occurred between
weeks six and seven in three participants and at week 12 in one participant. Other
symptoms reported were mild neck pain and headache for 2 days by one
participant after a period of working at a computer, and pyrexia (38 °C) and
coryzal symptoms for 2 days during week seven by another.
2.4.3.5 Response of symptoms to therapy
All symptoms resolved completely after treatment with mebendazole.
2.4.4 Lung function and allergen skin tests
The mean (SD) FEV1 and FVC at baseline for the eight participants completing
the study were 3.60L (0.53) and 4.48L (1.06) and at exit from the study were
3.57L (0.62) and 4.24L (0.98) respectively. The mean change in FEV1 from the
start to the end of the study was a fall by 0.03L (0.18) with a maximum fall in any
individual of 0.18L. The mean change in FEV1 for those who received ten larvae
was a fall by 0.01L (0.11) with a maximum fall of 0.13L, for those who received 25
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larvae was a fall of 0.00L (0.29) with a maximum fall of 0.18L and for those who
received 50 larvae was a fall of 0.13L (0.06) with a maximum fall of 0.17L. The
maximum fall of 0.18L was in a participant who had received 25 larvae. Similarly
there were no clinical important changes in FVC and no evidence of a dose-
related effect.
Only one participant who completed the study had positive allergen skin tests;
saline-adjusted wheal diameters in this participant at baseline were 5mm to cat fur
and 7mm to grass, reducing to 4mm and 5 mm respectively at the end of the
study.
2.4.5 Leucocyte counts and haemoglobin
The mean white cell count increased to a peak at 5 to 9 weeks post-infection
(Figure 2.6), due almost entirely to changes in eosinophils (Figure 2.7). All other
leucocyte counts remained within the normal range throughout the study. The
increase in eosinophil count was lower in the group who received ten larvae
compared with the groups who received a dose of 25 or 50 larvae (Figure 2.7).
There were no clinically important changes in haemoglobin level during the study.
The maximum fall was in a participant who had received ten larvae; their
haemoglobin level fell by 1g/dL from 15.5 g/dL to 14.5g/dL.
2.4.6 Immunoglobulin levels
Total IgE levels increased slightly during weeks 2 to 6 in the two higher dose
groups but overall there was little difference between the different doses (Figure
2.8). Specific IgG levels increased gradually from time of infection, peaking at
week 10 in those participants who received ten larvae and at week 12 in the two
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higher larval dose groups (Figure 2.9). Western blots of adult hookworm
secretions were probed with sera taken at baseline and from the week 12 blood
test prior to treatment. Eight out of ten volunteers demonstrated a typical IgG
antigen recognition profile to hookworm infection 255. The two volunteers who
withdrew early from the study failed to show a specific IgG response to hookworm
secretions.
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2.5 Discussion
2.5.1 Summary of findings
This study explored the dose-related effects of hookworm infection in normal
healthy volunteers in preparation for a study in people with asthma. The primary
aim was to establish the dose of larvae required to achieve an apparent protective
threshold of at least 50 eggs/g faeces. It also aimed to determine the feasibility of
giving experimental hookworm infection in the context of a trial and to establish
the side effects resulting from different doses of larvae.
The study demonstrates that infection with cutaneous doses of ten or more larvae
generated an intensity of infection resulting in faecal egg counts of at least 50
eggs/g, previously suggested to be the approximate threshold of intensity
necessary to offer protection against asthma and allergic disease 58. Localised
skin rash and itching occurring in the first few days after infection were reported
by almost all the participants and were most marked at the highest dose of larvae.
Abdominal discomfort was also experienced by the majority of participants and
again appeared to be dose-related. Symptoms were mild-moderate (up to 5/10 on
severity score) in all but two participants, who had both received the two higher
doses of larvae, and who withdrew from the study as a result. In those who had
received ten larvae, gastrointestinal symptoms were generally mild and well
tolerated. Respiratory symptoms were unusual, and malaise and fatigue, whilst
reported by almost half participants were mild and short lived. There was no
clinically significant change in lung function (FEV1 and FVC) over the course of
the study. One participant had positive allergen skin sensitisation to cat fur and
grass at the start of the study and although the wheal sizes reduced, their repeat
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tests remained positive after 12 weeks of infection. There were no clinically
important changes in haemoglobin levels during the study with any dose of larvae.
Eosinophil levels rose during the study and peaked as expected at weeks 5 to 9
with higher levels in those receiving greater doses of larvae. Total IgE levels also
rose slightly but there was no evidence of a dose effect.
2.5.2 Strengths and weaknesses
2.5.2.1 Measurement error
Non-differential error may have occurred in the reporting of the adverse
symptoms. No validated questionnaire was available to use to assess the
occurrence of adverse symptoms potentially attributable to the infection, so a set
of symptoms based on previous reports of intentional hookworm infection was
devised. A visual analogue scale of 0 to 10 was used on which to grade the
severity of these symptoms and this is recognised as a sensitive tool for rating
subjective experiences 257. However, there is likely to be a degree of variation
between individuals in their definition of symptoms; for example, some individuals
may consider three bowel movements a day to be normal, whereas for others,
this might be reported as diarrhoea. It is also likely that there will be inter-
participant variation in their perception of severity of symptoms and as the
questionnaire has not been validated, it is important not to place undue emphasis
on absolute scores.
The other main outcomes subject to non-differential measurement error were the
faecal egg counts, lung function and allergen skin sensitisation tests. No
automated system was used was used to count the faecal eggs, however, a
single experienced scientist in the University of Nottingham School of Pharmacy
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processed all the samples and followed a strict protocol to reduce the chance of
error. Similarly the lung function and allergen skin sensitisation were carried out
by a single clinician following a protocol using standard methods. Automated
machines in the pathology department at Nottingham City Hospital and University
of Nottingham School of Pharmacy were used to analyse the blood samples.
These are all used routinely and subject to quality control and so measurement
error of these results should have been minimal.
2.5.2.2 Success of blinding and bias
Blinding to the dose of larvae was important to reduce the chance of both reporter
and observer bias. Participants were unlikely to have become unblinded as there
was no obvious way for them to determine the dose they had been given at any
point during the study and it was emphasised at the time of randomisation that the
degree of reaction to the infection would be different for each individual,
regardless of dose, and so the occurrence of side effects of infection would not be
a reliable means of deducing the number of larvae received. The larvae are
microscopic and so it would not have been possible to observe the number of
larvae given at the time of application on to the skin. There is a theoretical chance
that a participant could guess the dose of larvae they had received if they had
noticed and counted the number of portals of entry on the skin (assuming one per
larva) after the plaster was removed, or alternatively, on the basis of the severity
of the rash. These are not likely to be accurate means of determining the dose of
larvae, particularly because there was no opportunity for participants to compare
their individual rashes and none of the participants had experienced previous
infection. If participants had become aware of the dose they had received,
reporter bias was most likely to arise in subjective reporting of adverse symptoms.
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However, given that symptoms appeared relatively consistent for each dose and
in keeping with previous studies, it is unlikely to have been a particular problem.
The study clinician carrying out the study visits and measures and who was also
responsible for the data analyses, remained successfully blind to dose of larvae
given minimising the chance of observer bias. In addition, the majority of the
outcomes were measured using objective methods and so less likely to be subject
to bias even if the clinician had been aware of the number of larvae given to each
participant.
2.5.2.3 Representativeness
One obvious source of bias in this study was the inclusion of four of the
investigators as participants. Although not conventional, it was felt on moral and
ethical grounds that the investigators should not recruit volunteers to the study
without being willing to undergo infection themselves. The doses received by the
investigators, as for all participants, were double-blind and allocated at random
but at the end of the study proved to be 25 in one instance and 50 in the other
three. The lower incidence of adverse effects in the ten larvae group in particular
is therefore not attributable to bias due to possible under-reporting of adverse
effects by participants who were also investigators.
2.5.2.4 Statistical power
The study was the first to look at the effect of different doses of experimental
intentional hookworm infection and there were no data available on which to base
a sample size calculation. Therefore, a pragmatic approach was taken to
randomise four individuals to each dose of larvae on the basis that this should
enable the main aim of the study to be met. Despite the use of randomisation, the
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small sample size means that the groups are likely to have been different in terms
of participants baseline characteristics, but this is unlikely to have had an impact
on the primary outcomes of the study. However, because of the small number of
participants who received each dose of larvae, the study lacked power and it was
not appropriate to use statistical tests to determine whether the differences
observed between the groups were significant or if they had arisen by chance and
so the analyses carried out were all exploratory analyses.
2.5.3 Results in context of other studies
Although previous studies, described in section 1.10.1, have also documented the
effect of experimental hookworm infection in humans over the last three decades,
none were carried out as a randomised clinical trial and all included only small
numbers of individuals 138;184;194;195;240;241. None of the previous studies have
compared the clinical and immunological response (including egg production) to
different doses of infection. Those previous studies reporting egg counts following
infection with a known number of larvae at a similar dose to the ones used in this
study have found comparable results: for example, a mean of 268 eggs/g faeces
eight weeks after being infected with 45 larvae 194. The side effects of infection
experienced by participants in this study were also similar to previous reports with
an early skin rash and abdominal discomfort between weeks 4 and 8 after
infection with around 50 larvae being the most commonly reported 194;195. Previous
studies have also reported a substantial increase in the number of circulating
eosinophils following infection with higher doses of larvae 194;195. Levels of specific
IgG increased in all intervention groups throughout the trial period, and Western
blots demonstrated a typical antigen recognition profile 258 at all doses of
hookworm larvae, but not in the post-infection serum samples of the two
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participants (4 and 12) who withdrew early from the study (Figure 2.9). This
suggests that infection beyond five weeks is required for this immune response to
be detected and may be linked to larval entry into the gastrointestinal tract, which
occurs around this time. Total IgE response to all doses were relatively low, and
failed to show any significant differences between different doses (Figure 2.8),
which is again consistent with other reports 184;185;195;241.
2.5.4 Interpretation of results
All doses of larvae generated a maximal egg count of greater than 50 eggs/g
faeces, the apparent protective threshold observed in the studies in asthma. A
range of predominantly dose-related adverse effects of infection were reported.
The initial adverse effect in most participants was a localised pruritic skin reaction
at the site of larval entry, which began within a day or so of infection and typically
lasted for up to a week. In about half of participants the rash relapsed or recurred
at around two to three weeks after infection for up to 10 days, before settling
completely. This biphasic effect is likely to reflect the lag period required for the
immune system to mount a response to larval antigens deposited in the skin soon
after entry. The most troublesome adverse effects were gastrointestinal
symptoms, causing two participants to withdraw from the study. Abdominal
discomfort was the most common symptom but the severity appeared to be dose-
related and scores were mild and infection well tolerated among those who
received ten larvae. Other gastrointestinal symptoms such as diarrhoea occurred
sporadically with no obvious association with timing of infection or dose and may
have been unrelated to the infection. The other most commonly reported adverse
effect was malaise or fatigue, occurring between weeks six and seven after
infection. These symptoms occurred when eosinophil counts were at their highest
96
and may therefore have been indirect effects arising from systemic eosinophilia or
an eosinophilic gastroenteritis 259 rather than directly from the parasite.
A major concern in exploring the therapeutic potential of hookworm infection in
asthma, and indeed in other conditions, is the theoretical risk of adverse
pulmonary effects during the lung migration phase. For this reason people with a
history of asthma or with measurable bronchial responsiveness were excluded
from participating, and FEV1 and respiratory symptoms were monitored
throughout the study. There was no evidence of a clinically important change in
lung function, or of any dose-related effect on lung function. However, symptoms
of cough, breathlessness or wheeze were reported by three participants, all of
whom had received doses higher than ten larvae, during the first four weeks of
infection, the period during which lung migration occurs. These were minimal, with
cough troublesome in one participant over the course of one day, while the
reported wheeze and breathlessness were not prominent.
The findings on adverse effects demonstrated that of the four doses tested, ten
larvae was the dose best tolerated. However, whilst there was a rise in total IgE
and eosinophil levels in response to this dose of infection, the peak levels were
also less than with the higher doses, so it may be that this greater tolerability is
offset by a lesser effect in provoking a potentially beneficial anti-asthma host
immune response.
Iron deficiency anaemia resulting from chronic gastrointestinal blood loss is the
most important complication of hookworm infection in endemic tropical areas,
where infected individuals can carry high loads of worms and are subject to
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repeated infections over their lifetime 136. Anaemia was not apparent in this study,
and is unlikely to pose a problem with a low dose of infection given to well-
nourished adults with no other risk factors for anaemia such as pregnancy.
2.5.5 Conclusions
In conclusion, infection with a dose of ten N. americanus larvae generates at least
50 eggs/g faeces and this dose is well tolerated and elicits a modest host
eosinophilic and antibody response. Clinical trials of intentional infection with N.
americanus are feasible and a dose of ten larvae is for use in preliminary
therapeutic trials exploring the effects of N. americanus on moderation of the
allergic response in atopic individuals.
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Figure 2-1: Odds Ratios, adjusted for age and sex, of wheeze in individuals
with dust mite sensitisation, according to intensity of total parasite infection
(taken from Scrivener et al 58)
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Figure 2-2: Study design and allocation of participants
Completed study
and analysed
n=0
Enrolment
n=10
Allocated and received
25 larvae
n=3
Completed study
and analysed
n=3
Allocated and received
10 larvae
n=3
Withdrew from
study due to
gastrointestinal
symptoms
n=1
Withdrew from
study due to
gastrointestinal
symptoms
n=1
Allocated and received
50 larvae
n=3
Allocated and received
100 larvae
n=1
Completed study
and analysed
n=3
Completed study
and analysed
n=2
A
n
a
ly
si
s
E
n
ro
lm
e
n
t
A
llo
ca
tio
n
F
o
llo
w
-u
p
100
Figure 2-3: Median number of hookworm eggs/g faeces in the eight
participants who completed the study by dose of hookworm larvae
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Figure 2-4: Symptom scores for skin rash by dose of hookworm larvae
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Figure 2-5: Symptom scores for abdominal discomfort by dose of hookworm larvae
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Figure 2-6: Geometric mean total white cell counts in the eight participants
who completed the study by dose of hookworm larvae
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Figure 2-7: Geometric mean eosinophil cell counts in the eight participants
who completed the study by dose of hookworm larvae
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Figure 2-8: Geometric mean total IgE in the eight participants who
completed the study by dose of hookworm larvae
Figure 2-9: Geometric mean specific IgG by dose of hookworm larvae
0 1 2 3 4 5 6 7 8 9 10 11 12 13
0
200
400
600
800
1000
1200
1400
1600
1800
10 larvae
25 larvae
50 larvae
Week
Ig
G
(P g
/m
l)
0 1 2 3 4 5 6 7 8 9 10 11 12 13
0
25
50
75
100
125
10 larvae
25 larvae
50 larvae
Week
Ig
E
ti
tr
e
(I
U
/m
l)
105
3 INTERVENTION STUDY OF HOOKWORM IN
ALLERGIC RHINOCONJUNCTIVITIS
3.1 Introduction
Whilst there is some evidence that intestinal helminths, such as A. lumbricoides,
may exacerbate asthma symptoms 260;261 this does not appear to be a problem
with hookworm infection, which, as outlined in section 1.9.2, appears to be
protective 13. However, during the design phase of these intervention studies it
was considered important to ensure that larval migration through the lung
(typically occurring during the first four weeks after infection (described in section
1.8.1)) would be unlikely to exacerbate bronchial hyper-responsiveness before
proceeding to a trial of N. americanus infection in people with asthma. Safety
studies were felt to be required in view of bronchoscopic findings during this time
in normal volunteers who had received infection 195 and also because animal
studies have demonstrated a pronounced TH2 phenotype associated with this
phase of the lifecycle 262;263, indicating the possibility of exacerbation of clinical
disease. The study presented in this chapter was therefore designed as a safety
study to determine whether hookworm infection exacerbates bronchial
responsiveness during the phase of larval pulmonary migration in preparation for
a trial in people with asthma.
The airway inflammation that occurs in asthma may be present in people with
asthma but who have no symptoms, and may also occur in atopic individuals who
are not asthmatic, suggesting that the inflammation needs to reach a threshold in
order to trigger symptoms 264;265. People with allergic rhinoconjunctivitis and
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measurable bronchial responsiveness, but no clinical symptoms of asthma, are an
ideal population to study in order to observe whether there is an increase in
bronchial responsiveness during larval lung migration. This is because changes in
bronchial responsiveness can be measured, but they are unlikely to develop
clinically significant airflow restriction when exposed to potential
bronchoconstrictors.
The study comprised a randomised, placebo-controlled, double-blind trial of
hookworm infection in adults (18 years of age or older) with allergic
rhinoconjunctivitis and was the first of its kind to be carried out. Participants were
not eligible if they had clinical symptoms of asthma, but needed to have
measurable bronchial responsiveness to adenosine monophosphate (AMP) below
a threshold considered to be indicative of asthma. The main aim was to compare
the maximum change in bronchial responsiveness (using PD10AMP) during the
first four weeks after being randomised to receive ten hookworm larvae or
placebo. Secondary aims were to establish the side effect profile of infection with
ten larvae in a greater number of individuals using a similar questionnaire as in
the dose-ranging study. The study also sought to establish effects of ten larvae on
symptoms of allergic rhinoconjunctivitis using a Juniper RQLQ, the effect on
allergen skin sensitisation and to characterise the immune response to infection
over the 12 weeks after randomisation.
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3.2 Methods
3.2.1 Recruitment
Potential participants for the study were recruited using several methods.
Advertisements were placed in local newspapers and public places around
Nottingham, and on websites and notice boards throughout Nottingham City
Hospital and the University of Nottingham. Emails advertising the study were also
sent to members of staff at the University. The recruitment attracted a large
amount of media interest, and the investigators were also approached by
volunteers who heard about the study from interviews on local and national radio
and television. All people who expressed an interest in the study were contacted
by telephone or email and the background to the study, and what participation
would entail, were explained. A patient information sheet (Appendix B) was then
sent to people who remained interested.
Study visits were held at the University of Nottingham in the Department of
Respiratory Medicine. I was responsible for recruiting participants and conducted
all the study visits, including the screening visits, and measured all clinical
outcomes, thereby eliminating the possibility of inter-observer variability.
Recruitment took place during February and August 2006.
3.2.2 Eligibility criteria
3.2.2.1 Inclusion criteria
Participants needed to be aged 18 or over, to have current symptoms of
rhinoconjunctivitis at the time of screening and to have a positive allergen skin
test to at least one of cat fur, grass or D. pteronyssinus. They also needed to have
108
measurable bronchial responsiveness to AMP at the screening and randomisation
visits.
3.2.2.2 Exclusion criteria
Individuals were excluded if they had a history of severe allergic reaction or
anaphylaxis, or a diagnosis of asthma, or if they used asthma medication. If they
had signs of possible undiagnosed asthma or chronic obstructive pulmonary
disease when spirometry was performed (one-second forced expiratory volume
(FEV1) less than 80% predicted (compared with standard reference ranges
266) or
one-second forced expiratory volume/forced vital capacity (FEV1/FVC) ratio
consistent with airflow obstruction (>70%)) they were also excluded. Women who
were breastfeeding or pregnant or who were of child-bearing potential and not
using contraception were also excluded. Individuals were excluded if they had a
positive serum IgG against hookworm signifying previous hookworm infection or
positive faecal egg counts signifying current infection at the time of recruitment.
Those individuals whose blood tests revealed evidence of anaemia (haemoglobin
<13g/dl (male) <11.5g/dl (female), mean corpuscular volume <76fl) were
excluded from the study and referred to their General Practitioner for appropriate
investigation.
3.2.3 Screening visit
3.2.3.1 Initial consultation and consent
Volunteers who had been sent information sheets and who remained interested in
taking part in the study were contacted by telephone or email and a screening
visit was arranged once they were experiencing regular (that is, on most days
each week) symptoms of allergic rhinoconjunctivitis. At this screening visit, the
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study was explained in detail including the background rationale, the study
design, what recruitment would involve in terms of tests performed and the
required time commitment. The potential side effects of the hookworm infection as
listed in the daily diary were described but it was emphasised that the extent to
which they occurred, if at all, would vary between individuals. The processes of
blinding and randomisation were also described and any questions answered. A
brief medical history was taken, and volunteers were excluded at this stage if they
had significant medical problems, or if women were pregnant or of child-bearing
potential and unwilling to use contraception for the duration of the study. Written
informed consent was then taken with two identical consent forms completed: one
for the study records and one for the individual to retain for future reference
(Appendix C). Permission was gained to inform the individuals General
Practitioner of his or her recruitment into the study. A number of measurements
were then made to further assess eligibility and to collect data on baseline
characteristics and outcomes.
3.2.3.2 Medical history and baseline characteristics
A full medical history was taken including details of allergic symptoms and other
atopic disease, past medical history, use of medication and smoking status.
Baseline height and weight measurements were made. Urine analysis for ȕ-HCG
(QuickVue, Quidel Corporation, San Diego, USA) was performed to confirm that
female participants of child-bearing age were not pregnant.
3.2.3.3 Lung function and bronchial challenge
Individuals were instructed on peak expiratory flow measurement (PEF) using a
miniWright peak flow meter (European Union scale) (Clement Clarke
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International) and the best reading of three adequate attempts was recorded.
FEV1 and FVC were measured according to international guidelines
17 using a
Spirometer R model (Vitalograph, Buckingham, UK) and taking the higher of two
values within 100mls.
A bronchial challenge was performed to measure bronchial responsiveness to
adenosine monophosphate (AMP), which causes bronchoconstriction in people
with asthma but also in a proportion of people without asthma but with allergic
rhinitis 264;265. Two grams of AMP (Sigma-Aldrich Company Ltd, Dorest, UK) was
dissolved in 5mls of 0.9% sterile saline solution to form an initial solution with a
concentration of 400mg/ml and then further diluted to make a number of
increasingly less concentrated solutions 267;268 (See Appendix D for dilution
scheme).
A breath-activated compressed air dosimeter (MEFAR, Brescia, Italy) was used to
deliver each dose of AMP 265;269. Two mls of each concentration were dispensed
using a pipette into a dedicated nebule pot which had been calibrated by
delivering 100 breaths of saline with the dosimeter and weighing the pot in grams
(to 4 decimal points) to ensure delivery was consistent. For the AMP challenge,
an initial dose of 0.9% saline control was inhaled, followed by doubling doses
(DD) of AMP (Sigma Chemical Co, UK) dissolved in 0.9% saline from 0.115 to a
maximum cumulative dose of 944ȝM (Appendix E) from a breath-activated
dosimeter (MEFAR, Brescia, Italy) set to nebulise for 1 second with a pause of 6
seconds at a pressure of 152kPa. FEV1 was measured 2 minutes after each dose
267;268 and the inhalation challenge was stopped once FEV1 had fallen by 10%
from the post-saline baseline value, or the maximum dose of AMP had been
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inhaled 268. The provocation dose in adenosine monophosphate (AMP) required
to reduce one-second forced expiratory volume (FEV1) by 10% (PD10AMP) was
then calculated by interpolation between the two last doses on the log dose-
response scale 17. The initial intention was to use the PD20AMP measure for
bronchial responsiveness but during study recruitment, very few volunteers
demonstrated this degree of bronchial responsiveness and therefore the PD10
measure was adopted, since this was more easily demonstrable and is a strong
predictor of PD20
270.
According to guidelines, individuals were instructed to abstain from the following
prior to the bronchial challenge:
x antihistamines for 24 hours 79;
x steroid nasal sprays for 12 hours;
x caffeine-containing food and drink for 12 hours 17;
x strenuous exercise for 12 hours 271.
The bronchial challenge was not performed on anyone who had an FEV1 of less
than 40% predicted or a value of less than 1 litre, or who were pregnant 17.
3.2.3.4 Allergen skin sensitisation
Allergen skin sensitisation to D. pteronyssinus, cat fur, grass pollen and positive
(histamine) and negative (saline) controls (Diagenics Ltd, Milton Keynes, UK) was
measured by standard skin prick test methods as described in section 2.2.2.2.
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3.2.3.5 Blood samples
Venesection was performed and samples for Full Blood Count analysis
(haemoglobin estimation and differential cell counting) and serum albumin were
processed in the Nottingham City Hospital pathology department. Samples were
also taken for immunological testing which was carried out in the University of
Nottingham School of Pharmacy.
3.2.3.6 Immunological Methods
The immunology tests were all performed by collaborators in the School of
Pharmacy at the University of Nottingham. To assess the immune phenotype,
cytokine responses to infection were assessed following T-cell stimulation and
serological responses to the parasite were assessed by enzyme-linked
immunosorbent assay and Western blot; these data are only presented briefly,
and for the sake of completeness, in this thesis.
3.2.3.7 Faecal egg count methods
A faecal sample collected within the previous 24 hours was provided by
participants to confirm they did not have pre-existing hookworm infection. Faecal
samples were analysed within 24 hours of production by a scientist in the
Department of Immunoparasitology at the University of Nottingham School of
Pharmacy. If it was not possible to provide a fresh specimen, samples were
frozen by participants and defrosted prior to analysis to ensure that eggs did not
hatch prior to being counted. The methods for determining egg counts are
described in section 2.2.4.
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3.2.3.8 Juniper Rhinoconjunctivitis Quality of Life Questionnaire
An interviewer-administered Juniper Rhinoconjunctivitis Quality of Life
Questionnaire (RQLQ) was completed 272 to ensure that participants had current
symptoms and to obtain a baseline symptom score. This questionnaire asks
participants to recall their experiences of their symptoms over the previous two
weeks and provides a measure of health-related quality of life in clinical trials of
rhinoconjunctivitis. It looks at the effects of symptoms on seven different domains
(activities, sleep, constitutional disturbance, practical problems, nasal, eye and
emotional symptoms) using 28 questions and provides a composite score out of
168 (Appendix F). Higher scores signify a higher impact of symptoms on quality of
life. It has been validated to show moderate to strong relations between changes
in symptom diary scores and changes in RQLQ scores 273.
3.2.4 Run-in period and daily diary
Individuals who fulfilled the entry criteria at the screening visit then took part in a
run-in period lasting approximately two weeks. During this run-in period, and for
the duration of the study, participants were asked to complete a daily diary which
included a record of the parameters described below (Appendix G).
3.2.4.1 Peak expiratory flow
Participants were asked to record morning and evening PEF, measured as the
best of three attempts as another marker of airflow variability.
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3.2.4.2 Medication use
Participants were asked to abstain from using antihistamines and steroid nasal
sprays for the duration of the study as far as possible. Where occasional usage of
antihistamines was unavoidable (for example, due to exceptional circumstances
at work), participants were provided with a supply of loratidine 10mg tablets to
standardise the antihistamine used, and were instructed to record use in their
daily diary; symptoms on that day were subsequently discounted from analysis. A
small proportion of participants requested to take antihistamines on a daily basis
due to the severity of their symptoms; these participants were asked to substitute
their usual medication with loratidine 10mg taken once daily for the duration of the
whole study period. Similarly, one participant elected to take a daily steroid nasal
spray throughout the entire study. Participants were asked to record use of any
medications in their daily diary.
3.2.4.3 Adverse symptoms
Participants were asked to assign a score using a visual analogue scale from 0
(no symptoms) to 10 (maximum possible severity of symptoms) for a range of pre-
determined possible adverse effects due to the hookworm, including local skin
reactions at the site of infection (redness and itching), gastrointestinal symptoms
(nausea, indigestion, abdominal pain, diarrhoea, wind), respiratory symptoms
(cough, wheeze, breathlessness) and constitutional symptoms (tiredness). It was
not possible to identify an appropriate and previously validated questionnaire for
use in the study. These particular symptoms have all been reported to occur in
conjunction with hookworm infection and were reported in the dose-ranging study
184;194;195;274. In addition, a space for free text was included in the diary for the
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recording of any other symptoms which the participants felt might be relevant (for
example change in eczema severity).
3.2.5 Randomisation visit
3.2.5.1 Clinical measurements
After the two week run-in period, participants were seen for the randomisation
visit. The bronchial challenge was repeated, the Juniper RQLQ was completed
and blood tests were taken for the same tests as at the screening visit. If any of
the eligibility criteria were no longer fulfilled, then the individual was not
randomised into the study.
3.2.5.2 Randomisation
Eligible participants then underwent double-blind randomisation to hookworm
infection or placebo, allocated in blocks of four according to a computer-
generated random code. Larval culture was performed by scientists based in the
Department of Immunoparasitology in the University of Nottingham School of
Pharmacy, as described in section 2.2.3.3. The solutions were administered by a
different member of the research team who was not involved in any of the study
measurements. The medical statistician responsible for randomisation was given
two sealed eppendorfs: one containing 200ȝl water into which had been counted
out 10 purified L3 N. americanus larvae by direct visualisation (active infection);
the other containing 200ȝl histamine dihydrochloride solution (1.7mg/ml)
(placebo). Histamine solution was chosen as a placebo solution in the study for
the following reasons. First, it is used for allergen skin sensitisation tests and is
therefore safe for cutaneous application. Second, it has the same visual
appearance as the solution containing the larvae and third, it causes similar
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immediate cutaneous effects as the larvae, namely itching and a red rash at the
site of application. Depending on the randomisation code, the participant was then
either infected with the larvae or, using the same technique, given the placebo.
The larvae were pipetted on to a piece of gauze measuring 2cm2 which was then
inverted on the ventral surface of the recruits non-dominant forearm. A water-tight
adhesive dressing (sleek, BSN medical Ltd, Hull, UK) was applied over the top
and pressed over the skin so that it sealed on all edges. Study participants were
told to avoid getting the plaster wet and to leave it in place for 24 hours, after
which time it could be removed and placed in a universal container containing
70% ethanol (with which they were provided). They were also given one tablet of
albendazole 400mg to take home in case they should want to withdraw from the
study at any time. Participants were provided with a 24-hour contact telephone
number in case of any problems or questions relating to the study. Randomisation
codes were placed in a sealed envelope in the department laboratory in case of a
medical emergency which might require the participant to withdraw from the study
and to be unblinded immediately.
3.2.5.3 Blinding
Various steps were taken in order to try and ensure participants were blind to
randomisation code. At the time of consent, they were told that they could expect
a degree of cutaneous itching and rash with both infection and placebo but the
extent of which would vary between individuals. They were also told to keep the
plaster on their arm for 24 hours after randomisation so that when it was removed
the most intense phase of the rash had subsided. In addition, the variation in the
extent to which individuals experienced side effects of infection (as listed in the
daily diaries) was emphasised to reduce the importance the individuals placed on
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the presence or absence of these symptoms. Steps were also taken to ensure
that I, the clinician conducting study visits (and therefore responsible for making
study protocol measurements and performing data analysis), remained blind to
the treatment allocation. At randomisation, the solutions were administered by an
independent member of the research team not involved in any of the study
protocol measurements. If participants had questions or concerns during the
study about any symptoms they were told to discuss these only with an
independent member of the research team (and were provided with 24-hour
contact details for this person). They were also asked to cover their forearms at
the site of application of the treatment solution for the first six weeks of the study
during visits, in case of the presence or absence of a visible rash. During the
study, Full Blood Count results were seen only by the trial medical statistician and
were checked and entered into a spreadsheet. At the end of the study, the trial
medical statistician or another independent researcher unblinded the participants
and, where appropriate, gave them the mebendazole tablets. Any visits
conducted after the participant had been unblinded (for checking of eosinophil
counts or collecting faecal samples) were arranged by another clinician who was
not otherwise involved with the study and were carried out without my knowledge.
3.2.6 Follow-up visits
After randomisation, participants attended study visits every week for four weeks
to cover the phase of lung migration (which typically occurs at between days 8
and 21 195), then every two weeks for a further eight weeks, until they had been in
the study for a total of 12 weeks post-randomisation (Figure 3.1).
118
At each study visit, the bronchial challenge to measure PD10AMP was performed,
the Juniper RQLQ was completed and venous bloods were taken for the same
tests as at the screening visit. Participants were asked to provide a faecal sample
less than 24 hours old to confirm establishment and survival of the adult
hookworms in the gastrointestinal tract of those in the treatment arm of the study
and to quantify egg burden 274. Finally, their daily diaries and symptom cards were
collected and participants were issued with new diaries and cards to last until their
next study visit.
3.2.7 Final visit
At the week 12 visit, in addition to the usual tests and measurements outlined
above, the allergen skin sensitisation testing was repeated, participants were
weighed and the female participants had a further urinary pregnancy (ȕ-HCG)
test.
Participants were then asked by an independent member of the research team
whether they thought they had received placebo or hookworm and to justify their
response, before being unblinded. If they had received placebo, no further follow-
up was arranged. Those in the hookworm group were provided with a course of
mebendazole tablets 100mg to be taken twice a day for three days in order to
eradicate the infection. This dose of mebendazole was found to be efficacious in
the dose-ranging study 274. Those participants who chose to take the tablets were
followed-up fortnightly and faecal egg counts and blood eosinophil counts were
checked until egg counts were zero and eosinophils had returned to within 0.2
x109/litre of their screening value, or to within normal reference ranges, on two
successive occasions.
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Those with hookworm infection but who chose not to take the tablets were given
written information outlining the potential risks (albeit minimal) of long-term
hookworm infection, namely anaemia and endomyocardial fibrosis. They were
also told to inform the blood transfusion service before donating blood in the
future and were advised that mebendazole was contraindicated in pregnancy and
breastfeeding (Appendix H). These participants were asked to sign two copies of
a document to show that they understood the risks of infection and that they
declined at that time to take the mebendazole tablets; one copy was retained by
the participant, the other was filed in their records. No further follow-up was
arranged for these participants.
3.2.8 Trial monitoring committee
All members of the trial monitoring committee were based at the University of
Nottingham and so were easily contactable at any time. The committee
comprised:
x Reader in Primary Care (chair);
x Professor of Medical Statistics in the Division of Epidemiology and Public
Health;
x Professor of Respiratory Medicine at Nottingham City Hospital;
x Senior Lecturer/Consultant in Respiratory Medicine at Nottingham City
Hospital.
Data on the adverse effects and haemoglobin, eosinophil and albumin levels were
monitored every week as the study progressed by the trial statistician, who was
aware of the randomisation codes. After discussions between the study
investigators and monitoring committee, the following parameters were set as a
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priori indicators of when the committee was to be informed immediately of
abnormal results:
x fall in haemoglobin by 2g/dl from baseline or to less than 10g/dl;
x fall in albumin by more than 5g from baseline;
x fall in baseline FEV1 by 20% from baseline;
x change in PD10AMPby greater than 2 doubling doses;
x any other serious adverse events or symptoms of concern to either the
participant or investigators on review of diary cards.
A decision would then be made by the committee, independent of the study
investigators, as to whether the participant in question needed to be withdrawn
from the study.
3.2.9 Ethical approval
The original study protocol and subsequent amendments were approved by the
Nottingham Research Ethics Committee and by the Research and Development
department at the Nottingham University Hospitals NHS Trust. The Medicines and
Health Regulatory Association was also informed of the studies and did not
require additional specific documentation to be completed, as hookworm was not
considered to be a medicine or drug at that time. The study was registered with
the Clinical Trials register (http://clinicaltrials.gov/ (trial reference NCT00232518)).
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3.3 Data Analysis
3.3.1 Data entry and checking
All the results were entered on to a spreadsheet (Microsoft Excel (2007)), cross-
checked for any discrepancies and then imported into SPSS version 14.0 (SPSS
Inc., Chicago, IL). SPSS was used for all the data analyses (unless otherwise
stated). I carried out all the data analyses (including entry of data and data
manipulation) blind to randomisation code.
3.3.2 Primary outcome
3.3.2.1 Computation of primary outcome variable
The primary outcome was maximum change in PD10AMP over the first four weeks
following randomisation. After entry into the study, participants who did not
demonstrate a fall in FEV1 of 10% with the maximum dose of AMP (944ȝm) were
assigned values of 944ȝm for analysis.
The equation for calculating PC20 (provocation concentration required to reduce
FEV1by 20%)
17 was extrapolated to calculate the PD10AMP:
where
C1 = penultimate AMP dose
C2 = final AMP dose
R1 = % fall in FEV1 after C1 from saline baseline
R2 = % fall in FEV1 after C2 from saline baseline
PD10 = anti log [LN (C1) + ((LN (C2)  LN (C1)) x (10-R1)/(R2-R1)]
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PD10AMP were calculated on two separate occasions for each study visit,
including the screening visit, and the two values obtained were cross-checked to
ensure they were identical. Where there was a discrepancy, the values were
recalculated by an independent researcher. On each occasion, the independent
researchers calculation correlated with one of the first values obtained and this
estimate of PD10AMP was therefore assigned for the visits.
To determine the primary outcome, first the lowest value obtained over the first
four weeks after randomisation was identified. PD10AMP values were not normally
distributed but could be transformed by taking the natural logarithm of each value.
The maximum change in PD10AMP over the first four weeks after randomisation
was then calculated for each participant as the difference between the natural
logarithm of the lowest PD10AMP value in the first four weeks and the natural
logarithm of the PD10AMP from the randomisation (week 0) visit. The result was
transformed into a doubling dose by dividing by the natural logarithm of 2 to
obtain the final outcome variable which does follow a normal distribution.
A positive value represented an increase in PD10AMP (that is, reduced bronchial
responsiveness, so an improvement) and a negative value represented a fall in
PD10AMP (that is, increased bronchial responsiveness, a deterioration).
The original intention had been to define the baseline measurement as the mean
of the two pre-infection values (screening and week 0). However, due to the
learning process observed in performing the bronchial challenge, there were
Change in PD10 = ln(lowest PD10AMP in first 4 weeks)  ln(baseline PD10AMP)
in doubling doses ln2
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concerns that the values obtained at the screening visit were not reliable and
therefore the week 0 values were used as the baseline for the primary analysis.
The results using the mean of screening and week 0 values as baseline were also
computed for comparison.
3.3.2.2 Statistical analysis of primary outcome variable
The final change in PD10AMP variable was normally distributed and compared
between the two intervention groups by computing means and the mean
difference (with 95% CI), and an independent samples t-test was performed to
assess statistical significance. Multiple linear regression was used to adjust,
where necessary, for any baseline differences in demographics. Using SPSS
version 14.0 (SPSS Inc., Chicago, IL), Levenes test was used to check for
equality of variances and appropriate adjusted results were used if there was
evidence of unequal variances.
3.3.3 Secondary outcomes
A variety of secondary outcomes were measured. In addition to the primary
outcome PD10AMP, PEF variability was used to assess safety during the larval
phase of lung phase over the first four weeks after randomisation. Change in
allergen skin sensitisation and the Juniper RQLQ were used to assess the impact
on allergic disease severity over the whole 12 week study period. The tolerability
of infection was assessed both over the whole period and different high risk
periods by measuring a range of symptoms potentially due to the infection. Finally
immunological parameters were measured over the 12 week study period to
identify the extent to which the infection had an impact on the immune system.
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3.3.3.1 PEF variability
PEF variability during the first four weeks after infection was computed as the two-
lowest percentage mean (mean of the two lowest PEF values during this period
as a percentage of the period mean), which has been shown in a comparison
paper to be the best performing PEF variability index 275. The final variable for
analysis was the two-lowest percentage mean for the first four weeks of the study;
with the values close to 100% signifying less variability and therefore less airway
lability.
Two-lowest % mean =
mean of lowest two readings in period
x 100 %
period mean
3.3.3.2 Quality of Life Scores
The Juniper Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
questionnaire 272 was completed using a Microsoft Access 2007 database and the
results were imported into SPSS version 14.0 (SPSS Inc., Chicago, IL). An
allergic symptom score out of 168 was recorded for each visit by summing
individual symptoms recorded on the Juniper RQLQ. The scores were logged to
achieve a normal distribution and then summarised over the 12 week study period
using area under the curve (AUC) (GraphPad prism 4, GraphPad Software Inc.,
San Diego, CA) to obtain the final variable for analysis.
3.3.3.3 Allergen skin sensitisation
Change in allergen skin sensitisation was computed for each allergen using the
same method as described in section 2.3.3.3.
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3.3.3.4 Adverse Symptoms
For each adverse effect potentially attributable to the hookworm infection, the
mean daily score was computed for both the whole 12 weeks and also a pre-
determined high-risk period chosen as the period during which time the
symptoms were predicted to be most likely to occur. This was to ensure that the
magnitude of effect of important adverse symptoms was not diluted by averaging
over the full 12 weeks of the study. These periods were days 1 to 21 (for localised
skin reactions as observed in the previous study) 274, days 1 to 28 (for respiratory
symptoms coinciding with the period of larval lung migration in the hookworm
lifecycle) 127, and days 29 to 70 (for gastrointestinal symptoms and tiredness
correlating with the period of elevated eosinophil counts which can result in an
eosinophilic gastroenteritis) 259.
3.3.3.5 Statistical analysis of secondary outcome variables
The PEF variability, Juniper RQLQ scores and allergen skin sensitisation
variables were normally distributed and the mean values for the two intervention
groups were therefore compared using the independent samples t-test with
multiple linear regression to adjust where necessary for any baseline differences
in demographics. The equality of variances was checked using Levenes test in
SPSS version 14.0 (SPSS Inc., Chicago, IL) and appropriate adjusted results
were used if there was evidence of unequal variances. The adverse symptom
score variables were not normally distributed and could not be transformed and
so medians were used as the summarised averages and the non-parametric
Mann-Whitney U test was used to compare the two intervention groups.
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3.3.4 Sensitivity analysis
Two sensitivity analyses were performed.
the PEF analysis was repeated excluding any participants who had provided less
than 75% of potential readings during the first four weeks;
the Juniper RQLQ analysis was repeated excluding participants who had used
antihistamines more than three times per week (unless used daily).
3.3.5 Other outcomes
3.3.5.1 Haemoglobin and albumin
Haemoglobin and albumin levels were monitored as the study progressed by the
trial statistician to ensure participants did not become anaemic or show signs of
becoming malnourished. At the end of the study, change in haemoglobin and
albumin levels were computed as the difference between week 12 and baseline
values. In addition, the net change in weight of each participant was calculated as
the difference between the weights at the week 12 visit and screening visit.
3.3.5.2 Markers of hookworm infection
Eosinophil counts and faecal egg counts were monitored at regular intervals
during the study as described and used to confirm presence of infection in those
who received hookworm infection.
3.3.5.3 Immunological parameters
The immunology tests were performed by collaborators in the University of
Nottingham School of Pharmacy and the results are included here for
completeness. Levels of total IgE, parasite-specific IgG, interleukins IL-10 and IL-
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regulatory cells were measured at each study visit. Each time point was plotted
and the AUC computed as a summary measure for each individual. If the AUC
values were normally distributed, the mean value for AUC was then calculated for
the hookworm and placebo groups and the groups compared using the
independent samples t-test; otherwise the groups were compared using the non-
parametric Mann-Whitney U test.
3.3.6 Sample size and power calculation
The primary objective was to detect an increase in bronchial responsiveness,
which was defined a priori to be one doubling dose or more in magnitude, in the
active group, relative to the placebo group, over the first four weeks of the study.
This time period correlates with the lung phase of migration of the stage L3
larvae. With a sample size of 30 (15 in each group) the study would have
approximately 80% power to detect a difference of this magnitude in the
maximum fall in PD10AMP between active and placebo groups, assuming a
similar repeatability to that reported for PD20AMP
267;268.
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3.4 Results
3.4.1 Participant flow
Thirty people were randomised to the study: 15 were randomised to active
hookworm infection and 15 to placebo (Figure 3.2). Three participants withdrew
from the study and were subsequently unblinded: one from the placebo group on
day 6, due to an inter-current viral illness; one from the hookworm group on day
12, after becoming pregnant despite a negative pregnancy test at entry into the
study and use of contraception; and one from the hookworm group on day 40,
due to abdominal pain and diarrhoea, who was treated with mebendazole to
eradicate the infection. The participant who withdrew because of pregnancy kept
the infection and completed an otherwise uneventful and successful pregnancy.
Four participants were unable to attend the week 12 visit and were seen at the
earliest possible occasion thereafter which for three of the four was during week
13, and for the fourth was day 112 (during week 16).
3.4.2 Baseline characteristics of participants
There were more current smokers in the placebo group, but otherwise the
demographic characteristics of the two groups were similar (Table 3.1). 60% of
participants in each group were male, and all were Caucasian with the exception
of two participants in the hookworm group. Participants were relatively young, with
mean ages of 30.3 (SD 8.97) (hookworm group) and 33.2 (SD 8.82) (placebo
group). Exclusion of data from the participants who withdrew early from the study
did not appreciably change the overall demographic characteristics of the two
groups.
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3.4.3 Primary outcome
Data on bronchial responsiveness over the first for 4 weeks following
randomisation were available for 28 participants. The mean of the maximum fall in
PD10AMP during this period was slightly greater in the hookworm group than the
placebo group (-1.67 and -1.16 DD respectively), but the difference between the
groups was small (-0.51 DD, 95% CI: -1.80 to 0.78 DD) and not statistically
significant either before or after adjusting for the baseline difference in smoking
status (p=0.42 and p=0.34 respectively, Table 3.2). The individual greatest falls,
or if no fall, then the smallest improvement, ranged from -5.55 to 0.81 DD in the
hookworm group and -4.26 to 1.47 DD in the placebo group.
3.4.4 Secondary outcomes
3.4.4.1 Peak expiratory flow variability
Peak flow variability over the first four weeks was slightly less (i.e. closer to 100%
which means no variability) in the hookworm group (mean 92.31% (SD 3.73%))
compared with placebo (mean 89.30% (SD 6.70%)), but not significantly so
(adjusted mean difference 3.62%, 95% CI: -0.66 to 7.90%; p=0.09) (Table 3.2).
Two participants did not complete 75% of their PEF recordings; excluding them
from the analysis had little impact on the results (adjusted mean difference 3.70%,
95% CI: -0.99 to 8.39%; p=0.12).
3.4.4.2 Allergen skin sensitisation
The size of wheal increased on average in both hookworm and placebo groups
for grass (mean change over study period = 0.73mm and 0.11mm respectively)
and D. pteronyssinus (1.27mm and 0.54mm respectively) allergens and reduced
in both groups for cat fur (-0.27mm and -0.75mm respectively). There was no
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significant difference between the two intervention groups in change in the
magnitude of the wheal response to any of the individual allergens tested (table
3.3).
3.4.4.3 Allergic rhinoconjunctivitis symptoms
The hookworm group reported higher scores for the Juniper RQLQ over the 12
week study period than the placebo group (mean log AUC 6.01 (SD 0.82) vs. 5.68
(SD 0.85)), but again this difference was small and not statistically significant
either before or after adjustment for smoking and baseline score (adjusted mean
difference 0.26, 95% CI: -0.45 to 0.97; p=0.46 (table 3.3)). There was also no
difference between the two groups after excluding the seven participants who had
used antihistamines on more than three occasions in a one week period (unless
taken daily; adjusted mean difference 0.42, 95% CI: -0.49 to 1.32; p=0.34).
3.4.4.4 Adverse effects
Table 3.4 shows the reported symptom scores for the potential adverse effects
attributable to hookworm. Both localised skin itching and redness were
significantly higher in the hookworm compared with the placebo group, and
differences were even greater during the high risk period (difference in medians
for mean daily score for itching 1.12 (p=0.001) and redness 1.02 (p<0.001))
(Figure 3.3). These symptoms peaked in the hookworm group in the first week
with some participants experiencing a second, less marked peak in week 2. For
the non-skin symptoms, there was more of a range of different participant
experiences, with many reporting mean daily scores of zero (i.e. no symptoms).
Scores tended to be higher in the hookworm than the placebo group, but the
magnitude of the differences was fairly small. A significant difference was seen for
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indigestion (difference in medians 0.1, p=0.03) during the high risk period, and a
borderline significant effect was seen for abdominal pain (difference in medians
0.48, p=0.06). Breathlessness was also higher in the hookworm group but not
statistically so, and during the high risk period this difference was even less
marked. Notably, there was no difference between the two groups for the other
respiratory symptoms (Table 3.4).
3.4.5 Other outcomes
3.4.5.1 Effect on eosinophil levels
Twelve of the 13 participants in the hookworm group who completed the study
had a rise in eosinophil counts, which typically started between 21 and 28 days
after infection and reached a peak at weeks 6 to 8 (days 42 to 56), with maximum
counts ranging from 1.53 x109/litre to 9.70 x109/litre (Figure 3.4). All eosinophil
counts decreased after this time but had not returned to baseline values by the
end of the study at week 12 (day 84). The change in eosinophil counts was
reflected by a rise in total white cell counts, which also peaked during this time
with a maximum eosinophilia (eosinophil count as a percentage of total white cell
count) ranging between 21% and 60% (normal range 1% to 5%). No change was
seen in numbers of any other leucocyte type. There was no rise in the eosinophil
counts in any of participants in the placebo group.
3.4.5.2 Other clinical parameters
All participants had haemoglobin and albumin levels within the normal ranges at
entry into the study. No clinically important falls in haemoglobin were seen in
either group, with the maximum fall in haemoglobin from baseline being 1.4g/dL in
the hookworm group and 0.8g/dL in the placebo group (Figure 3.5). Similarly,
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there was no suggestion of any significant changes in serum albumin levels, with
the greatest fall from baseline being 7g/dL in both groups, to a minimum of 36g/dL
and 31g/dL in the hookworm and placebo groups respectively. There were no
clinically important changes in participants weight during the study.
3.4.5.3 Immunology results
The immunology tests were performed by collaborators in the University of
Nottingham School of Pharmacy and the results are included here for
completeness. In those who received hookworm, a significant increase was seen
in parasite-specific IgG from week 8 onwards (Figure 3.6); this was confirmed
using Western blot. There was a non-significant fall in production of the pro-
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detection of appearance of eggs and may suggest a degree of regulation by
mature hookworm in the gut (Figures 3.7, 3.8). Otherwise, there was no
significant change in total IgE levels, number of T-lymphocytes (absolute numbers
or relative percentage of T-regulatory cells) or IL-10 or IL-13 production (Figures
3.9-3.13) 276.
3.4.5.4 Confirmation of hookworm infection
Eggs were found in faecal samples of nine participants out of the 13 completing
the study in the hookworm group, appearing at either week 6 (six people) or 8
(three people) after infection. The presence of these eggs was confirmed by
culturing faecal material obtained at week 12 to detect presence of infective
larvae. Three of the four participants in the hookworm group with negative faecal
samples had a rise in their eosinophil count (peaks of 3.3-9.6 x109/litre), implying
that the hookworm larvae had reached the bowel and successfully developed into
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adult worms. In all nine participants with positive samples, more than 50 eggs/g
faeces were found on each occasion. Eggs were not seen in any participants in
the placebo group. Repeating the primary outcome analysis after excluding the
four participants without eggs in their faeces yielded similar results (mean change
in PD10AMP for hookworm group -0.62 DD: adjusted mean difference -0.81 DD,
95% CI: -2.12 to 0.51 DD). In addition, a rise in eosinophil count (section 3.4.5.1)
was also used to confirm the presence of establishment of adult worms in the
duodenum.
3.4.6 Assessment of participant blinding
Before being unblinded at their final study visit, participants were asked if they
thought they knew whether they had received hookworm or placebo infection. Of
the 14 individuals in the placebo group who completed the study, three correctly
thought they had received placebo, five thought they had received hookworm, and
six did not know. Of the 13 with hookworm infection who completed the study,
eight correctly thought that they had received hookworm, two thought they had
received placebo, and three did not know.
3.4.7 Post study follow-up
All participants who received hookworm were provided with mebendazole at the
end of the study to eradicate the infection. Eleven of the 13 participants who
completed the study chose not to take the treatment, citing either a perceived
improvement in hay fever symptoms, or that they wished to see if they had an
improvement in symptoms the following year. In accordance with the protocol,
participants in the placebo group were offered hookworm infection at the end of
the trial, of whom 11 chose to be infected. These individuals were provided with
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an information sheet outlining the adverse symptoms reported in the dose-ranging
study (Appendix I) and were asked to sign three copies of a consent form, one for
the study records, one for their General Practitioner and one for them to retain.
They were provided with a contact telephone number to use in case of a question
or problem relating to the study, but were otherwise asked to see their General
Practitioner if they had concerns regarding the infection in the future.
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3.5 Discussion
3.5.1 Summary of findings
This is the first reported randomised placebo-controlled double-blind study of
hookworm infection in people with allergic disease. The study was designed
primarily as a safety study to determine whether hookworm infection exacerbates
bronchial responsiveness during the phase of larval pulmonary migration in
preparation for a trial in people with asthma. A dose of larvae was used which
was shown in the dose-ranging study (Chapter 2) to be well tolerated and to result
in an infection intensity of over 50 eggs/g faeces, the level associated with a
reduced risk of wheeze in a previous observational study 58. Participants with
allergic rhinoconjunctivitis and measurable bronchial responsiveness, but without
clinical asthma, were chosen 277 to enable evaluation of an increase in bronchial
responsiveness in the active treatment group while minimising the risk of serious
clinical exacerbation of asthma.
The study found no evidence of a clinically important increase in bronchial
responsiveness during the first four weeks following infection, which corresponds
to the period of larval lung migration. The mean of the maximum fall in PD10AMP
during this period was slightly greater in the hookworm group than the placebo
group (-1.67 and -1.16 DD respectively), but the difference between the groups
was small and not statistically significant after adjusting for the baseline difference
in smoking status (-0.51 DD, 95% CI: -1.80 to 0.78 DD; p=0.34). Similarly, there
was no clinically important difference between the two groups in change in PEF
variability. In addition, though only designed and powered to detect effects on
bronchial responsiveness, the study also provided an opportunity to explore the
136
effect of infection on rhinoconjunctivitis symptom severity and allergen skin
sensitivity. No clinically important differences between the two groups were found
for either allergen skin sensitisation test or Juniper RQLQ scores over the course
of the study.
Participants were also monitored for any symptoms potentially attributable to the
hookworm infection. The infection was generally well tolerated, with only one
participant withdrawing from the study as a result of adverse symptoms. The
majority of people who received hookworm reported a pruritic erythematous rash
at the site of infection. Gastrointestinal symptoms were also commonly reported,
occurring around six weeks after infection.
3.5.2 Strengths and weaknesses
3.5.2.1 Measurement error
During the screening visits it was observed that certain participants took some
time to learn how to use the dosimeter properly, resulting in unreliable screening
measurements of their bronchial responsiveness. This would not have been
affected by the group to which they had been randomised, however, to try and
minimise the impact of this measurement error, week 0 results were chosen as
the baseline measurement for the primary analysis but the results are also
presented using the mean of the screening and week 0 values as baseline, as per
protocol (Table 3.2). In the hookworm group, the mean value of the primary
outcome variable, maximum fall in PD10AMP, was similar using the two different
definitions for baseline, but this was less so in the placebo group where the mean
value was lower when the definition included the screening data (-0.62 DD) than
when based on week 0 data alone (-0.16 DD; Table 3.2). Further exploration
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revealed that this discrepancy was primarily due to one individual who responded
rapidly to AMP at screening and thus had a very low value, but who had a much
higher value at week 0. Exclusion of this participant from the analysis resulted in a
similar estimated mean difference between hookworm and placebo groups
regardless of baseline definition (-0.51 DD using week 0 as baseline and -0.55
using mean of screening and week 0).
Allergic rhinoconjunctivitis is a particularly difficult condition to study in view of the
variability of symptoms from week to week and year to year. This study was not
designed to look at the effect of infection on allergic rhinoconjunctivitis, but given
that the participants had symptoms at the time of enrolment, the opportunity was
taken to see if there were any changes in symptoms over the course of the study.
Symptoms were measured using the Juniper RQLQ which is well validated to
show moderate to strong relations between changes in symptom diary scores and
changes in RQLQ scores 273 but no other measures of allergic rhinoconjunctivitis
disease activity were included in the study design. It is therefore possible that
infection did have an effect on participants symptoms of allergic
rhinoconjunctivitis but because of the limited methods used, it was not detected.
There is also the possibility of measurement error when evaluating the occurrence
of adverse symptoms of infection. No validated questionnaire was available to
record the presence of adverse symptoms of infection and so a diary, based on
the symptoms reported by other reports of experimental hookworm infection and
symptoms reported in the dose ranging study was instead used. However, as
described in section 2.5.2.1 there is likely to be variation between participants in
their definition of symptoms and in their perception of severity of symptoms.
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Blood samples were all measured using automated mechanisms used regularly in
the laboratories and are subject to regular quality control; as such the
measurement error in these results should have been minimal.
3.5.2.2 Success of blinding and bias
Blinding in a clinical trial is important to try and reduce reporter and observer bias,
especially for outcomes which are subjectively measured and so particularly
susceptible to differential bias. Objective measures were used for the majority of
outcomes, including the primary outcome, in this trial and therefore theoretically
should not have been subject to bias even if the participants or clinician carrying
out the study visits had correctly deduced the treatment allocation. The
procedures adopted to ensure that participants and clinical investigators remained
blind to treatment allocation were successful for the investigator, and
predominantly so for participants. Most of those participants who did correctly
guess their treatment allocation were in the active treatment group, and usually
based their judgment on seeing entry portals on their arm when the plasters were
removed 24 hours after infection, or the presence of gastrointestinal disturbance
at a later stage. The histamine solution used as a placebo did cause local redness
and itching, as reflected in the adverse symptoms scores, but these symptoms
lasted for a shorter period than those attributable to hookworm. Despite the fact
that some participants were aware of the treatment to which they had been
randomised, it is unlikely that they would have been aware of how to influence the
primary outcome results. In theory, observer bias may have been slightly harder
to overcome as, for example; the bronchial challenge tests are not truly objective
in that a degree of judgement is involved in carrying out the test and recording the
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results. However, the investigator carrying out study visits remained successfully
blind to treatment allocation and thus observer bias should have been minimal.
If participants had correctly guessed the intervention to which they had been
allocated, it could have resulted in reporter bias, particularly for the two trial
outcomes which were subjective. First, participants may have under-reported the
impact of their allergic rhinoconjunctivitis symptoms in completing the Juniper
RQLQ if they thought they had received infection. However, several participants in
the placebo group also thought they had infection and may also have under-
reported symptoms. Second, adverse symptoms potentially attributable to
infection were also measured subjectively and were therefore subject to reporter
bias if participants correctly guessed the intervention group to which they had
been allocated. This is most likely to have resulted in over-reporting of symptoms
in people who thought they had received hookworm and possible under-reporting
of symptoms in those who believed they had received placebo. Despite this, the
reported adverse effects were broadly similar to those previously reported, again
suggesting little effect, if any on the results. For example, the cutaneous rash
peaked in the hookworm group in the first week with some participants
experiencing a second, less marked peak in week 2 274.
3.5.2.3 Success of infection
Hookworm infection was confirmed by the presence of eggs in faeces for nine of
the infected group; of the other six participants randomised to hookworm, two
withdrew before eggs were expected to be seen in faeces, and three
demonstrated increases in eosinophil counts similar to those with proven
infection, suggesting that they were actively infected but with same-sex organisms
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or non-fecund females. It therefore appears that the infection process failed in
only one participant in the hookworm group, in whom there was no evidence of
active infection. Excluding this individual or all participants with negative egg
counts from the analyses had no material impact on the findings of the study.
3.5.2.4 Representativeness and loss to follow-up
The entry criteria for this study were fairly strict, requiring people to have regular
symptoms of hay fever and measureable bronchial responsiveness and being
willing to commit to regular study visits over the course of four months. People
volunteering to take part in a study of experimental hookworm infection are as
such unlikely to be representative of the population in general; however, there is
no reason to suspect that any such differences would interact with the clinical
effect of hookworm infection and impact on the trial results. It is therefore
reasonable to assume that the results are likely to be generalisable.
Three participants withdrew from the study, two for reasons unrelated to the
study, and one as a result of developing gastrointestinal symptoms. There is no
evidence that these individuals were experiencing different effects from the other
participants on the primary outcome (such as greater changes in PD10AMP) and
other than the one individual with gastrointestinal symptoms, on the secondary
outcomes. It is therefore unlikely that the results of the study would have been
significantly different had these participants remained in the trial.
3.5.2.5 Statistical power
The sample size of the study was small (n=30) and the power calculation was
based on the primary outcome. Three participants withdrew from the study, and
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so the final analysis was performed on 27 individuals which resulted in a slightly
smaller sample size than planned and reduced power. The effect on power is
likely to be minimal as the number of participants withdrawing was small, but
there is still a possibility that an adverse effect on PD10AMP was missed as a
result. Regardless, the confidence intervals suggest that there is unlikely to have
been a true large effect of infection. In addition to the effects on primary outcome,
it is also possible, that a difference between the two groups may have existed for
some of the secondary outcomes, such as symptoms of allergic
rhinoconjunctivitis, but the study was not powered to show this difference.
3.5.2.6 Confounding and success of randomisation
The process of randomisation was generally successful in that the baseline
characteristics of two groups were similar with the exception of smoking status.
Data were collected on several different potential confounders at baseline and
were accounted for in the data analyses as appropriate. However, given the small
sample size, there may still be differences between the two groups in
unmeasured confounders which could have had an impact on the results.
3.5.3 Results in context of other studies
Although there is some observational evidence suggesting that allergic
rhinoconjunctivitis is less common in individuals infected with intestinal parasites
223, and specifically E. vermicularis 227, the majority of studies have shown little
convincing evidence of a significant association 207;224-226. One possible
explanation for this is that different species may exert different effects and the
studies have mainly been carried out in areas of endemic A. lumbricoides
infection. Previous intervention studies with hookworm in allergic
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rhinoconjunctivitis until recently were limited to an early anecdotal report, which
described an improvement in hay fever symptoms after self-infection with
hookworm 241; and an eradication study in Vietnam in an area where hookworm
was endemic, which found no effect of anti-helminth treatment on symptoms of
allergic rhinoconjunctivitis 243. Since the studies reported in this thesis were
carried out, a Danish group has published the first randomised controlled trial
specifically designed to evaluate parasite infection as a potential treatment for
allergic rhinoconjunctivitis. In this study 2500 Trichuris suis (pig whipworm) ova, or
placebo, were administered orally at 21-day intervals on eight occasions during
2008 278. Measured outcomes were daily symptom scores for allergic rhinitis 279,
use of rescue medication, exhaled nitric oxide, haemoglobin levels, leucocyte
counts, total histamine levels (as a proxy for the basophil count), serum antibody
titres and symptoms of asthma, diarrhoea, flatulence and pruritus ani. Data from
96 individuals were analysed. Significantly more gastrointestinal disturbance was
reported by those who received infection compared with those who received
placebo. Predictably, a significantly greater increase in eosinophil counts during
the study was seen in the treatment group compared with placebo. T. suis-
specific antibody titres were also significantly higher in the treatment group. There
was no difference in symptom scores; percentage well days; medication scores;
nasal spray and eye drop usage; percentage of individuals assessing an
improvement in their pollen allergy symptoms compared with preceding year;
specific IgE to grass titres; total histamine levels; or exhaled nitric oxide or change
in allergen skin sensitisation. Tablet usage was less in the treatment group
compared with placebo (p=0.04). In this context, it is perhaps not surprising that in
the study reported in this thesis, no evidence of a significant improvement in
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allergic rhinoconjunctivitis symptoms in the infected group relative to the controls
was detected; particularly as it was not powered or specifically designed to do so.
3.5.4 Interpretation of results
Since it is not possible to predict when lung migration will take place in any
individual participant, the largest observed increase in bronchial responsiveness
at any time during the first four weeks after infection was used as the primary
outcome. A small increase in bronchial responsiveness was observed in the
hookworm group relative to placebo, estimated to be less than one doubling dose
of AMP in magnitude, but this effect was not statistically significant. Furthermore,
this size of effect is unlikely to be clinically significant, considering the magnitude
of normal repeatability for bronchial responsiveness to bronchial challenge testing
is large (95% confidence limits of approximately ±1.5 doubling doses for two-week
repeated challenge to methacholine) 17. The magnitude of effect observed is also
less than that seen to be associated with established therapies for asthma 280;281.
Bronchial challenge is the gold standard method of measuring bronchial
responsiveness but PEF was also used to increase the chance of seeing an effect
if one did exist.
Infection was generally well tolerated with only one participant withdrawing from
the study as a result of adverse effects of infection. The most common adverse
symptoms to be reported were localised skin reactions and gastrointestinal
symptoms, which is consistent with previous reports of intentional hookworm
infection and the dose ranging study in Chapter 2 194;195. All participants in the
hookworm group experienced skin reactions (both itching and redness) which
occurred in the first few days following infection and, in some, the redness
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reappeared in the second week as has been previously reported. The
gastrointestinal effects occurred in conjunction with a rise in eosinophil counts and
are therefore likely to be due to an eosinophilic gastroenteritis 259 although it
should be noted that not all participants reported gastrointestinal symptoms with
several reporting scores of zero. Whist the highest scores were around 6/10, the
questionnaire is not validated and undue emphasis should not be placed on
absolute scores. Some of the symptoms experienced were spurious, occurring on
individual days and are likely to be due to coincidence rather than directly related
to the infection.
There were no clinically important changes in allergen skin sensitisation in any of
the participants nor was there any effect of infection on symptoms of allergic
rhinoconjunctivitis. Whilst the study was neither designed nor powered to detect
changes in these allergic disease outcomes, there are other possible reasons why
if there is a true effect, it was not seen. First, it may be that the hypothesis is
incorrect, and that hookworm has no effect on allergic disease outcomes. If this is
so, then previously observed associations between infection and allergy may be
due to the reverse causation and unmeasured confounders. Second, it may be
that the design of this intervention study was wrong and that the duration of the
study was too short, or the dose of larvae too small. This is likely to be particularly
important given the lack of immune modulation demonstrated by the immunology
results. In observational studies of natural infection where an inverse association
between infection and allergy has been identified, infection is generally acquired
in childhood, with repeated re-infection thereafter. It may be therefore that the
timing of infection is paramount and the protective effect of hookworm infection
arises from infection in early childhood, rather than from current infection in adults
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who have an established allergic phenotype. In this study a single dose of larvae
were given to people already sensitised to allergens and it may be infection needs
to be given much earlier to have an effect.
In addition to the reasons given above, a true effect of infection on allergic
rhinoconjunctivitis may not have been seen because of the limited assessment of
the condition that was carried out in this trial. As discussed in section 3.5.2.1,
allergic rhinoconjunctivitis is a particularly challenging condition to study because
of the intermittent nature of symptoms and its variability from year to year. This
trial was designed as a safety study; however, the opportunity was also taken to
investigate the effects of infection on allergic rhinoconjunctivitis symptoms using
the Juniper RQLQ. The clinical effectiveness of hookworm infection in allergic
rhinoconjunctivitis needs to be tested in larger specifically designed studies and
should include a number of specific outcome measures; these are discussed
more fully in section 6.2.1.
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which coincides with detection of appearance of eggs and may suggest a degree
of regulation by mature hookworm in the gut. However these changes were not
significant, and neither were there significant changes in levels of T-lymphocytes
IL-10 or IL-13 production which would be expected if a notable effect on the
immune system had taken place. There was no significant rise in total IgE levels
but this has been previously noted in another report of intentional infection and
levels in this study rose when infection was repeated 184. However, overall this
suggests that the single dose of ten larvae had not been adequate to exert the
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desired immunoregulatory effect; possible strategies for overcoming this in future
trials are discussed in section 6.2.1.
3.5.5 Conclusions
This is the first randomised double-blind placebo-controlled trial of parasite
infection to be carried out in people with allergic disease. The trial found no
evidence to suggest that hookworm infection was likely to cause clinically relevant
increases in bronchial responsiveness, thereby indicating that infection with ten
larvae is unlikely to exacerbate asthma. The adverse effects reported by
participants who were infected with hookworm were principally skin itching and
gastrointestinal disturbance, and in the majority of cases were mild, with only one
person choosing to withdraw from the study as a consequence. This study thus
indicates that this level of infection is likely to be tolerated by the majority of
participants in trials, and that exacerbation of asthma is unlikely. On the basis of
these results, further definitive trials are feasible and it is safe to proceed with
studies to determine whether infection is effective in the management of asthma.
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Table 3-1: Baseline characteristics of study participants
Hookworm
(n=15)
Placebo
(n=15)
Males (%) 9 (60) 9 (60)
Mean age (years) at entry (SD) 30.3 (8.97) 33.2 (8.82)
Current smoker (%) 3 (20) 6 (40)
Caucasian (%) 13 (87) 15 (100)
Median PD10AMP at screening (IQR) 13.3 (4.3, 48.3)* 24.8 (9.2, 68.8)*
Median PD10AMP at week 0 (IQR) 19.8 (6.4, 52.1)** 42.1 (23.6, 102.2)*
*n=13; ** n=14
IQR: inter-quartile range; PD10AMP: provocation dose of adenosine monophosphate to
reduce one-second forced expiratory volume by 10%; SD: standard deviation
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Table 3-2: Respiratory outcomes measured over the first four weeks following randomisation
Hookworm mean
(SD) (n=14)
Placebo mean
(SD) (n=14)
Mean difference
(95% CI)
P value Adjusted* mean
difference (95% CI)
P value
Change in bronchial reactivity using week 0 as
baseline (DD PD10AMP)
-1.67 (1.72) -1.16 (1.60) -0.51
(-1.80, 0.78)
0.42 -0.63
(-1.97, 0.70)
0.34
Change in bronchial reactivity using mean of
screening and week 0 values as baseline (DD
PD10AMP)
-1.52 (1.55) -0.62 (1.92) -0.89
(-2.25, 0.46)
0.19 -0.99
(-2.40, 0.43)
0.16
Peak flow variability
(Two-lowest%mean)
92.31 (3.73) 89.30 (6.70) 3.01
(-1.21, 7.22)
0.15 3.62
(-0.66, 7.90)
0.09
*adjusted for smoking status
95% CI: 95% confidence interval; DD: doubling dose; PD10AMP: provocation dose to reduce one-second forced expiratory volume by 10%; SD: standard deviation
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Table 3-3: Allergic outcomes measured over the 12 week study period
Hookworm
mean (SD)
(n=13)
Placebo mean
(SD)
(n=14)
Mean difference
(95% CI)
P
value
Adjusted* mean
difference (95% CI)
P
value
Juniper RQLQ score (log AUC) 6.01(0.82) 5.68 (0.85) 0.33 (-0.33, 1.00) 0.31 0.26 (-0.45, 0.97) 0.46
Change in grass SPT reaction (mm) 0.73(2.65) 0 0.11 (2.65) 0.62 (-1.48, 2.73) 0.55 1.18 (-0.94, 3.30) 0.26
Change in cat fur SPT reaction (mm) -0.27 (2.09) -0.75 (1.83) 0.48 (-1.07, 2.03) 0.53 0.64 (-1.01, 2.29) 0.43
Change in D.P. SPT reaction (mm) 1.27 (2.19) 0.54 (2.59) 0.74 (-1.18, 2.64) 0.44 0.85 (-1.19, 2.90) 0.40
*all adjusted for smoking status; Juniper RQLQ additionally adjusted for baseline score
95% CI: 95% confidence interval; AUC: area under curve; D.P.: Dermatophagoides pteronyssinus; RQLQ: rhinoconjunctivitis quality of life questionnaire; SD: standard deviation;
SPT: skin prick test
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Table 3-4: Adverse effects reported in participants with and without hookworm infection
Symptoms Mean daily score (scale 0-10) over total 12 week period Mean daily score (scale 0-10) over high risk period
Hookworm group
median (range)
Placebo group
median (range)
Difference in
medians
P value Hookworm group
median (range)
Placebo group
median (range)
Difference in
medians
P
value
Localised skin itching
Localised skin redness
Wheeze
Cough
Breathlessness
Nausea
Diarrhoea
Abdominal pain
Flatulence
Indigestion
Loss of appetite
Tiredness
0.30 (0.05  1.10)
0.22 (0.02  1.04)
0.30 (0  1.11)
0.22 (0  1.02)
0.14 (0  6.04)
0.17 (0  2.45)
0.12 (0  3.37)
0.24 (0  3.81)
0.28 (0  1.76)
0.11 (0  2.39)
0.14 (0  2.25)
0.86 (0  6.34)
0.00 (0  1.32)
0.00 (0  0.48)
0.07 (0  0.98)
0.10 (0  1.54)
0.00 (0  0.98)
0.00 (0  1.85)
0.11 (0  3.88)
0.02 (0  3.00)
0.13 (0  2.62)
0.00 (0  0.87)
0.03 (0  2.21)
0.14 (0  2.99)
0.30
0.22
0.23
0.12
0.14
0.17
0.01
0.22
0.15
0.11
0.11
0.72
0.003*
0.001*
0.14
0.56
0.07
0.10
0.59
0.06
0.36
0.02*
0.67
0.25
1.12 (0.19  3.11)
1.02 (0.10  5.00)
0.36 (0  2.07)
0.43 (0  1.35)
0.05 (0  5.14)
0 (0  4.72)
0.06 (0  5.64)
0.48 (0  5.92)
0.31 (0  1.98)
0.10 (0  3.92)
0.24 (0  4.28)
0.41 (0  6.55)
0.00 (0  1.76)
0.00 (0  1.90)
0.14 (0  2.00)
0.11 (0  2.79)
0.00 (0  1.86)
0.00 (0  2.07)
0.06 (0  3.95)
0.00 (0  3.64)
0.05 (0  3.05)
0.00 (0  1.19)
0.00 (0  2.60)
0.15 (0  2.93)
1.12
1.02
0.22
0.32
0.05
0.00
0.00
0.48
0.26
0.10
0.24
0.26
0.001*
<0.001*
0.29
0.30
0.34
0.13
0.84
0.06
0.16
0.03*
0.30
0.51
* p<0.05 (p value for Mann-Whitney U test)
High risk periods: localised skin symptoms (days 1-21), respiratory symptoms (days 1-28), gastrointestinal symptoms and tiredness (days 29-70); Range = minimum-maximum
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Figure 3-1: Allergic rhinoconjunctivitis study visit timeline
screening visit
week 0 visit randomisation
week 1 visit
week 2 visit
week 3 visit
week 4 visit
week 6 visit
week 8 visit
week 10 visit
week 12 visit unblinding
post eradication
follow-up visit (1)
(for those eradicating hookworm infection)
post eradication
follow-up visit (2)
(for those eradicating hookworm infection)
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Figure 3-2: Flow chart of study participants
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Figure 3-3: Skin symptoms measured on a visual analogue scale (0-10)
over the first four weeks after randomisation
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Figure 3-4: Individuals peripheral blood eosinophil counts over the 12
week study period
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Figure 3-5: Individuals haemoglobin levels over the 12 week study
period
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Figure 3-6: Mean parasite specific IgG in those with hookworm and
placebo
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Figure 3-7: Mean TNF-Į in those with hookworm and placebo
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Figure 3-9: Total IgE counts in those with hookworm and placebo
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Figure 3-10: Mean T-cell counts in those with hookworm and placebo
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Figure 3-11: Mean T-regulatory cell counts in those with hookworm and
placebo
0 4 8 12
0.00
0.05
0.10
0.15
Weeks post-treatment
T
r
e
g
u1
0
9
p
er
L
158
Figure 3-12: Mean IL-10 in those with hookworm and placebo
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Figure 3-13: Mean IL-13 in those with hookworm and placebo
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4 INTERVENTION STUDY OF HOOKWORM IN
ASTHMA
4.1 Introduction
The dose-ranging study in normal volunteers (described in Chapter 2) found
that infection with ten N. americanus larvae established a level of intensity of
infection identified in previous epidemiological work to be strongly associated
with protection against asthma symptoms 58;274. The safety study in people
with allergic rhinoconjunctivitis and measurable bronchial responsiveness but
not clinically diagnosed asthma (presented in Chapter 3) established that the
lung migration phase of intentional hookworm infection did not significantly
exacerbate bronchial responsiveness and that infection at a dose of ten larvae
was generally well tolerated 282. The results of these preliminary studies
allowed us to conduct the randomised controlled trial now described, in people
with asthma, to test the hypothesis that infection improves peoples asthma.
The use of data from epidemiological studies on the risk of having asthma to
inform a study investigating the potential effect of intervention on asthma in
people with established disease is not ideal as the risk factors for asthma
development and those for disease severity and exacerbations are not likely to
be the same. However, it was felt important to determine any effect on those
with established disease - and thus whether it could be used in treatment for
affected individuals - before embarking on studies of the possible preventative
effects of hookworm infection on development of disease.
The primary aim of this study was to determine the effects of experimental
hookworm infection on bronchial hyper-responsiveness by comparing change
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in PD20AMP over a 16 week period after being randomised to receive ten
hookworm larvae or placebo. Secondary aims were to investigate the effects
on other indicators of asthma control over the same 16 week time period using
records of PEF variability, asthma symptom scores, reliever inhaler usage and
quality of life scores (using a Juniper AQLQ). Other secondary aims were to
investigate the effect of infection on allergen skin sensitisation and to monitor
the occurrence of adverse effects (using the same questionnaire as the study
reported in Chapter 3) due to the infection over the 16 weeks after
randomisation.
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4.2 Methods
4.2.1 Recruitment
Potential participants for the study were identified by local advertisement using
posters, articles in local newspapers and the University of Nottingham and
Nottingham City Hospital websites. All those who expressed an interest in the
study were contacted by telephone or email and the background to the study
and what participation would entail was explained. A patient information sheet
(Appendix J) was then sent to people who remained interested.
Study visits were held at the University of Nottingham in the Department of
Respiratory Medicine. I conducted all the study visits (other than those
between May 13th and 23rd 2007), including the screening visits, and
measured all clinical outcomes, thereby reducing the possibility of inter-
observer variability. Recruitment took place during January and June 2007.
4.2.2 Eligibility criteria
4.2.2.1 Inclusion criteria
Participants needed to be aged 18 or over and to have a diagnosis of asthma
treated with regular inhaled corticosteroids at a dose of up to 1000mcg
beclomethasone (or equivalent) per day as reported by the participant and
which was checked at the screening visit. They needed to have measurable
bronchial hyper-responsiveness to AMP with a fall in FEV1 by 20% at baseline
and positive skin sensitisation test to at least one of D. pteronyssinus, cat fur
and grass pollen.
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4.2.2.2 Exclusion criteria
Women who were breastfeeding or pregnant, or who were sexually active and
of child-bearing potential but unwilling to use contraception for the duration of
study, were excluded. Individuals were also excluded if they had a history of
severe allergic reaction or anaphylaxis or if they had any significant medical
problems (other than asthma) in my judgement as the study clinical
researcher, such as inflammatory bowel disease. Individuals were excluded if
they had a positive serum IgG against hookworm signifying previous
hookworm infection or any evidence of current parasite infection on faecal
analysis at the time of recruitment. Those individuals whose blood tests
revealed evidence of anaemia (haemoglobin <13g/dl (male) <11.5g/dl
(female), mean corpuscular volume <76fl) were excluded from the study and
referred to their General Practitioner for appropriate investigation.
4.2.3 Screening visit
4.2.3.1 Initial consultation and consent
Volunteers who had been sent information sheets were contacted by
telephone and a screening visit was arranged for those who remained
interested in taking part in the study. At this visit, the study was explained in
detail including the background rationale, the study design, what recruitment
would involve in terms of tests performed and the required time commitment.
The potential side effects of the hookworm infection and the processes of
blinding and randomisation were described and any questions answered. A
brief medical history was also taken from the volunteer. After excluding those
with significant medical problems (other than asthma) and women who were
pregnant or of child-bearing potential and unwilling to use contraception for the
duration of the study, written informed consent was obtained and two identical
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consent forms completed: one for the study records and one for the potential
participant to retain for future reference (Appendix C). Permission was
obtained to inform the potential participants General Practitioners of his or her
recruitment into the trial. A number of measurements were then made to
further assess eligibility and to collect data on baseline characteristics and
clinical outcomes.
4.2.3.2 Medical history and baseline characteristics
A full medical history was then taken and the diagnosis of asthma confirmed
by the study clinician. This included taking details of the severity of the
asthma, presence of any other allergic disease, past medical history, use of
medication and smoking status. Baseline height and weight measurements
were made. Urine analysis for ȕ-HCG (QuickVue, Quidel Corporation, San
Diego, USA) was performed to confirm that female participants of child-
bearing age were not pregnant. Participants were asked to bring their inhalers
to the visit so that the drug and dose and expiry date could be checked and
inhaler technique was assessed and optimised in all individuals. For the
duration of the study, participants were asked to continue with their usual
asthma medication at a static dose of inhaled corticosteroids and to use
inhaled short-acting ȕ2-agonists as normal for relief of asthma symptoms.
4.2.3.3 Lung function and bronchial challenge
Individuals were provided with a miniWright peak flow meter (European Union
scale). Instruction on peak expiratory flow (PEF) measurement was given and
the best of three attempts recorded. One-second forced expiratory volume
(FEV1) was measured according to international guidelines
17 using a
Spirometer R model (Vitalograph, Buckingham, UK) and taking the higher of
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two values within 100mls. Bronchial hyper-responsiveness was then
measured by adenosine monophosphate (AMP) challenge. This was
performed using an identical method to that described in section 3.2.3.3 with
sequential inhalations given in doubling increments from 0.115 to 944ȝM at
two-minute intervals 282. The challenge was continued until FEV1 fell by at
least 20% from post-saline baseline or until the maximum dose of AMP had
been inhaled. The provocation dose of AMP required to reduce FEV1 by 20%
(PD20AMP) was estimated by interpolation between the two last doses on the
log dose-response plot 17.
According to guidelines, potential participants were instructed to abstain from
the following prior to the bronchial challenge:
x antihistamines for 24 hours 79;
x steroid nasal sprays for 24 hours;
x caffeine-containing food and drink for 12 hours 17;
x strenuous exercise for 12 hours 271;
x inhalers containing long-acting ȕ2-agonists (e.g. Salmeterol, Seretide,
Symbicort) for 12 hours;
x inhalers containing short-acting ȕ2-agonists for 4 hours (e.g.
Terbutaline, Salbutamol).
The bronchial challenge was not performed on individuals who had an FEV1 of
less 40% predicted or a value of less than 1 litre, or who were pregnant 17.
4.2.3.4 Allergen skin sensitisation
Allergen skin sensitisation to D. pteronyssinus, cat fur, grass pollen and
positive (histamine) and negative (saline) controls (Diagenics Ltd, Milton
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Keynes, UK) was measured using standard skin prick test methods as
described in section 2.2.2.2.
4.2.3.5 Blood samples
Venesection was performed, and samples for Full Blood Count analysis
(haemoglobin estimation and differential cell counting) and serum albumin
were processed in the Nottingham City Hospital pathology department.
4.2.3.6 Faecal egg count methods
Individuals were asked to provide a faecal sample collected within the
previous 24 hours. This was analysed for parasite eggs using the methods
described in sections 2.2.4 and 3.2.3.7.
4.2.3.7 Juniper Asthma Quality of Life Questionnaire
An interviewer-administered Juniper Asthma Quality of Life Questionnaire
(AQLQ) based on individuals recall of their experiences over the preceding
fortnight was completed 283. This questionnaire has been validated to provide
a quantified impact of asthma on symptoms, physical activities, emotional
function and exposure to environment stimuli. It contains 32 questions and
provides a composite score out of a total of 224, with lower scores indicating a
greater impact of asthma on quality of life. (Appendix K)
4.2.4 Run-in period and daily diary
Individuals who fulfilled the entry criteria at the screening visit then took part in
a run-in period lasting approximately two weeks. During this run-in period, and
for the duration of the study, participants were asked to complete a daily diary
which included a record of the parameters detailed below. (Appendix L)
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4.2.4.1 Peak expiratory flow
Individuals were asked to record twice-daily (morning and evening) PEF,
measured as the best of three attempts.
4.2.4.2 Asthma symptom scores
Individuals were asked to record twice-daily scores (morning and night) of how
severe they perceived their asthma symptoms to be in the preceding 12 hours
using a scale of 0 (no symptoms) to 5 (maximal symptoms).
4.2.4.3 Use of reliever medication
Individuals were asked to record on a twice-daily basis (morning and night) the
number of puffs of their asthma reliever inhaler they had used in the preceding
12 hours.
4.2.4.4 Adverse symptoms
The same method of recording adverse symptoms were used for this study as
for the study in people with allergic rhinoconjunctivitis, as an appropriate
validated questionnaire did not exist. Individuals were asked to assign a score
using a visual analogue scale from 0 (no symptoms) to 10 (maximum possible
severity of symptoms) for a range of pre-determined possible adverse effects
due to the hookworm, including local skin reactions at the site of infection
(redness and itching), gastrointestinal symptoms (nausea, indigestion,
abdominal pain, diarrhoea, wind) and constitutional symptoms (tiredness). In
addition, a space for free text was included in the diary for the recording of any
other symptoms which the potential participants felt might be relevant (for
example, change in eczema severity).
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4.2.5 Randomisation visit
4.2.5.1 Clinical measurements
After the two week run-in period, potential participants were seen for the
randomisation visit. The bronchial challenge, Juniper AQLQ and blood tests
were repeated. If any of the eligibility criteria were no longer fulfilled, then the
individual was not enrolled into the study.
4.2.5.2 Randomisation
Eligible participants then underwent concealed randomisation to active or
placebo infection, allocated in blocks of four according to a computer-
generated random code. Larvae were obtained by a culture of faecal material
as described in section 2.2.3.3. To ensure that I, the clinical researcher
carrying out the protocol measures, remained blind to the treatment allocation,
solutions were administered by an independent member of the research team
who was not involved in any of the study measurements, using the methods
described in section 3.2.5.2.
As in the previous study, participants were told to avoid getting the plaster wet
for 24 hours and after that time to remove the plaster and place it in a
universal container containing 70% ethanol with which they were provided.
They were also given one tablet of albendazole 400mg to take home in case
they should want to withdraw from the study at any time. Participants were
provided with a 24-hour contact telephone number in case of any problems or
questions relating to the study. Randomisation codes were placed in a sealed
envelope in the department laboratory in case of a medical emergency which
might require the participant to withdraw from the study and to be unblinded
immediately.
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4.2.5.3 Blinding
The same steps were taken as described in section 3.2.5.3 to ensure that both
trial participants and I remained blind to the treatment allocation.
4.2.6 Follow-up visits
After randomisation, participants attended study visits every fortnight for eight
weeks, and then at 12 and 16 weeks. The original protocol specified a total of
12 weeks of follow-up, but because the eosinophilia observed in the study in
allergic rhinoconjunctivitis was still decreasing at 12 weeks 282 it was decided,
before commencing the present study, to increase follow-up to 16 weeks. In
addition, participants had a blood sample taken for Full Blood Count analysis
three weeks after randomisation to coincide with the expected time of onset of
hookworm-associated eosinophilia observed in the dose-ranging study and
study in allergic rhinoconjunctivitis 274;282.
At each study visit PD20AMP was measured, the Juniper AQLQ was
completed, venous blood taken for the same tests as at the screening visit and
a faecal sample, collected within the preceding 24 hours, provided to confirm
establishment and survival of the adult hookworms in the gastrointestinal tract
of those in the treatment arm of the study and to quantify egg burden 274.
Participants daily diaries and symptom cards from the preceding fortnight
were also collected and participants were issued with new diaries and cards to
last until their next study visit. .
4.2.7 Final visit
At the final visit at week 16, in addition to the test and measurements
performed at the follow-up visits, allergen skin tests were repeated,
participants were weighed and female participants had a repeat urinary
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pregnancy test. The appearance of the eggs in faecal samples is relatively
non-specific and thus can be mistakenly identified, for example, as pollen
grains. For this reason, at the final visit, all faecal samples were cultured and
infection was confirmed by the presence of visible larvae.
Participants were then seen by an independent member of the research team
(to ensure that I remained blind to allocation) and asked whether they thought
they had received placebo or hookworm and to justify their response, before
being unblinded. If they had received placebo, no further follow-up was
arranged. Those in the hookworm group were supplied with a course of
mebendazole 100mg to be taken twice a day for three days in order to
eradicate the infection. Those participants choosing to take the tablets were
followed-up fortnightly and faecal egg counts and blood eosinophil counts
were checked until egg counts were zero and eosinophils had returned to
within 0.2 x109/litre of their screening value or were within normal reference
ranges on two successive occasions (Figure 4.1).
Those participants in the hookworm group who chose not to eradicate the
infection were given written information outlining the potential risks (albeit
minimal) of long-term hookworm infection, namely anaemia and
endomyocardial fibrosis. They were also told to inform the blood transfusion
service before donating blood and were advised that mebendazole was
contraindicated in pregnancy and during breastfeeding. (Appendix H) They
were asked to sign two copies of a document to show that they understood the
risks of infection and that they declined at that time to take the mebendazole
tablets; one copy was retained by the participant, the other was filed in their
records. These participants had no further follow-up arranged.
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4.2.8 Trial monitoring committee
The same trial monitoring committee was used for this study as for the study
in allergic rhinoconjunctivitis, and identical parameters were set to indicate
when the committee was to be informed of abnormal results and
circumstances where a decision regarding possible withdrawal from the study
needed to be made (see section 3.2.8).
4.2.9 Ethical Approval
Data on adverse effects and haemoglobin, eosinophil and serum albumin
levels were monitored regularly by the trial statistician and a data monitoring
committee. The study was approved by the Nottingham Research Ethics
Committee and by the Research and Development department at Nottingham
University Hospitals NHS Trust and was registered with the Clinical Trials
register (http://clinicaltrials.gov/ (trial reference NCT00469989)). The
Medicines and Health Regulatory Association was also informed of the studies
and did not require additional specific documentation to be completed.
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4.3 Data analysis
4.3.1 Data entry and checking
All the results were entered on to a spreadsheet (Microsoft Excel (2007)) and
cross-checked for any discrepancies; they were then imported into Stata
version 10 (STATA Corp 2007, College Station, Texas, USA). Stata was used
to perform data manipulation, computation of variables and all analyses unless
otherwise stated. I carried out all the data analyses, including entry of data
and manipulation of data, blind to randomisation code.
4.3.2 Primary outcome
4.3.2.1 Computation of primary outcome variable
The primary outcome was change in PD20AMP from baseline to the week 16
(final visit) value, expressed in doubling doses. If after entry into the study
participants no longer responded with a 20% reduction in FEV1 at below the
maximum administered dose of AMP, a censored value of one doubling dose
higher than the maximum dose of AMP administered (1888mcg) was assigned
284;285. The equation for calculating PC20 (provocation concentration required to
reduce FEV1 by 20%)
17 used to calculate the PD20AMP:
where
C1 = penultimate AMP dose
C2 = final AMP dose
R1 = percent fall in FEV1 after C1 from saline baseline
R2 = percent fall in FEV1 after C2 from saline baseline
PD20AMP were calculated on two separate occasions for each study visit,
including the screening visit, and the two values obtained were cross-checked
PD20 = anti log [LN (C1) + ((LN (C2)  LN (C1)) x (20-R1)/(R2-R1)]
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to ensure that they were identical. Where there was a discrepancy, they were
recalculated by an independent researcher. On each occasion, the
independent researchers calculation correlated with one of the first values
obtained, and this estimate of PD20AMP was therefore assigned for the visits.
PD20AMP values were not normally distributed but could be transformed by
taking the natural logarithm of each value. So, for each participant, the
difference between the natural logarithm of the PD20AMP of the final visit and
the natural logarithm of the baseline PD20AMP was computed and then divided
by the natural logarithm of 2 to obtain the change in doubling doses which was
the final variable for analysis and which does follow a normal distribution.
A positive value represented an increase in PD20AMP (that is, reduced
bronchial hyper-responsiveness, so an improvement), and a negative value
represented a fall in PD20AMP (that is, increased bronchial hyper-
responsiveness, a deterioration).
Baseline PD20AMP was defined as the mean of the screening and
randomisation visit values. However, if participants were found to have
breached the protocol for bronchial challenge testing following measurement
of PD20AMP at either the screening or randomisation visit (for example, due to
caffeine ingestion or use of ȕ2-agonist medication on the morning of the visit),
the value for that particular visit was discounted. In such cases, the single
valid value for either screening or the randomisation weeks was used for the
baseline PD20AMP instead of the mean.
Change in PD20 = ln(PD20AMP at final visit)  ln(mean of baseline PD20AMP)
in doubling doses ln2
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4.3.2.2 Statistical analysis of primary outcome variable
The final change in PD20AMP variable was compared between the two groups
by computing means and mean difference (with 95% CI) and an independent
samples t-test was performed to assess statistical significance. Analyses were
repeated, first excluding any participants without both a screening and
randomisation value, and second, with baseline defined as the randomisation
week only since for some participants there appeared to be a learning effect in
using the dosimeter properly and performing the bronchial challenge test,
possibly resulting in less reliable measurements of PD20AMP at their screening
visits.
4.3.3 Secondary outcomes
Secondary outcomes were changes in the following variables over the course
of the study:
x peak expiratory flow variability;
x asthma symptoms;
x reliever inhaler usage;
x Juniper AQLQ scores 283;
x allergen skin sensitisation (mm);
Other secondary outcomes were the occurrence of adverse symptoms
potentially attributable to hookworm larvae during the study.
4.3.3.1 PEF variability
PEF variability was computed as the two-lowest percentage mean for each
two-week period of the study i.e. mean of the two lowest PEF values during
each fortnight, as a percentage of the fortnight mean. This measure of PEF
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variability has been shown in a comparison paper to be the best performing
PEF variability index 275.
Two-lowest % mean =
mean of lowest two readings in period
x 100 %
period mean
The final variable for analysis was computed as the two-lowest percentage
mean for the final two weeks of the study (weeks 15 and 16) minus the two-
lowest percentage mean for the run-in period (baseline).
4.3.3.2 Asthma symptom scores
Using the twice-daily asthma control symptoms scores recorded in the daily
diary, the percentage of symptom-free days was determined for each two-
week period of the study using the equation below.
% symptom-
free days
=
Number of days with daytime symptom score of zero
in two-week period x 100 %
Number of days in two-week period score completed
The final variable for analysis was then computed as the percentage
symptom-free days for the final two weeks of the study (weeks 15 and 16)
minus the percentage symptom-free days for the run-in period (baseline). This
computation was then repeated substituting symptom-free nights (that is, a
night symptom score of 0) for symptom-free days to generate a second
variable for the final analysis.
4.3.3.3 Reliever inhaler use
Using the records from the daily diary, the percentage of reliever inhaler-free
days was determined for each two-week period of the study using the
equation below. The final variable for analysis was then computed as the
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difference between the percentage reliever inhaler-free days for the final two
weeks of the study (weeks 15 and 16) and the percentage reliever inhaler-free
days for the run-in period. This computation was then repeated substituting
reliever inhaler-free nights for reliever inhaler-free days to generate a second
variable for the final analysis.
% reliever
inhaler-free days
=
Number of days where reliever inhaler not used
in two-week period
x 100 %
Number of days in two-week period record
completed
4.3.3.4 Quality of Life scores
The Juniper AQLQ questionnaire was completed using a Microsoft Access
2007 database and the results were then imported into Stata version 10 for
analysis as described in section 4.3.1. A score out of 224 was recorded at
each visit which reflected participants experiences over the preceding
fortnight (computed by summing individual symptoms recorded on the AQLQ).
The final variable for analysis was calculated as the score for the final two
weeks of the study (weeks 15 and 16) minus the score at the week 0 visit
(reflecting experiences in the fortnight preceding randomisation).
4.3.3.5 Allergen skin sensitisation
Change in allergen skin sensitisation was computed for each allergen using
the same method as described in section 2.3.3.3.
4.3.3.6 Adverse effects
A mean daily symptom score variable for each adverse effect potentially
attributable to the hookworm infection was computed by taking the mean of
the daily score over the whole 16 weeks and also for a pre-determined high-
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risk period, chosen as the period during which the symptoms were most likely
to occur, as observed in previous studies of deliberate hookworm infection
127;259, the dose ranging study and the study in people with allergic
rhinoconjunctivitis (see section 3.3.3.4).
4.3.3.7 Statistical analysis of secondary outcome variables
The variables for change from baseline to the end of the study (4.3.3.1 
4.3.3.5) were compared between the intervention groups using the
independent samples t-test and a mean difference and 95% CI computed. The
adverse symptom score variables were not normally distributed and could not
be transformed and so the medians were used as the summarised average in
each intervention group and statistical significance was assessed using the
non-parametric Mann-Whitney U test.
4.3.4 Area under the curve analyses
To ensure that an effect was not missed if the results from the final two week
period of the study had been spurious, time trends were also explored by
plotting two week period variables for PD20AMP, PEF variability, Juniper
AQLQ scores, asthma symptom-free day and nights and reliever inhaler-free
days and nights, to check if there were any obvious trends. The area under
the curve (AUC) (GraphPad Prism 5, GraphPad Software Inc., San Diego, CA)
was then computed for each diary outcome using the period from weeks 5 to
16 (for PEF and symptoms and reliever inhaler usage) and weeks 6 to 16 for
those variables measured at study visits (all other outcomes) as an alternative
summary variable to ensure that any effect of larval migration through the
airways in the first four weeks after randomisation did not affect the results.
For the asthma symptom-free day and nights and reliever inhaler-free days
and nights the period from week 5 to 16 was adjusted for by subtracting the
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AUC value for the run-in period. For those AUC variables which were normally
distributed, the means were compared and independent samples t-test used
to assess for a significant difference between the two intervention groups. For
those AUC variables which were not normally distributed, the medians were
used as summarised averages for each intervention group and statistical
significance between the two groups was assessed using Mann-Whitney U
tests.
4.3.5 Sensitivity analyses
Three sensitivity analyses for each outcome were also performed, whereby
analyses were repeated excluding:
i) participants who breached the protocol (such as changing dose of inhaled
steroid during the study);
II) participants who had less than 75% of potentially available data complete
for the outcome variable;
III) participants who were infected with hookworm but did not have a positive
faecal culture for larvae at week 16.
4.3.6 Other clinical parameters
Haemoglobin and albumin levels were monitored as the study progressed by
the trial statistician to ensure participant did not become anaemic or show
signs of becoming malnourished. At the end of the study, change in
haemoglobin and albumin levels were computed as the difference between
week 16 values and baseline. In addition, the net change in weight of each
participant was calculated as the difference between the weights at the week
16 visit and screening visit.
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4.3.7 Markers of hookworm infection
Eosinophil counts and faecal egg counts were monitored at regular intervals
during the study as described and used to confirm presence of infection in
those who received hookworm infection.
4.3.8 Sample size and power calculation
With a sample size of 30 (15 in each group), the study had an estimated 80%
power to detect one doubling dose difference in the primary outcome, change
in PD20AMP, between hookworm and placebo groups assuming a standard
deviation of approximately one doubling dose.
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4.4 Results
4.4.1 Participant flow
Thirty-four participants were recruited between December 2006 and June
2007, with 17 randomised to each intervention arm. Two participants withdrew
before the primary endpoint could be measured, and indeed before parasite
maturation was complete (one from the placebo group on day 6, due to
psychological problems, and one from the hookworm group on day 34, due to
abdominal pain). These participants were excluded from further analysis
(Figure 4.2).
4.4.2 Baseline characteristics of participants
Baseline characteristics of the two study groups were similar with respect to
gender, age, body mass index, smoking history, social deprivation (Townsend
score 286), use of asthma medication (Table 4.1); baseline clinical measures,
namely bronchial hyper-responsiveness (PD20AMP), lung function (percentage
predicted FEV1 and PEF variability), Juniper AQLQ score and symptom-free
and reliever inhaler-free days and nights, were also similar (Table 4.2). All
participants were Caucasian.
4.4.3 Primary outcome
PD20AMP improved relative to baseline (positive value of variable) in 11 of the
16 participants finishing the study who received hookworm (69%), and in 8 of
the 16 who received placebo (50%). The mean change in PD20AMP was
slightly higher in the hookworm group at 1.49 (SD 2.00) DD, than in the
placebo group at 0.98 (SD 4.02) DD, but the difference in means between the
two intervention groups was not statistically significant (0.51 DD, 95% CI: -
1.79 to 2.80; p=0.65, Table 4.3).
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When the analysis was repeated excluding the four participants whose
baseline PD20AMP was based on only the screening or randomisation visit
values rather than the mean, this made little difference to the results: the
mean change in PD20AMP was higher in the hookworm group (n=15) at 1.62
(SD 2.00) DD than in the placebo group (n=13) at 1.06 (SD 3.99) DD
(difference in means = 0.56 DD, 95% CI: -1.84 to 2.96; p=0.64). Using the
randomisation week values as the baseline instead of the mean also made
minimal difference to the results: the mean change in PD20AMP was higher in
the hookworm group (n=15) at 1.20 (SD 1.83) DD than in the placebo group
(n=16) at 0.71 (SD 4.05) DD (difference in means = 0.49 DD, 95% CI: -1.85 to
2.83; p=0.67).
4.4.4 Secondary outcomes
4.4.4.1 PEF Variability
PEF variability changed on average between run-in and weeks 15-16 by just
over 1% in both groups, with an improvement (mean increase) of 1.03% in the
hookworm group (SD 6.17) and a deterioration (mean decrease) of 1.21% (SD
7.17) in the placebo group. However, the difference between these was
neither clinically important nor statistically significant (difference in means =
2.24%, 95% CI: -2.60 to 7.06; p=0.35, Table 4.3).
4.4.4.2 Asthma symptoms
Self-reported asthma symptom-free days and nights scores improved in both
groups, more in the placebo group than the hookworm group (mean change in
% symptom-free days 12.72% vs. 9.05%; mean change in % symptom-free
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nights 12.59% vs. 8.43%), but the differences between the two intervention
groups for each outcome were not significant (Table 4.3).
4.4.4.3 Reliever inhaler usage
Percentage of reliever inhaler-free days improved in both groups during the
study, more so for the placebo group than the hookworm group (mean change
in reliever-free days 1.39% vs. 0.37%). Percentage of reliever inhaler-free
nights improved in the placebo group but fell in the hookworm group by a
minimal amount (mean change in reliever-free nights 3.59% vs. -0.01%).
However, there were no significant differences between the two intervention
groups for either of these outcomes (Table 4.3).
4.4.4.4 Quality of life scores
Juniper AQLQ scores improved in both groups during the study indicating an
improvement in asthma related quality of life. The mean change in score from
baseline to the end of the study was greater in the placebo group (15.34) than
in the hookworm group (10.66), but the difference between the two
intervention groups was not statistically significant (Table 4.3).
4.4.4.5 Allergen skin sensitisation
On average, size of wheal increased between baseline and week 16 in both
the hookworm and placebo groups for cat fur allergen (mean change of
0.19mm and 0.03mm respectively) and reduced in both the hookworm and
placebo groups for grass (mean change of -0.59mm and -0.19mm
respectively) and D. pteronyssinus allergen (mean change of -0.66mm and -
0.19mm respectively), but there was no statistically significant difference
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between the intervention groups for any of the individual allergens tested
(Table 4.3).
4.4.4.6 Adverse effects
Higher scores for localised skin reactions at the site of infection were reported
in the hookworm group compared with the placebo group, particularly between
days 1 to 21 after infection (median daily score for itching 1.40 vs. 0.00,
difference in medians = 1.40; p<0.001, and median daily score for redness
2.18 vs. 0.00, difference in medians = 2.18; p<0.001). Daily scores of
gastrointestinal symptoms were generally low but tended to be slightly higher
in the hookworm group than the placebo group, significantly so for abdominal
pain (median = 0.23 vs. 0.03, difference in medians = 0.20; p=0.02), and
additionally for loss of appetite (median = 0.08 vs. 0.00; difference in medians
= 0.08; p=0.04) and nausea (median = 0.05 vs. 0.00; difference in medians =
0.05; p=0.04) during the high-risk period (days 29 to 112). Reported
respiratory symptoms did not suggest a worsening of asthma during the first
four weeks of the study (Table 4.4).
4.4.5 Area under the curve analyses
The time trends showed no evidence of spurious results in the last two week
period of the study for any outcomes. There was no statistically significant
differences between the two intervention groups when outcomes were
assessed using AUC (weeks 5/616) instead of change from the beginning to
the end of the study (Table 4.5).
4.4.6 Sensitivity analyses
At the final visit, three participants were deemed to have breached the
protocol during the study. The first had a change of dose of inhaled
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corticosteroid in week 15, the second started using a volumatic device with
their inhaler in the first week of the study and the third changed their dose of
inhaled corticosteroid throughout the study according to their symptoms.
The majority of participants had more than 75% of all data available for each
variable during the study, the exceptions being three participants for adverse
effects and three for PEF variability (one had minimal data from the run-in
period and the other two had data missing in the study after randomisation).
Seven participants were infected with hookworm but did not have a positive
faecal culture for larvae at week 16.
When the sensitivity analyses were carried out, the measures of effect did not
change materially for the majority of the outcomes (Table 4.6 for those who
breached the protocol, Tables 4.7 and 4.8 for those with missing data and
Table 4.9 for those in the hookworm group without positive cultures) and with
the exception of some of the adverse effects, those outcomes not statistically
significant originally did not become significant in the sensitivity analyses.
When those participants who had breached the protocol were excluded the
effects on PD20AMP, PEF variability, Juniper AQLQ scores and allergen skin
sensitisation tests were minimal (Table 4.6). There was, however, a greater
difference between the two groups for symptom-free days and nights, largely
due to better control in the placebo group. For example, the difference
between the two groups in % symptom-free days was 8.49% compared with
3.66% in the original analysis (Table 4.6). A similar change was also observed
for the reliever inhaler-free days with a greater % of reliever inhaler-free days
in both groups, but more so for the placebo group resulting in a larger overall
difference between the groups (1.03% in the original analysis vs. 4.34% in the
sensitivity analysis).
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Excluding those participants with missing data on adverse symptoms resulted
in a change for nausea and loss of appetite, which were originally significant
but no longer in the sensitivity analysis (Table 4.7). However, the size of
difference between the groups was the same and therefore the loss of
significance was as purely due to the smaller sample size. There was also a
change in the symptom-free days and nights and reliever inhaler-free nights
when these participants were excluded but the differences between the
hookworm and placebo groups did not become statistically significant (Table
4.8). Values did not change for those in the hookworm group, but excluding
the two participants with incomplete data who were both in the placebo group
resulted in a greater difference between the two groups. For example, the %
of symptom-free days in the original analysis was 3.66% and 9.56% in the
sensitivity analysis.
Excluding the seven people who received hookworm but who did not have
positive cultures resulted in a smaller difference between the two groups for
the primary outcome but the improvement was still greater in the hookworm
group. There was a change in direction of effect with a fewer symptom-free
days and nights for those in the hookworm group, and therefore a greater
difference between the groups (3.66% symptom-free days in the original
analysis and 14.05% in the sensitivity analysis; 4.16% symptom-free nights in
the original analysis and 14.46% in the sensitivity analysis). However the
numbers of participants were much smaller and confidence intervals wide and
the difference was not significant. A similar change was seen for reliever free
days, but to a lesser extent (Table 4.9).
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4.4.7 Other clinical parameters
All participants had haemoglobin and albumin levels within the normal ranges
at entry into the study. No clinically important change was observed during the
study in either of the intervention groups in haemoglobin or serum albumin
levels. The maximum fall from baseline in haemoglobin in the hookworm
group was 0.9g/dL and in the placebo group was 0.4g/dL. There were no
significant differences in change in weights seen between the two intervention
groups. The mean change in weight for the placebo group was an increase in
weight of 0.48kg (SD 2.96; range -6.4kg to 5.4kg) and for the hookworm group
was an increase in weight of 0.11kg (SD 2.21; range -4.1kg to 3.6kg).
4.4.8 Markers of hookworm infection
All participants who received hookworm infection had a rise in eosinophil
counts, which began at around day 21 and peaked at between 1.4 and 8.5
x109/litre between days 42 and 84. The eosinophil counts in the hookworm
group were all higher at the end of the study than at the time of infection
(Figure 4.3). Nine of the 16 participants who received hookworm and
completed the study had eggs detected in their faecal samples, appearing by
week 6 in three participants and by week 8 in six participants. At the final visit,
faecal cultures were positive for nine participants, eight of whom had had
detectable eggs in their faecal samples previously. All positive egg counts at
this final visit were between 95 and 213 eggs/g faeces.
4.4.9 Assessment of participant blinding
At the end of the study, 11 participants in the hookworm group correctly
thought that they had received infection (due to visible portals of entry on the
skin and gastrointestinal disturbance) and four did not know. Of those who
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received placebo, eight correctly thought they had been allocated placebo, two
incorrectly thought they had received hookworm and six did not know.
4.4.10 Post study follow-up
Thirteen out of 16 participants who received hookworm and completed the
study elected to keep their infection. Follow-up for these individuals, and for
the three who chose to eradicate the infection, was the same as described in
section 3.2.7.
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4.5 Discussion
4.5.1 Summary of findings
This is the first reported intervention study of experimental hookworm infection
in people with asthma. It was carried out following the two safety studies
reported in Chapters 2 and 3 in this thesis and comprised a double-blind
placebo-controlled trial.
The primary aim was to determine the effects of experimental hookworm
infection on bronchial hyper-responsiveness by comparing change in
PD20AMP over a 16 week period after being randomised to receive ten
hookworm larvae or placebo. Secondary aims were to investigate the effects
on other indicators of asthma control over the same 16 week time period using
records of PEF variability, asthma symptom scores, reliever inhaler usage and
quality of life scores. The study found that bronchial hyper-responsiveness
improved in individuals with hookworm infection on average by half a doubling
dose more than in those who received placebo but this was not statistically
significant (difference in means = 0.51 DD, 95% CI: -1.79 to 2.80; p=0.65).
There was no significant difference between the two groups for any of the
other markers of asthma control.
Other secondary aims were to investigate the effect of infection on allergen
skin sensitisation and to monitor the occurrence of adverse effects potentially
due to the infection. There was no significant difference between the two
groups in change in allergen skin sensitisation testing. As in the previous
study, infection with a dose of ten larvae was generally well tolerated with only
one participant withdrawing from the study as a result of symptoms due to the
infection. The most commonly occurring side effects were of a localised rash
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at the site of infection occurring in the first few days after infection and
gastrointestinal disturbance coinciding with the increase in eosinophil counts.
The study also proves that trials of experimental hookworm infection are
feasible and since the majority of participants chose to retain their infection at
the end of the trial, provides evidence that sustained infection is acceptable to
patients.
4.5.2 Strengths and weakness of the study
4.5.2.1 Measurement error
A number of different markers of asthma control were used as study outcomes
to try and increase the chance of finding an effect of infection, if one existed. It
was also important to use a variety of outcome measure as there can be poor
correlation between different outcome measures of asthma such as PEF
variability and symptoms 287 or lung function and quality of life 288. Bronchial
challenge testing is often considered as a gold standard method of evaluating
bronchial hyper-responsiveness; similarly, PEF variability provides a well
validated objective measure of day to day airflow obstruction 275;287. Guidelines
published since the completion of this trial have recommended that clinical
trials of asthma include the use of daily diaries which detail presence of
symptoms, night-time waking, and reliever inhaler usage as was done here 287.
It also suggests that symptom free days are a useful discerning variable
provided the population is not experiencing either very frequent or very
infrequent symptoms. It is important to assess the impact of any chronic
disease on quality of life and some treatment effects will only be identified by
the patient. The Juniper AQLQ used in this study has been validated to
quantify the impact of asthma on various aspects of patients daily life 283 and
has been widely used in clinical trials 288;289. Biomarkers of airway inflammation
are now increasingly being used in clinical trials of asthma and include
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measurement of the fraction of exhaled nitric oxide and analysis of induced
sputum to phenotype patients. These were not used in this trial, but it is
unlikely that there would have been a significant effect of hookworm on these
biomarkers given that no effect was seen on any other asthma outcomes.
There is a possibility of random error in the measurement of PD20AMP values,
and to reduce the impact if any spurious results had occurred at the
randomisation visit, the mean of the randomisation and screening visits values
were used to define baseline PD20AMP, in accordance with the protocol. It was
observed that there was a tendency in both groups for PD20AMP values to be
higher at the randomisation visit than at the screening visit, most likely due to
a combination of improvement in inhaler technique and compliance with
asthma treatment following education at the screening visit. However, a similar
estimated difference in change in PD20AMP of 0.5 DD was observed between
the groups regardless of whether the value from the screening visit, from the
randomisation visit or the mean of the two was used as the baseline value.
As discussed in section 3.5.2.1, there is a chance of measurement error in the
reporting of adverse symptoms because the questionnaire used has not been
validated, although the experiences of participants who received ten
hookworm larvae in the trials in allergic rhinoconjunctivitis and in asthma were
broadly similar suggesting this wasnt a major problem. As before,
measurement error in blood sample measurements should be minimal due to
the use of automated equipment and use of quality controls.
4.5.2.2 Success of blinding and bias
Blinding of treatment allocation was successful for those who received
placebo and for the clinical researcher who conducted the study visits and
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analysed the data, but less so for the participants who received hookworm.
This is unlikely to have influenced the primary outcome results or PEF
recordings as they were both measured objectively. Other secondary
outcomes were measured subjectively and therefore could have resulted in
differential bias for those participants who were aware of the intervention to
which they had been allocated. For example, those participants who correctly
guessed that they had been given hookworm may have perceived there to be
an improvement in their asthma with under-reporting of symptoms (possibly
reduced frequency of reliever inhaler use) and higher Juniper AQLQ scores.
This group may also have reported higher scores for adverse symptoms
potentially due to infection. This bias would have led to a greater difference in
secondary outcomes between the two groups and an apparent increase in
effect of infection on improving asthma. Given that there was minimal
difference between the two groups for most outcomes, it would suggest that
reporting bias of this nature was minimal. Of course, if they thought the
hookworm was not likely to help their asthma, it may have had the reverse
effect on their perception of their asthma with over-reporting of the presence of
asthma symptoms, and the impact on their quality of life (with lower Juniper
AQLQ scores) and under-reported adverse symptoms in their daily diary.
4.5.2.3 Success of infection
Although the two previous studies described in Chapers 2 and 3 showed ten
larvae to be effective in establishing infection to an intensity producing more
than 50 eggs/g faeces, in the present study eggs were not observed at any
time in faeces from several participants. However, all active group participants
exhibited marked elevation of peripheral blood eosinophilia, indicating that
infection had occurred and therefore that those with no eggs in faeces had
perhaps been infected with non-fecund or same-sex organisms. Previous
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research in Papua New Guinea has also shown that total IgE levels are
inversely related to hookworm fecundity, so it is possible that the presence of
high levels in these participants (due to allergic disease) may have reduced
hookworm fecundity, though IgE was not tested in this study so no evidence is
available either to confirm or refute this theory 290.
4.5.2.4 Representativeness and loss to follow-up
Whilst people volunteering to take part in a study of experimental hookworm
infection (or indeed any clinical trial) may not be representative of the asthma
population in general, there is no reason to suspect that any such differences
would interact with the clinical effect of hookworm infection and impact on the
trial results. The study in allergic rhinoconjunctivitis found no effect of infection
on people with very mild bronchial hyper-responsiveness and the participants
in the study all had moderate asthma (steps 2 or 3 of treatment ladder) 291.
Only around 5% of people with asthma are classed as having severe asthma
and will be receiving higher doses of medication (on steps 4 or 5) 292 and
therefore the participants in this study are representative of the majority of the
population with asthma.
Only two participants withdrew from the study; one from the placebo group for
psychological reasons, and one as a result of abdominal discomfort. There is
no evidence to suggest that they were any different from the other participants
with respect to their asthma symptoms and it is therefore unlikely that the
results of the trial would have varied significantly had they remained in the
study.
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4.5.2.5 Statistical power
The observed level of variability (SD) in the primary outcome, change in
PD20AMP, was anticipated to be one doubling dose (DD), but in the study it
was far greater, being standard deviations of 2.00 and 4.02 DD in the
hookworm and placebo groups respectively. As a result, the study had
insufficient power to detect a true effect and this may, as such, have resulted
in a false negative result for the primary outcome.
4.5.2.6 Confounding and success of randomisation
Randomisation appeared to be successful in ensuring baseline characteristics
of each group were broadly similar. This included data on several different
potential confounders (ethnic origin, gender, age, body mass index, smoking
history, social deprivation, use of asthma medication) and baseline clinical
measures, namely bronchial hyper-responsiveness (PD20AMP), lung function
(percentage predicted FEV1 and PEF variability), Juniper AQLQ score and
symptom-free and reliever inhaler-free days and nights. However, there is
always the possibility of there being other unmeasured differences in
confounding factors between the two groups given the small sample size.
4.5.3 Results in the context of other studies
The hypothesis tested in this study arises from multiple epidemiological
studies which demonstrate an inverse relation between helminth infection,
especially hookworm, and asthma. Whilst some of the observational data are
inconsistent, the larger, more recent and better designed studies were in
agreement, which suggests that the effect could be real and that the
magnitude of effect might even be greater than that found in the meta-analysis
13. It should be remembered, however, that these observational studies have
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looked at whole populations and have looked at the prevalence of asthma;
these associations therefore, may reflect protection from developing asthma.
In contrast, in this study the intention was to improve symptoms in people
already with a diagnosis of asthma. Previous intervention studies of parasites
and asthma are limited to eradication studies and have produced largely
negative results. These are described more comprehensively in Chapter 1.
The studies were mostly carried out in areas where T. trichiura and A.
lumbricoides were the predominant endemic infection, so one possible reason
for their findings might be that there is a species-specific effect with hookworm
being the only parasite to exert a protective effect.
4.5.4 Interpretation of results
If the difference between the two groups in PD20AMP is true, it is very small
and unlikely to have clinical significance as it lies within the limits of intra-
observer repeatability 17. However, the sample size in the study was small and
the confidence interval wide and if the true size of effect is towards the upper
limit of the confidence interval (2.80 DD) then this would be equivalent to the
effect seen in drug trials and would be clinically important 280;281. For this
reason, it is important to not to exclude the possibility of there being an effect
on asthma and to ensure that modified, larger trials are carried out in the
future.
A number of factors may explain why this trial did not demonstrate a
statistically significant effect on asthma. First it may be that hookworm
infection does have a true effect on asthma but it was not observed in this
study as a result of the study design. Whilst no immunological parameters
were measured in this study, it may be that the dose of ten larvae failed to
generate an adequate host immune response resulting in the finding of a
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small, non-significant effect. The dose of larvae may have been too small, or
repeated infections more closely mimicking natural infection may be needed to
induce a full immune response. It may also be that sustained infection and a
longer period of follow-up are required in order to observe an effect. The age
of infection may be crucial, with parasite exposure needing to occur in
childhood whilst the immune system is still developing; this may be particularly
relevant, as many of the observational studies which have identified an
association between infection and allergy have been performed in children.
Moreover, as described above, it may be that the effect on asthma only relates
to initial development of disease (in which case infection would need to occur
in childhood), rather than having a modifying effect in people who already
have established disease.
Another explanation for the findings of the study may be that the underlying
hypothesis on which these studies were based is incorrect and that there is no
true effect of hookworm infection on asthma. The cross-sectional observations
may be due to reverse causation, whereby immunological bias in atopic
individuals renders them less likely to establish hookworm infection, but the
high level of infection in the intervention studies in people with allergic
rhinoconjunctivitis does not support this 282. Alternatively, other bias or
unmeasured confounders, that is, factors independently associated with both
hookworm infection and asthma, might explain the observations from previous
observational studies. This seems unlikely, given the consistency of the
evidence from the more recent, larger studies that support the hypothesis 13.
Polyparasitism is common in the areas where natural infection occurs, and this
may be a pre-requisite for the observation of a protective effect, though the
results of the meta-analysis imply that single infection should be sufficient 13.
Host genetic factors have been demonstrated to be important in the immune
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interaction between individual and parasite and it may be that the participants
in these intervention studies had genetic profiles which were unfavourable 293-
295, although the high level of infection in the previous study, carried out in
individuals with allergic rhinoconjunctivitis, argues against this.
It may also be that the anticipated immune modulation by hookworm could
have been suppressed by the use of inhaled corticosteroids, though this is
only likely if triggered during larval pulmonary migration, as there is little
evidence of systemic immunosuppression at the doses of inhaled
corticosteroids taken by these participants 296. Although it was not possible to
measure immunological parameters in this study, it is reasonable to assume
that the immunological response would be the same infection as in the study
in allergic rhinoconjunctivitis (Chapter 3), where ten larvae had no significant
effect on specific or total IgE, T-regulatory cells or IL-10 276. The dose-ranging
study (Chapter 2) produced higher peak levels of IgE with doses of 25 and 50
larvae, indicating that higher doses are necessary to generate such a
response, though this work was carried out in non-allergic participants who
may mount different responses to the infection compared with atopic
individuals 274.
As with the study in people with allergic rhinoconjunctivitis, there were no
clinically important changes in the size of wheal in allergen skin sensitisation
testing in any of the participants. This study in asthma was different in that
sample size was slightly greater and the infection was given for longer. In
addition, it could be argued that the participants in this study had more severe
allergic disease in that they had asthma treated with inhaled corticosteroids
rather than allergic rhinoconjunctivitis. Regardless, it provides stronger
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evidence for a lack of an effect on atopy with a dose of ten larvae and possible
explanations for why this might be are discussed in section 3.5.4.
The side effects of infection experienced in this study were broadly similar to
those previously reported in the two previous intervention studies and in other
reports of intentional hookworm infection 194;195. This is particularly important
as the consistent results suggest that there is unlikely to be any serious
adverse effects of infection with ten N. americanus larvae which have not
been detected because of the small sample sizes of the individual studies.
This thus provides further evidence that, at this dose, infection is safe.
4.5.5 Conclusions
This is the first randomised double-blind placebo-controlled trial of the effects
of parasite infection on asthma. It found no evidence to suggest that
hookworm infection had a positive effect on a number of clinical outcomes of
asthma in people with mild to moderate disease. There are a number of
possible explanations for this which have been discussed above, and further
intervention studies, more closely mimicking naturally acquired infection,
should proceed and are discussed further in Chapter 6.
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Table 4-1: Baseline characteristics of participants completing the study
Hookworm (n=16) Placebo (n=16)
Demographics
Gender Male 8 (50%) 9 (56%)
Female 8 (50%) 7 (44%)
Age Mean (SD) 40.9 (10.67) 39.8 (15.18)
Body mass index Median (IQR) 25.6 (23.52, 26.77) 26.9 (23.81, 29.63)
Townsend score286 Median (IQR) -0.27 (-3.49, 2.48) -0.11 (-2.75, 1.89)*
Smoking status Never 10 (63%) 11 (69%)
Ever 6 (38%) 5 (31%)
Asthma Medication
Daily inhaled
corticosteroid dose
<500 mcg/d 9 (56%) 10 (63%)
500 mcg/d 7 (44%) 6 (38%)
Past oral steroid usage Never 8 (50%) 4 (25%)
None in last 2 years 5 (31%) 8 (50%)
Some <2 years 3 (19%) 4 (25%)
Daily long-acting
ȕ2-agonist usage
None 11 (69%) 9 (56%)
Some 5 (31%) 7 (44%)
*n=12 (Townsend scores not available for participants living in houses built after 2004)
higher Townsend scores donate more deprived and disadvantaged areas
IQR: Inter-quartile range; SD: standard deviation
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Table 4-2: Baseline clinical measures
Hookworm (n=16) Placebo (n=16)
Lung function (mean (SD))
% predicted FEV1 at screening visit 83.38 (15.77) 87.06 (23.13)
% predicted FEV1 at randomisation 80.25 (17.98) 85.93 (18.37)
Bronchial responsiveness (median (IQR))
PD20AMP (DD) at screening visit 2.34 (0.78, 7.30) 3.67 (1.49, 7.52)*
PD20AMP (DD) at randomisation 4.10 (1.53, 11.26)** 6.98 (1.93, 17.22)
Skin sensitisation to allergen at screening visit
(wheal size in mm) (mean (SD))
Grass 5.13 (3.00) 5.31 (5.23)
Cat fur 4.25 (2.58) 3.91 (3.72)
Dermatophagoides pteronyssinus 6.53 (3.29) 6.38 (4.36)
Juniper AQLQ symptom scores (median (IQR))
Juniper score at screening visit for run-in period 193.00 (186.00, 212.50) 175.00 (154.00, 203.00)
Juniper score at randomisation for run-in period 200.00 (186.50, 212.00) 186.50 (174.00, 209.00)
PEF variability (median (IQR))
PEF variability (%) during run-in period 91.99 (87.96, 93.10) 91.68 (85.62, 94.25)
% Symptom-free days/nights (median (IQR))
% symptom-free days during run-in period 66.07 (21.43, 88.31) 46.43 (8.12, 96.43)
% symptom-free nights during run-in period 66.76 (40.66, 95.83) 85.71 (57.69, 92.58)
% Reliever inhaler-free days/nights (median (IQR))
% reliever-free days during run-in period 84.52 (7.42, 92.26) 60.71 (3.57, 92.86)
% reliever-free nights during run-in period 75.65 (44.78, 100.00) 92.86 (76.92, 100.00)
*n=13; **n=15
Maximum score of 224 where the higher scores indicate better quality of life
% PEF variability: a value of 100 indicates no variability, i.e. perfect control
% predicted FEV1: percentage predicted one-second forced expiratory volume; AQLQ: Asthma
Quality of Life Questionnaire; IQR: interquartile range; PD20AMP (DD): provocation dose of adenosine
monophosphate to reduce one-second forced expiratory volume by 20% in doubling doses;
PEF: peak expiratory flow; SD: standard deviation
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Table 4-3: Change in outcomes from baseline/run-in period to week 16 for asthma and allergic outcomes
Hookworm (n=16)
mean (SD)
Placebo (n=16)
mean (SD)
Difference
in means
95% CI P value
Bronchial responsiveness (DD)
Change in PD20AMP (DD)(final visit - baseline) 1.49 (2.00) 0.98 (4.02) 0.51 -1.79, 2.80 0.65
Skin sensitivity in mm
Change in skin sensitisation to grass (final visit  screening visit) -0.59 (2.42) -0.19 (2.37) -0.41 -2.14, 1.32 0.63
Change in skin sensitisation to cat fur (final visit  screening visit) 0.19 (1.74) 0.03 (1.63) 0.16 -1.06, 1.37 0.79
Change in skin sensitisation to D. pteronyssinus (final visit  screening visit) -0.66 (1.46) -0.19 (2.45) -0.47 -1.94, 1.00 0.52
Juniper AQLQ symptom scores
Change in Juniper score (final visit - mean of screening and randomisation visits) 10.66 (14.08) 15.34 (22.41) -4.69 -18.20, 8.82 0.48
PEF variability
Change in PEF variability (%) (final 2 weeks  run-in period) 1.03 (6.17) -1.21 (7.17) 2.24 -2.60, 7.06 0.35
% Symptom free days/nights
Change in % symptom free days (final 2 weeks - run-in period) 9.05 (32.50) 12.72 (48.98) -3.66 -33.68, 26.35 0.80
Change in % symptom free nights (final 2 weeks - run-in period) 8.43 (39.67) 12.59 (46.39) -4.16 -35.32, 27.01 0.79
% Reliever free days/nights
Change in % reliever free days (final 2 weeks - run-in period) 0.37 (24.87) 1.39 (34.46) -1.03 -22.72, 20.67 0.92
Change in % reliever free nights (final 2 weeks - run-in period) -0.01 (21.49) 3.59 (27.17) -3.60 -21.28, 14.09 0.68
 P value for independent samples t-test;  Higher scores indicate best quality of life % PEF variability a value of 100 indicates no variability, i.e. perfect control
95% CI: 95% confidence interval; AQLQ: Asthma Quality of Life Questionnaire; DD: doubling dose; PD20AMP: provocation dose of adenosine monophosphate to reduce
one-second forced expiratory volume by 20%; PEF: Peak Expiratory Flow; SD: standard deviation
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Table 4-4: Symptoms potentially attributable to hookworm infection experienced during the 16 week study period and high-risk period
for participants with and without infection
Symptoms Mean daily score (scale 0-10) over total 16 week period Mean daily score (scale 0-10) over high-risk period
Hookworm
median (range)
(n=16)
Placebo
median (range)
(n=16)
Difference in
medians
P value Hookworm
median (range)
(n=16)
Placebo
median (range)
(n=16)
Difference in
medians
P Value
Localised skin itching
Localised skin redness
Nausea
Diarrhoea
Abdominal pain
Flatulence
Indigestion
Loss of appetite
Tiredness
0.28 (0.04, 2.17)
0.45 (0.06, 2.13)
0.08 (0, 1.51)
0.06 (0, 2.53)
0.23 (0, 2.05)
0.24 (0, 5.43)
0.00 (0, 0.67)
0.08 (0, 0.42)
0.18 (0, 4.47)
0.00 (0, 0.16)
0.00 (0, 0.23)
0.01 (0, 0.46)
0.06 (0, 0.52)
0.03 (0, 1.04)
0.12 (0, 1.65)
0.01 (0, 0.43)
0.00 (0, 1.18)
0.67 (0, 5.00)
0.28
0.45
0.07
0.00
0.20
0.12
-0.01
0.08
-0.49
<0.001*
<0.001*
0.17
0.69
0.02*
0.25
0.24
0.08
0.51
1.40 (0.24, 4.43)
2.18 (0.33, 4.19)
0.05 ( 0, 1.84)
0.04 (0, 1.90)
0.30 (0, 2.59)
0.20 (0, 6.07)
0.07 (0, 3.03)
0.08 (0, 0.38)
0.20 (0, 5.10)
0.00 (0, 0.67)
0.00 (0, 1.19)
0.00 (0, 0.61)
0.05 (0, 0.29)
0.01 (0, 0.92)
0.05 (0, 1.77)
0.00 (0, 0.67)
0.00 (0, 0.83)
0.36 (0, 5.52)
1.40
2.18
0.05
-0.01
0.29
0.15
0.07
0.08
-0.16
<0.001*
<0.001*
0.04*
0.85
0.02*
0.23
0.24
0.04*
0.52
*P value <0.001
P value for Mann-Whitney U test
High risk periods: localised skin symptoms (days 1-21), gastrointestinal symptoms and tiredness (days 29-112)
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Table 4-5: Comparison of asthma and allergic outcomes for the period weeks 5 to 16 between treatment groups
Hookworm Placebo Difference
in means
95% CI P
Value
n mean n mean
Log PD20AMP (AUC weeks 6 to 16) (mean (SD)) 14* 4.38(2.19) 15* 4.56 (2.35) -0.18 -1.91, 1.56 0.84
PEF variability (AUC weeks 5 to 16) (median (IQR)) 16 456 (428, 473) 15 457 (432, 464) 0.83
Juniper AQLQ (AUC weeks 6 to 16) (median (IQR)) 16 1975 (1861, 2170) 15 2037 (1881, 2178) 1.00
Change in % symptom free days/nights (mean (SD))
% of symptom free days from weeks 5 to 16  run-in period 16 4.44 (30.72) 16 20.30 (33.24) -15.86 -38.97, 7.25 0.17
% of symptom free nights from weeks 5 to 16  run-in period 16 4.65 (32.52) 16 15.34 (30.64) -10.68 -33.49, 12.13 0.35
Change in % reliever inhaler free days/nights (mean (SD))
% of reliever free days from weeks 5 to 16  run-in period 16 -2.51 (27.89) 16 7.33 (23.16) -9.84 -28.35, 8.67 0.29
% of reliever free nights from weeks 5 to 16  run-in period 16 -3.99 (17.49) 16 6.66 (20.35) -10.65 -24.35, 3.05 0.12
*no PD20AMP for week 6 so unable to calculate AUC
independent samples t-test; Mann-Whitney U test
95% CI: 95% confidence interval; AQLQ: Asthma Quality of Life Questionnaire; AUC: Area under Curve; IQR: Interquartile range; PEF: Peak Expiratory Flow; PD20AMP: provocation dose of
adenosine monophosphate to reduce one-second forced expiratory volume by 20%; SD: standard deviation
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Table 4-6: Change in outcomes from baseline/run-in period to week 16 for asthma and allergic outcomes excluding those who
breached the protocol
Hookworm Placebo Difference
in means
95% CI P
value
n mean (SD) n mean (SD)
Bronchial responsiveness (DD)
Change in PD20AMP (DD)(final visit - baseline) 14 1.15 (1.45) 15 0.72 (4.02) 0.44 -1.90, 2.77 0.70
Skin sensitivity in mm
Change in skin sensitisation to grass (final visit  screening visit) 14 -0.29 (2.44) 15 -0.10 (2.42) -0.19 -2.04, 1.67 0.84
Change in skin sensitisation to cat fur (final visit  screening visit) 14 0.18 (1.87) 15 0.03 (1.68) 0.15 -1.21, 1.50 0.83
Change in skin sensitisation to D. pteronyssinus (final visit  screening visit) 14 -0.68 (1.51) 15 -0.20 (2.53) -0.48 -1.13, 2.08 0.55
Juniper AQLQ symptom scores
Change in Juniper score (final visit - mean of screening and randomisation visits) 14 12.14 (14.47) 15 16.27 22.88) -4.12 -18.84, 10.59 0.57
PEF variability
Change in PEF variability (%) (final 2 weeks  run-in period) 14 1.17 (6.60) 15 -1.64 (7.20) 2.81 -2.46, 8.09 0.28
% Symptom free days/nights
Change in % symptom free days (final 2 weeks - run-in period) 14 9.83 (34.58) 15 18.33 45.06) -8.49 -39.26, 22.28 0.58
Change in % symptom free nights (final 2 weeks - run-in period) 14 9.64 (42.47) 15 16.66 44.96) -7.03 -40.41, 26.35 0.67
% Reliever free days/nights
Change in % reliever free days (final 2 weeks - run-in period) 14 1.95 (26.27) 15 4.34 (33.51) -2.39 -25.45, 20.67 0.83
Change in % reliever free nights (final 2 weeks - run-in period) 14 -0.01 (23.08) 15 3.83 (28.11) -3.84 -23.52, 15.84 0.69
P value for independent samples t-test; Higher scores indicate better quality of life; % PEF variability a value of 100 indicates no variability, i.e. perfect control.
95% CI: 95% confidence interval; AQLQ: Asthma Quality of Life Questionnaire; DD: doubling dose; PD20AMP: provocation dose of adenosine monophosphate to reduce one-second forced
expiratory volume by 20%; PEF: Peak Expiratory Flow; SD: standard deviation
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Table 4-7: Symptoms potentially attributable to hookworm infection experienced during the 16 week study period and high-risk period
for participants with and without infection excluding those with missing data for more than 25% readings
Symptoms Daily score (scale 0-10) over total 16 week period Daily score (scale 0-10) over high-risk period 
Hookworm Placebo Difference
in medians
P value  Hookworm Placebo Difference
in medians
P Value 
n median (range) n median
(range)
n median (range) n median
(range)
Localised skin itching
Localised skin redness
Nausea
Diarrhoea
Abdominal pain
Flatulence
Indigestion
Loss of appetite
Tiredness
15
15
15
15
15
15
15
15
15
0.27 (0.04, 2.17)
0.46 (0.06, 2.13)
0.08 (0, 1.51)
0.05 (0, 2.03)
0.25 (0, 2.05)
0.22 (0, 5.43)
0.13 (0, 2.56)
0.07 (0, 0.42)
0.15 (0, 4.47)
14
14
14
14
14
14
14
14
14
0 (0, 0.13)
0 (0, 0.23)
0.03 (0, 0.46)
0.07 (0, 0.52)
0.05 (0, 1.04)
0.12 (0, 1.65)
0.01 (0, 0.43)
0.01 (0, 1.18)
0.67 (0, 5.00)
0.27
0.46
0.05
-0.02
0.20
0.10
0.12
0.06
-0.52
<0.001*
<0.001*
0.35
0.95
0.04*
0.26
0.19
0.22
0.65
16
16
16
16
16
16
16
16
16
1.40 (0.24, 4.43)
2.18 (0.33, 4.19)
0.05 (0, 1.84)
0.04 (0, 1.90)
0.30 (0, 2.59)
0.20 (0, 6.07)
0.07 (0, 3.03)
0.08 (0, 0.38)
0.20 (0, 5.10)
15
15
14
14
14
14
14
14
14
0 (0, 0.67)
0 (0, 1.19)
0 (0, 0.61)
0.07 (0, 0.29)
0.04 (0, 0.92)
0.05 (0, 1.77)
0 (0, 0.45)
0 (0, 0.83)
0.47 (0, 5.52)
1.40
2.18
0.05
-0.03
0.26
0.15
0.07
0.08
-0.27
<0.001*
<0.001*
0.08
0.87
0.04*
0.21
0.20
0.10
0.53
* P value <0.001;  P value for Mann-Whitney U test;  High risk periods: localised skin symptoms (days 1-21), gastrointestinal symptoms and tiredness (days 29-112)
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Table 4-8: Change in outcomes from baseline/run-in period to week 16 for asthma and allergic outcomes excluding those with
missing data for more than 25% readings
Hookworm Placebo Difference
in means
95% CI P value
n mean (SD) n mean (SD)
PEF variability 
Change in PEF variability (%) (final 2 weeks  run-in period) 14 1.02 (6.39) 15 -1.51 (7.35) 2.52 -2.71, 7.76 0.33
% Symptom free days/nights
Change in % symptom free days (final 2 weeks - run-in period) 16 9.05 (32.50) 14 18.61 (48.40) -9.56 -40.04, 20.92 0.53
Change in % symptom free nights (final 2 weeks - run-in period) 16 8.43 (39.67) 14 17.79 (47.01) -9.37 -41.77, 23.05 0.56
% Reliever free days/nights
Change in % reliever free days (final 2 weeks - run-in period) 16 0.37 (24.87) 16 1.39 (34.46) -1.03 -22.72, 20.67 0.92
Change in % reliever free nights (final 2 weeks - run-in period) 16 -0.01 (21.49) 14 8.49 (22.35) -8.50 -24.91, 7.91 0.30
P value for independent samples t-test; % PEF variability a value of 100 indicates no variability, i.e. perfect control.
95% CI: 95% confidence interval; PEF: Peak Expiratory Flow; SD: standard deviation
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Table 4-9: Change in outcomes from baseline/run-in period to week 16 for asthma and allergic outcomes excluding those in
hookworm group without positive cultures
Hookworm mean
(SD) (n=9)
Placebo mean
(SD) (n=16)
Difference
in means
95% CI P value
Bronchial responsiveness (DD)
Change in PD20AMP (DD)(final visit - baseline) 1.15 (1.77) 0.98 (4.02) 0.17 -2.77, 3.11 0.91
Skin sensitivity in mm
Change in skin sensitisation to grass (final visit  screening visit) -0.56 (2.63) -0.19 (2.37) -0.37 -2.49, 1.75 0.72
Change in skin sensitisation to cat fur (final visit  screening visit) 0.11 (1.95) 0.03 (1.63) 0.08 -1.43, 1.58 0.91
Change in skin sensitisation to D. pteronyssinus (final visit  screening visit) -0.56 (1.55) -0.19 (2.45) -0.37 -2.25, 1.51 0.69
Juniper AQLQ symptom scores
Change in Juniper score (final visit - mean of screening and randomisation visits) 12.05 (12.27) 15.34 (22.41) -3.29 -20.09, 13.52 0.69
PEF variability 
Change in PEF variability (%) (final 2 weeks  run-in period) 2.81 (5.58) -1.21 (7.17) 4.02 -1.72, 9.76 0.16
% Symptom free days/nights
Change in % symptom free days (final 2 weeks - run-in period) -1.34 (25.60) 12.72 (48.98) -14.05 -50.54, 22.44 0.43
Change in % symptom free nights (final 2 weeks - run-in period) -1.87 (31.20) 12.59 (46.39) -14.46 -50.43, 21.52 0.41
% Reliever free days/nights
Change in % reliever free days (final 2 weeks - run-in period) -4.24 (21.78) 1.39 (34.46) -5.63 -32.05, 20.78 0.66
Change in % reliever free nights (final 2 weeks - run-in period) -1.37 (17.67) 3.59 (27.17) -4.95 -25.89, 15.99 0.63
P value for independent samples t-test; Higher scores indicate better quality of life; % PEF variability a value of 100 indicates no variability, i.e. perfect control
95% CI: 95% confidence interval; AQLQ: Asthma Quality of Life Questionnaire; DD: doubling dose; PEF: Peak Expiratory Flow; PD20AMP: provocation dose of adenosine monophosphate to reduce
one-second forced expiratory volume by 20%; SD: standard deviation
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Figure 4-1: Asthma study timetable of visits
screening visit
week 0 visit randomisation
week 2 visit
week 3 visit blood test only
week 4 visit
week 8 visit
week 12 visit
week 16 visit unblinding at final visit
post eradication
follow-up visit (1)
(for those eradicating hookworm infection)
post eradication
follow-up visit (2)
(for those eradicating hookworm infection)
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Figure 4-2: Flow chart of asthma study participants
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Figure 4-3: Individuals peripheral blood eosinophil counts in over 16 week study period
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5 SYSTEMATIC REVIEW AND META-ANALYSIS
OF THE ASSOCIATION BETWEEN PARASITE
INFECTION AND ATOPY
5.1 Introduction
Current hookworm infection was shown to halve the risk of asthma in a
systematic review and meta-analysis 13. Similarly, several studies of the
association between atopy and parasite infection have also suggested a
possible link, although this relation has not been subjected to a rigorous and
comprehensive review 146. A systematic review and meta-analysis of the
epidemiological literature was therefore performed to determine the relation
between intestinal parasite infection and atopy and to establish whether, as
with asthma, the relation was species-specific 13. The specific aims of the
study were therefore as follows: first, to determine the relation between current
infection with any intestinal parasite and allergen skin sensitisation. Second, to
determine the relation between current intestinal parasite infection and the
presence of allergen-specific IgE. Finally, to establish if any observed
associations were species-specific.
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5.2 Methods
5.2.1 Systematic review methods
A comprehensive literature search in MEDLINE/PUBMED (1966 to March
2009), EMBASE (1980 to March 2009), LILACS (1982 to March 2009) and
CAB Abstracts (January 2000 to March 2009) was performed according to
standard guidelines 297 to identify all epidemiological studies, with no
restrictions on language, using the search strategy detailed in section 5.2.2.
Studies were included if they met the following criteria: [1] the design was a
comparative epidemiological study (cross-sectional, cohort, case-control) or
presented baseline data from a randomised controlled trial; [2] atopy was
described using current allergen skin sensitisation or presence of specific IgE
to allergens; [3] direct faecal microscopy was used to measure current
parasite infection. Studies were initially selected on the basis of their titles and
the abstracts, and full texts were then obtained for those potentially fulfilling
the inclusion criteria. To identify any additional papers, the reference lists of
published reviews and papers for which the full text was obtained were
checked. Assessment of eligibility of papers and data extraction were
independently performed by two researchers (myself and a statistician) and
cross-checked, with discrepancies decided by consensus opinion. Studies by
the same research groups were checked for replicated data to ensure they
were not included more than once. Included studies were scored for
methodological quality using the Newcastle-Ottawa quality assessment scale
298 with a score of 7 or more (from a maximum of 7 for cross-sectional studies
(unable to score for selection or definition of controls) and 9 for case-control
studies) chosen a priori to indicate a high standard for comparative
observational studies (see Appendix M). Cochrane Collaborations tool was
used to assess risk of bias for randomised controlled trials 299. The systematic
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review was carried out in accordance with the MOOSE (Meta-analysis of
Observational Studies in Epidemiology) guidelines 300.
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5.2.2 Search strategy
The following search strategy, using appropriate Medical Subject Headings
prefixes and suffixes 301, was used to identify potential papers.
Incidence or exp mortality or follow-up studies.mp or prognos.tw or
prognosis.tw or predict.tw or exp cohort studies or exp risk or (odds and
ratio).tw or (relative and risk).tw or (case and control) or (Systematic adj
review.tw) or (data adj synthesis).tw or *(published adj studies).ab or meta
analysis/ or meta analysis.ti or comment.pt or letter.pt or editorial.pt or (data
adj extraction).ab
AND
(Pteronyssinus.mp or skin test.mp or RAST.mp or house dust.mp or
feather.mp or cotton flock.mp or skin reaction.mp or antigen.mp or
dermatophagoides,.mp or mold.mp or skin prick.mp or mite.mp or skin
test.mp)
AND
(Parasite infection.mp or helminth infection.mp or parasites or helminths or
Ascaris.mp or Trichuris.mp or enterobius.mp or hookworm.mp or Necator.mp)
NOT
(HIV.mp or AIDS.mp or wounds.mp or TB.mp or leprosy.mp or transplant.mp
or cancer.mp or virus.mp or arthritis.mp or coeliac.mp or hepatitis,mp )
LIMIT TO HUMAN
Key to Medical Subject Headings suffixes and prefixes:
exp = exploded search; tw = text word; mp= key word; adj = adjacent words;
ab= in abstract; ti= in title; pt = publication type
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5.2.3 Data extraction
Data were analysed to yield effect estimates using unadjusted odds ratios
(OR) from extracted data from the papers, or preferably, if available, using
adjusted ORs using a data extraction form designed for the study. This form
was used to record the study design, the method used to measure parasite
infection, the parasite species present, the method of measuring atopy, the
allergens to which skin sensitisation or IgE were tested and the country in
which the study was carried out. It also recorded inclusion and exclusion
criteria for the study, the number of participants studied and lost to follow-up
and their ages. Finally, it recorded the methodological quality using the
Newcastle-Ottawa scale 298 and the study results (Appendix M). Where
exposure was expressed based on burden of infection, the highest exposure
category was compared with those without infection.
5.2.4 Statistical analysis
Data were analysed using Review Manager Version 5.0 (Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration, 2008). Where possible,
the individual effect estimates from the studies were combined using a random
study effects model 302 to estimate the pooled OR with 95% confidence
intervals (95% CI) to allow for heterogeneity between the estimates of effect.
Publication bias was assessed where adequate numbers of studies were
included in the meta-analyses, using a funnel plot where the size of effect
(OR) was plotted against the standard error 303. Heterogeneity (I2) between
studies was anticipated due to inherent biases in the studies and so
heterogeneity between study estimates was assessed using established
methods 304 and any differences explored using subgroup analyses.
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For the primary analysis of current infection with any intestinal parasite and
skin sensitisation to at least one allergen, subgroup analyses were carried out
according to the study methodological quality, study design, size of wheal
used to define atopy, study population (children, adults or both) and
geographical area (by continent) where the studies were undertaken.
Subgroup analyses were also performed to look at current infection with any
geohelminths (which included T. trichiura, A. lumbricoides, hookworm, E.
vermicularis, Toxocara canis and T. cati and Strongyloides stercoralis) and the
individual parasite species T. trichiura, A. lumbricoides, hookworm and
intestinal Schistosoma species. In addition, the possibility of estimating pooled
effects according to burden of infection was explored by identifying any studies
which had reported analyses where presence of parasite infection had been
stratified according to number or quantile of parasite eggs detected. Whilst the
main measure of outcome was skin sensitisation to at least one allergen,
several studies reported separate results for specific skin sensitisation to
cockroach and mite and therefore these effects are reported individually as
secondary outcomes. The results of the studies where atopy was defined as
presence of specific IgE were analysed separately.
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5.3 Results: skin sensitisation used to define atopy
5.3.1 Overview of studies
The search strategy initially identified 1273 studies published between 1966
and March 2009. The full texts of 225 papers were obtained and, of these, 20
met the inclusion criteria using allergen skin sensitisation to define atopy,
including one paper which contained unpublished data but which was
identified to us by the authors 305 (Figure 5.1). The most common reasons for
excluding papers were that appropriate data were not presented, or that a
different definition of atopy had been used, such as history of allergic disease.
Table 5.1 presents the details of each of the 20 studies which were included.
Fifteen of the 20 included studies used a cross-sectional design
142;160;205;207;219;221;225;226;233-235;237;305-307; four used case-control designs
58;218;260;308; and the remaining study was a randomised controlled trial from
which the baseline data were used 242. No studies using a cohort design were
found.
Twelve of the studies were undertaken in children aged 5 to 19 years with one
in infants aged 1 to 4 years 218. Five were performed in both adults and
children 160;219;233;307;308 and two in adults alone 58;237. The total number of
individuals included in all 20 included studies was 28,305. Eleven studies
presented data using any intestinal parasite infection as an exposure
142;205;207;219;221;225;234;237;242;305;306 and these were used for the primary analysis;
the remaining 9 studies had results only for species-specific infection
58;160;218;226;233;235;260;307;308. A positive skin sensitisation test was defined in one
study as a saline-adjusted wheal of 2mm 218 and in another as 1mm 260; all
other included studies used adjusted wheal sizes of 3mm
216
58;142;205;207;219;221;225;226;233-235;237;242;305-308 or 4mm 160. Six studies presented
results for sensitisation to cockroach and mite separately 58;218;219;235;305;307 with
the remaining 14 studies presenting results for sensitisation to any allergen.
The details of the allergens tested for in each study are presented in Table
5.2. The majority tested for mite and cockroach and then of the 20 studies, 12
tested for mould or fungi, 11 for animal extracts and 10 for grass or tree
extracts. One study did not give details of which allergen were tested for 308.
All allergens were common aeroallergens in the region in which the study was
conducted; one study additionally tested for sensitisation to peanuts 305.
Finally, one study analysed data for rural and urban populations independently
58.
5.3.2 Methodological quality and publication bias of studies
16 of the 20 included studies were of higher quality and four were judged to be
of lower quality due to an inadequate definition of their control population, a
failure to adjust for age or other factors, or omission of non-response rate. In
total, 16 of the included studies presented their data after adjusting their
analyses for confounders. The median overall score was 7 (range 3 to 9)
(Table 5.1) confirming that the quality was generally high using this particular
scoring system 298. The randomised controlled trial also scored a higher level
of methodological quality by stating adequate methods of randomisation,
allocation concealment and blinding 242.
5.3.3 Effects of infection with any intestinal parasite
A funnel plot of the studies related to the primary outcome of any current
intestinal parasite infection and positive skin sensitisation to at least one
allergen was generated and showed no clear deviation from symmetry;
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however, due to the small number of included studies it is difficult to determine
the presence of asymmetry (Figure 5.2). The pooled analysis of estimates
from the eleven studies of current infection with any intestinal parasite
demonstrated a statistically significant reduction of around 30% in the risk of
atopy in individuals with infection (OR 0.69, 95% CI: 0.60 to 0.79; p<0.01)
142;205;207;219;221;225;234;237;242;305;306. Moderate levels of heterogeneity were
observed across these studies (I2=45%). Whilst there was a significant effect
on sensitisation to any allergen, no significant effect was seen for specific
sensitisation to mite or cockroach although this was based on only two studies
(Figure 5.4).
Subgroup analysis indicated that the findings did not differ according to the
methodological quality of the study (higher quality studies (Newcastle-Ottawa
scale score 7); OR 0.67, 95% CI: 0.59 to 0.75; p<0.01), study design (cross-
sectional studies; OR 0.67, 95% CI: 0.57 to 0.78; p<0.01) or the definition of
wheal response used (all of these studies used a wheal size of 3 mm to
define a positive skin sensitisation test) (Table 5.2). Limiting studies to the
eight studies of just children made little difference to the results (OR 0.70, 95%
CI: 0.61 to 0.80; p<0.01). Restriction of the analyses by geographical area to
the seven studies conducted in Central or South America found similar effects
(OR 0.68, 95% CI: 0.60 to 0.75; p<0.01). When the analysis was restricted to
those nine studies of any current geohelminth infection the effect was similar
(OR 0.68, 95% CI: 0.60 to 0.76; p<0.01) 142;207;219;221;225;234;237;242;305.
A number of papers provided information on egg counts but pooled effects of
burden of infection could not be determined due to the format of the data
presented. Some of these studies did find a stronger effect with higher burden
of infection for the relation between A. lumbricoides 205;225;234 and T. trichiura
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225;234 and sensitisation to any allergen; and also with hookworm 235 and T.
trichiura 58 and sensitisation to mite. In contrast, other analyses found no effect
of intensity of infection was in the relation between A. lumbricoides and
sensitisation to any allergen 307; A. lumbricoides or hookworm and
sensitisation to mite 58 or T. trichiura and sensitisation to cockroach 218.
5.3.4 Effects of infection with individual intestinal parasite
species on atopy
Fifteen of the 20 studies provided species-specific data on current intestinal
parasite infection, all of which were helminths. The individual effects of four
helminth species that were present in at least 1% of the study populations
were analysed.
5.3.4.1 Ascaris lumbricoides
Fifteen studies described the relation between current A. lumbricoides
infection and the risk of atopy 58;142;205;207;218;219;221;225;226;234;235;260;305;307;308. A
pooled analysis of nine studies demonstrated a statistically significant
reduction in the odds of atopy to at least one allergen in individuals with
current A. lumbricoides infection (OR 0.69, 95% CI: 0.59 to 0.80; p<0.01), with
little heterogeneity between the studies (I2=30%) 142;205;207;221;225;226;234;260;308. In
contrast to this general effect on allergen sensitisation, there were no
statistically significant effects in four studies on specific sensitisation to
cockroach (OR 0.90, 95% CI: 0.75 to 1.08; p=0.25 (I2=0%)) 218;219;235;305 or in
six studies to mite (OR 1.03, 95% CI: 0.73 to 1.46; p=0.86 (I2=47%))
58;218;219;235;305;307 (Figure 5.5).
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5.3.4.2 Hookworm
Nine studies reported the association between hookworm infection and the
risk of current atopy 58;142;207;218;219;221;234;235;305. Pooled data from four
homogeneous studies (I2=14%) indicated that current infection with hookworm
was associated with a borderline significant reduction in skin sensitisation to at
least one allergen (OR 0.68, 95% CI: 0.46 to 1.01; p=0.06) 142;207;221;234. The
pooled effects of hookworm infection on sensitisation to cockroach in four of
these studies were not significant (OR 0.81, 95% CI: 0.62 to 1.08; p=0.15
(I2=52%)) 218;219;235;305; nor did hookworm have a significant effect in the five
studies of sensitisation to mite (OR 0.94, 95% CI: 0.65 to 1.36; p=0.73
(I2=62%))58;218;219;235;305 (Figure 5.6).
5.3.4.3 Trichuris trichiura
Eight studies looked at the effects of T. trichiura infection on the risk of current
atopy 58;142;207;218;221;225;234;305. Pooled effects of five homogenous studies
reporting current T. trichiura infection showed a significant reduction in atopy
to at least one allergen (OR 0.75, 95% CI: 0.65 to 0.86; p<0.01 (I2=7%))
142;207;221;225;234. In contrast, two studies of sensitisation to cockroach found that
infection was associated with a significant increase in current atopy (OR 1.86,
95% CI: 1.24 to 2.80; p=0.003 (I2=13%)) 218;305; and three studies of
sensitisation to mite found that infection was non-significantly associated with
an increase in atopy (OR 1.72, 95% CI: 0.90 to 3.29; p=0.10 (I2=47%)) 58;218;305
(Figure 5.6).
5.3.4.4 Other individual intestinal parasite species
Three studies reported the effects of S. mansoni infection on atopy 160;233.
Studies were only included if the infection had been detected in the faecal
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samples and studies reporting the association with S. haematobium which is
detected in the urine were not included in this analysis 305. Two studies, both
judged to be of lower methodological quality, reported the association with
sensitisation to any allergen and found infection to be associated with a
reduction in atopy (OR 0.14, 95% CI: 0.03 to 0.63) 233 and (OR 0.01, 95% CI:
0.00 to 0.15) 160. The third study found no significant effect of infection on
sensitisation to mite in an urban population (OR 1.78, 95% CI: 0.45 to 6.98) 58.
Pooled analyses were not carried out due to the small numbers of studies
involved. No effect on the risk of current atopy was seen with E. vermicularis
207;306, Giardia intestinalis 306 or Blastocystis hominis 306.
5.4 Results: specific IgE used to define atopy
Six studies were identified which defined atopy as a positive specific IgE to
mite or other aeroallergens and looked at its association with intestinal
parasite infection 160;233;260;307;309;310. Extraction of data was not possible in three
studies due to the format of the data 307, because no uninfected individuals
had specific IgE tests performed 160, or because no data were presented 260,
although the authors of this last paper did comment that they had found no
significant association between A. lumbricoides infection and specific IgE.
The three remaining studies reported inconsistent findings in the relation
between infection and presence of specific IgE. One study found the
combination of A. lumbricoides and T. trichiura infection to be associated with
a statistically significant increase in the likelihood of having raised specific IgE
(>1.0 IU/ml) to mite (OR 1.94, 95% CI: 1.20 to 3.15; p<0.01) 310. In contrast,
another study reported no significant association in multivariate analyses
between specific IgE to mite and infection with either A. lumbricoides (OR
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1.74, 95% CI: 0.55 to 5.51) or T. trichiura (OR 2.70, 95% CI: 0.95 to 7.67) 309.
Finally, a study of S. mansoni found current infection to be associated with a
significant reduction in presence of aeroallergen-specific IgE (OR 0.24, 95%
CI: 0.09 to 0.60; p<0.01) 233.
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5.5 Discussion
5.5.1 Main findings
This systematic review and meta-analysis of the epidemiological literature
provides strong evidence that current intestinal parasite infection, in particular
geohelminth infection, is associated with a reduced prevalence of allergic skin
sensitisation to at least one allergen (OR 0.68, 95% CI: 0.60 to 0.76; p<0.01)
(although not specifically to cockroach or mite which were analysed
separately). A similar pattern was seen for the individual geohelminth species
with the strongest effect for hookworm although this was based on only four
studies and therefore lacked power and the association had only borderline
statistical significance. There was no evidence that current intestinal parasite
infection was associated with an increase in risk of skin sensitisation to
cockroach or mite, with the exception of T. trichiura, which was associated
with a significant increase in risk of specific skin sensitisation to cockroach.
There were too few studies reporting the association between parasite
infection and specific IgE to combine data.
5.5.2 Strengths and limitations
The literature search was comprehensive and, so far as it is possible to
ascertain, identified all potentially suitable studies in this area. In addition, the
funnel plot did not suggest that the results would have been significantly
affected by publication bias. There was a surprisingly low degree of
heterogeneity between some of the studies, which may be attributable to the
majority of studies being published by a small number of research groups. The
methodological quality of the studies included in this review were, with few
exceptions, very good. The MOOSE guidelines recommend assessing the
impact of key components of study design (such as case-control, cohort and
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cross-sectional) using subgroup or sensitivity analysis 300; however, it was not
possible to do this as most of the studies were of the same design, namely
cross-sectional. The impact of quality on the findings was therefore explored
using subgroup analyses (as recommended by the MOOSE guidelines);
removing the one study judged lower quality made little difference to the
results (Tables 5.2 and 5.3). The majority of studies were published within the
past 10 years. Since 18 of the 20 included studies were carried out in Central
or South America or Africa, (the remaining two studies were from Vietnam 235
and Turkey 306), the findings are particularly applicable to those regions of the
world, although there are no grounds to suggest that the findings will not be
generalisable elsewhere where similar environmental conditions exist.
Whilst the primary analysis was for infection with any intestinal parasite, of the
20 included studies, only two contained data on infection with species other
than helminths, and the majority of parasites were, in fact, geohelminths. It
may therefore be that other parasite infections will demonstrate a different
relationship with atopy but the studies have not yet been carried out and
further studies with these infections are needed before any conclusions can be
drawn. To maximise the validity of the results a definition of current infection
ascertained by direct faecal microscopy was used, rather than reported history
of infection or serological testing, neither of which differentiates between past
and current infection. Outcomes were defined using skin sensitisation, a
relatively simple and cheap test and unlikely to be subjected to measurement
bias (compared with a subjective history of atopic disease). Validity was also
increased by using sensitisation to different allergens. The main limitation of
the meta-analysis was that it was not possible to account for the effects of
age, gender, socio-economic status and other confounders in a number of
studies which presented unadjusted estimates of effect. However, less than
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half of the studies included in the meta-analysis did not adjust for confounding
factors (and were therefore assigned a lower score for methodological quality),
and low levels of heterogeneity were generally detected between the studies,
indicating that the findings were similar. Age could be of particular importance
as different intestinal parasites are acquired at different ages throughout
childhood, most commonly after weaning or as infants become mobile. The
subgroup analysis of studies including only children did not suggest that the
size of effect varied significantly between adults and children. However,
because skin sensitisation to allergens increases with age there is a chance
that the study of infants aged less than five years may be misleading.
The paucity of studies describing the association between current intestinal
parasite infection and specific IgE to allergens makes it difficult to draw
definitive conclusions. The preference of researchers for using allergen skin
sensitisation over serological testing to define atopy is unsurprising; it is
logistically easier and cheaper to perform skin prick testing, which is
particularly important given that the sample size of most epidemiology studies
is large. In addition, results are obtained faster with skin prick testing, and this
method is also likely to be more acceptable to participants compared with
venesection.
5.5.3 Possible explanations for observed results
The variation in effect estimates observed between species is likely to reflect
in part, the relatively small number of available species-specific studies, and
also genuine differences of effect on allergy between species. Previous
research has suggested that the protective effect of intestinal parasites on
asthma may arise from a host systemic phase in the parasite life cycle 58 but
there is no biological reason for this to be required to effect atopy and T.
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trichiura has no such systemic phase. It is of note that none of the parasites
was associated with an increase in the odds of atopy to at least one allergen,
though T. trichiura infection was associated with an increased risk of specific
sensitisation to cockroach. Several authors presented results separately for
sensitisation to cockroach and mite. Interestingly, Flohr et al were the only
authors to find both A. lumbricoides and hookworm infection to be significantly
associated with a reduction in atopy to mite and cockroach 235, which may
reflect geographical variation as this was the only study performed in Asia.
With these few exceptions, no association was found between mite and
cockroach and skin sensitisation, suggesting that other allergens, namely
grasses, fungi or animal extract are responsible for the reduced risk of atopy.
It has been previously reported that, in the relation between current intestinal
parasite infection and asthma, hookworm was associated with a 50%
reduction in wheeze, in contrast to A. lumbricoides which was associated with
an increase in wheeze 58. This association between A. lumbricoides infection
and asthma is surprising in the context of the results from this meta-analysis of
atopy and raises questions about the relation between intestinal parasite
infection and different allergic conditions, and indeed about the relation
between allergic sensitisation and clinical symptoms. Whilst atopy is a strong
risk factor for allergic disease in higher income countries, studies have shown
that it appears to be less closely related, or not at all, in low and middle
income settings 221;311.
Finally, whilst this meta-analysis suggested a clear inverse association
between hookworm and atopy measured using skin sensitisation, there were
no consistent changes in allergen skin sensitisation tests over the course of
the three intervention studies reported in this thesis. This however, is maybe
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unsurprising as it was not the primary aim of the trials and the trials were
neither powered nor designed to show an effect. In addition, the relatively
short duration of the study may have been a factor.
5.5.4 Conclusions
This study thus provides evidence, from a synthesis of observational studies,
that intestinal parasite infections, particularly geohelminth infections appear to
protect against atopy. A clearer understanding of the aetiology of allergic
disease and the relation between environment and host is important for many
reasons. Allergy is already a common cause of chronic disease in childhood in
economically developed countries. The prevalence of allergic disease is
increasing, particularly in low and middle income countries, placing a huge
burden on already stretched health services. An increase in comprehension of
the mechanisms underlying development of allergic disease may help to direct
future therapeutic advancements, which are at present limited to treatments
with undesirable side effects. Parasite infection is endemic in large parts of the
world, and whilst eradication is acknowledged to be an important aspect of
ensuring public health, there is a chance that this may in fact lead to an
increase in allergic disease. It is for this reason that characterisation of the
relation between the two is especially important.
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Table 5-1: Studies included in meta-analysis of skin sensitisation
Author, year Study
Design
Number in
study
Age in years
mean (SD) or range
Parasite Country Adjusted
data
Methodologic
quality score

Araujo 2000 233 XS 175 U: 20.2 (11.9); I: 18.0 (9.7) Schistosoma mansoni Brazil Yes 5
Araujo 2004 160 XS 43 6-40 S. mansoni Brazil No 4
Bahceciler 2007 306 XS 997 4-12 Any parasite1 Turkey No 6
Calvert 2005 260 CC 743 8-13 Ascaris lumbricoides South Africa Yes 8
Cooper 2003a 234 XS 2865 5-18 Any geohelminth
A. lumbricoides; hookworm; Trichuris trichiura
Ecuador Yes 8
Cooper 2003b 221 XS 3681 5-19 Any geohelminth
A. lumbricoides; hookworm; T. trichiura
Ecuador Yes 8
Cooper 2004 225 XS 987 7-17 Any geohelminth
A. lumbricoides; T. trichiura
Ecuador Yes 8
Cooper 2006 242 RCT 2331 C: 9.8 (2.1); V: 9.6 (2.0) Any geohelminth Ecuador Yes A*
Dagoye 2003 218 CC 563 1-4 A. lumbricoides; hookworm; T. trichiura Ethiopia Yes 9
Davey 2005 219 XS 7508 5-95 Any geohelminth
A. lumbricoides; hookworm
Ethiopia Yes 8
Flohr 2006 235 XS 1601 6-18 A. lumbricoides; hookworm Vietnam Yes 8
Joubert 1979 308 CC 109 12-44 A. lumbricoides South Africa Yes 4
Nyan 2001 237 XS 429 15 Any geohelminth Gambia Yes 8
Obeng (unpublished
data)305
XS 2019 5-16 Any geohelminth
A. lumbricoides; hookworm; T. trichiura
Schistosoma haematobium
Ghana Yes 7
Obihara 2006 226 XS 359 6-14 A. lumbricoides South Africa Yes 8
Peireira 2007205 XS 1011 9-13 Any helminth
A. lumbricoides
Brazil No 8
Ponte 2006 307 XS 113 12-30 A. lumbricoides Brazil Yes 7
Rodrigues 2008 142 XS 1055 4-12 Any geohelminth
A. lumbricoides; hookworm; T. trichiura
Brazil No 7
Scrivener 2001 58 CC 403 16 A. lumbricoides
hookworm; T. trichiura; S. mansoni
Ethiopia Yes 8
Wördemann 2008 207 XS 1313 4-14 Any geohelminth
A. lumbricoides; hookworm; T. trichiura
Enterobius vermicularis
Cuba Yes 8
*A denotes a higher methodological quality for the randomised controlled trial;  means (standard deviation) presented separately for uninfected (U), infected (I), control (C) and intervention (V)
groups Based on Newcastle Ottawa quality assessment scale from a maximum score of 8 for cross-sectional studies (XS)/randomised controlled trials (RCT) and 9 for case-control (CC) studies;
1 E.vermicularis 23.3% (using perianal tape), Blastocystis hominis 22.4%, Giardia intestinalis 13%, Entamoeba coli 2.2%, Entamoeba histolytica 1.7% (other parasites contribute less than 1%)
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Table 5-2 Allergens to which skin sensitisation tests were performed in studies included in the meta-analysis
Author, year Mites Cockroaches Grasses Mould and Fungus Animal extract Other
Araujo 2000 233 Dermatophagoides.
pteronyssinus
Blomia tropicalis
Blattella germanica
Periplaneta americana
mixture of fungi cat epithelium,
dog epithelium
Araujo 2004 160 D.pteronyssinus,
D.farinae, B. tropicalis,
P. Americana, B.
germanica
Bahceciler
2007 306
D.pteronyssinus,
D. farinae
mixture of 12 grasses, Betulaceae, mixture
of 4 cereals, Salicaceae,
Alternaria, Aspergillus mix,
Cladosporium, Penecillium mix,
Candida albicans
cat hair, dog
hair, feather
mixture
composites
Calvert 2005
260
D.pteronyssinus,
D.farinae, B. tropicalis
cockroach Timothy grass, Bermuda grass Aspergillus, Cladoporium, Alternaria cat, dog
Cooper 2003a
234
D.pteronyssinus,
D.farinae
American cockroach grass pollen mix (9 Southern grass mix), tree
pollen mix (11 North American tree mix)
Alternaria tenuis cat
Cooper 2003b
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D.pteronyssinus,
D.farinae
cockroach grass pollen, tree pollen Alternaria tenuis cat fur
Cooper 2004
225
D.pteronyssinus,
D.farinae
American cockroach grass pollen mix (9 Southern grass mix ),
tree pollen mix (11 North American tree mix)
Alternaria tenuis cat
Cooper 2006
242
D.pteronyssinus,
D.farinae
American cockroach grass pollen mix, tree pollen Alternaria tenuis cat
Dagoye 2003
218
D.pteronyssinus, B. germanica
Davey 2005 219 D.pteronyssinus cockroach
Flohr 2006 235 D.pteronyssinus,
D.farinae
P. americana
Joubert 1979
308
15 common
aeroallergens
Nyan 2001 237 D.pteronyssinus, cockroach mix
(American and German)
grass mix mould mix (including Aspergillus,
Alternaria, Penicillium)
Obeng 305
(unpublished
data)
D.pteronyssinus,
D.farinae, mixed mite,
cockroach peanut
Obihara 2006
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house dust mite Bermuda grass, Rye grass Aspergillus, Cladoporium herbarium,
Alternaria alternata
cat dander, dog
dander
Peireira
2007205
D.pteronyssinus,
D.farinae
grass mix, tree mix Alternaria alternata cat dander
Ponte 2006 307 D.pteronyssinus,
D.farinae, B. tropicalis
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Rodrigues
2008 142
D.pteronyssinus,
B. tropicalis
P. americana, B.
germanica,
fungi (Aspergillus amstelodami,
A.fumigatus, A.niger, A.terrus,
Penicillium brevicompactum, P.
expansum, P.notatum, P. roquefoti,
Cladosporium fulvum. C. herbarum)
cat epithelium,
dog epithelium
Scrivener 2001
58
D.pteronyssinus cockroach grass mix, mixed cereals mould mix, aspergillus cat fur, dog
dander
Wördemann
2008 207
D.pteronyssinus,
D.farinae
cockroach mixed grass, mixed tree Alternaria alternata cat dander
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Table 5-3: Subgroup analyses for association between any parasite and
sensitisation to at least one allergen
Subgroup analyses Total
trials, n
Odds Ratio
(95% CI)
I2, % P Value for
Heterogeneity
P Value for
association
Methodological quality score
7 8 0.67 (0.59, 0.75) 29% p=0.20 p<0.01
<7 1 1.10 (0.71, 1.70) n/a n/a p=0.67
Skin wheal size
3mm 9 0.69 (0.60, 0.79) 45% p=0.07 p<0.01
<3mm 0
Study population
Children only 8 0.70 (0.61, 0.80) 41% p=0.11 p<0.01
Adults only 1 0.30 (0.11, 0.80) n/a n/a p=0.02
Adults and children 0
Geographical location
South/central America 7 0.68 (0.60, 0.75) 17% p=0.30 p<0.01
Africa 1 0.30 (0.11, 0.80) n/a n/a p=0.02
Europe/Asia 1 1.10 (0.71, 1.70) n/a n/a p=0.67
Study design
Cross-sectional study 8 0.67 (0.57, 0.78) 44% p=0.09 p<0.01
Randomised
controlled trial
1 0.78 (0.64, 0.95) n/a n/a P=0.01
Case-control study 0 n/a n/a n/a n/a
Table 5-4 Subgroup analyses for association between individual parasite
species and allergen sensitisation to at least one allergen, cockroach
and mite
Parasite Allergen skin
sensitisation
Total
trials,
n
Odds Ratio
(95% CI)
I2, % P Value for
Heterogeneity
P Value for
association
A. lumbricoides 1 allergen 9 0.69 (0.59, 0.80) 30 p<0.01 p<0.01
cockroach 4 0.90 (0.75, 1.08) 0 p=0.25 p=0.25
mite 6 1.03 (0.73, 1.46) 47 P=0.86 P=0.86
hookworm 1 allergen 4 0.68 (0.46, 1.01) 14 p=0.06 p=0.06
cockroach 4 0.81 (0.62, 1.08) 52 P=0.15 P=0.15
mite 5 0.94 (0.65, 1.36) 62 p=0.73 p=0.73
T. trichiura 1 allergen 5 0.75 (0.65, 0.86) 7 p<0.01 p<0.01
cockroach 2 1.86 (1.24, 2.80) 13 p=0.003 p=0.003
mite 3 1.72 (0.90, 3.29) 47 p=0.10 p=0.10
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Figure 5-1: Flow diagram of included and excluded studies for skin
sensitisation
1273 titles identified by search
and screened for suitability
1026 excluded on basis of title
247 potentially relevant studies
identified and screened for
inclusion on basis of abstract
22 excluded on basis of abstract
225 full texts obtained,
screened on basis of full text.
References also checked for
potentially appropriate studies
for inclusion
204 excluded on basis of full text
66: descriptive studies with no data
40: alternative definition of atopy used
25: no combined data for atopy and parasite infection
25: no data presented for parasite infection
20: serology used to determine parasite infection
20 studies included in meta-
analysis
11: no unexposed group
4 : data not extractable
3: data duplicated
3: specific IgE used to define atopy
8: other reasons
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Figure 5-2: Funnel plot for studies of the association between any
current parasite infection and skin sensitisation to at least one allergen
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Figure 5-3: Forest plot of studies of the association between infection
with any parasite and atopy
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Figure 5-4: Forest plot of studies of the association between infection
with Ascaris lumbricoides and atopy
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Figure 5-5: Forest plot of studies of the association between infection
with hookworm species and atopy
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Figure 5-6: Forest plot of studies of the association between infection
with Trichuris trichiura and atopy
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6 GENERAL DISCUSSION AND CONCLUSIONS
6.1 Main findings of thesis
This thesis has looked at several different aspects of the association between
parasite infection and asthma and allergic disease. A growing body of
epidemiological evidence, mainly from observational studies carried out in
areas of the world where parasite infection is endemic, has supported an
inverse relation between helminth infection and allergy, but no placebo-
controlled randomised controlled trials had been conducted, and meta-
analysis of observational studies was only available for asthma. In this thesis,
a systematic review and meta-analysis of observational studies has confirmed
that helminth infection appears to protect against atopic sensitisation, thus
supporting the previous review showing a protective association between
infection and asthma 13. The clinical trials in this thesis have shown that
intervention trials of experimental hookworm infection are feasible to pursue in
a clinical setting, that infection with ten larvae is generally well tolerated, but
the findings did not provide evidence that a single infection at this dose leads
to a significant improvement in asthma. The primary reason why it was
important to carry out these studies is that despite substantial investment and
research, there are still a (currently unquantified) proportion of patients who
appear to have refractory disease and remain symptomatic despite using
standard available treatments 312 so new therapeutic approaches are still
needed. Infection with parasites, or with therapeutically active products
derived from them, could prove to be a novel effective treatment for asthma. In
addition, the studies contribute data that further characterise the relation
between infection and allergy observed in countries where helminth infection is
endemic.
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6.1.1 Association between parasite infection and atopy
The meta-analysis confirmed that there is a clear inverse association, in
observational studies, between helminth infection and atopy measured using
skin sensitisation. This relation appears to vary only little according to species,
with a similar size of effect for the geohelminths hookworm, A. lumbricoides
and T. trichiura. S. mansoni may have had a greater effect but there were too
few studies to pool the results and the neither of the studies included in the
meta-analysis were judged to be of high methodological quality. As in asthma,
the association seems to be weakest for infection with A. lumbricoides. Whilst
this meta-analysis was performed after the clinical trials, it provides more
robust evidence using pooled analyses that an association between these
infections and allergy does exist and that the clinical trials were justified.
Despite the evidence from the observational studies, in the three intervention
trials, there were no consistent changes in allergen skin sensitisation tests
although this was not their primary aim and none were appropriately powered
to show an effect if one did exist. No previous intervention studies of
intentional infection with hookworm have reported the effects on atopy.
However, given the results of eradication studies where anti-helminth
treatment appeared to increase atopy, these results are perhaps surprising.
There are several possible explanations for why no change was observed in
atopy in the clinical trials which are explored in more detail in section 3.5.4. In
brief, one explanation is that the studies were not adequately powered to
explore this as an outcome. Other possible explanations relating to the study
design include that the duration of the study was too short and too few larvae
were given. Importantly, the age at which study participants were infected
when compared with naturally acquired infection may be relevant. Regardless,
research should continue in order to ascertain the association between atopy
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and allergic disease, with particular attention to any variations according to
different economic settings 313.
6.1.2 Effects of hookworm infection on asthma and allergic
rhinoconjunctivitis
The first clinical study reported in this thesis established that a dose of ten
hookworm larvae was sufficient to produce an intensity of infection generating
at least 50 eggs/g faeces, the level found to be protective in an observational
study in Ethiopia 58. However, using a single dose of ten larvae was not
enough to induce an effect on immune modulation. Nor did this dose
demonstrate a role in the intervention studies for infection in treatment of
allergic rhinoconjunctivitis or asthma, although in the case of allergic
rhinoconjunctivitis the study was not designed or powered to do so. The only
other study to intentionally infect people with allergic rhinoconjunctivitis with
parasites, in this case using 2500 T. suis ova, also found no effect on
symptoms 278. There are several possible explanations for why no effect was
seen on asthma which are explored more fully in Chapter 4. In brief, one
explanation is that there is a true effect but it was not seen due to problems
with the design of the intervention study, the most important of which are likely
to be that the study was not adequately powered to show an effect if one did
exist and that the dosing regimen was wrong. This is likely to be particularly
important given the lack of immune modulation observed in the study in
allergic rhinoconjunctivitis. It may also be that there is a true effect but this is
only on the development of asthma and not on improving control of pre-
existing asthma and the timing of infection needs to be earlier. Finally, it may
be that the hypothesis is wrong and the observed relation between parasites
and allergic disease is due to other unmeasured factors or reverse causation.
The results of the intervention studies neither prove nor refute the hypothesis
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that hookworm infection may confer protection against asthma, and further
studies - probably using different dosing regimens - are required in order to
provide a more conclusive answer.
Despite the apparent lack of effect of infection on allergic disease, the clinical
trials presented here are unique, and contribute important data to an area
where there are still many unanswered questions. They are the first to report
the effects of intentional hookworm infection in the setting of a randomised
controlled clinical trial. More specifically, they are the first to report the egg
counts and side effects of different dosing regimens and the first to measure
the effects of infection on allergic disease. Whilst the studies were limited in
size, the results are useful in informing future trials in terms of dosing
regimens, length of study and safety data including the occurrence and range
of adverse effects infection notably the effects on bronchial responsiveness. In
addition, whilst there was no significant effect of infection on asthma, the
sample size was small and the effect on the primary outcome, bronchial hyper-
responsiveness, was in the right direction suggesting that further larger trials
are worth pursuing.
6.1.3 Adverse effects of hookworm infection
The three clinical trials reported the adverse effects of hookworm infection
which were broadly consistent with the findings of other published studies and
which appeared to be related to the dose of larvae administered. The most
common of these was a localised pruritic erythematous rash in the first five
days following infection, with a recurrence in many participants during the
second week. Gastrointestinal symptoms (particularly nausea, abdominal pain
and indigestion) were also reported in several cases and, as they coincided
with a rise in eosinophil counts, probably related to an eosinophilic
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gastroenteritis 259. Whilst the severity of the gastrointestinal symptoms in a few
of the participants led to them withdrawing from the studies, the average
scores were not high and the range of experiences was varied, with a number
of people reporting scores of zero. These are the most comprehensive studies
to date to describe the adverse effects of intentional hookworm infection in a
clinical trial setting and can be used in informing future trials of infection, not
just in allergic disease but also in other conditions.
6.2 Recommendations for further areas for research
Several different research strategies could be employed in order to advance
our understanding of the association between parasite infection and allergic
disease, and which of these are used will be determined by the primary aim of
the recommended intervention study, as detailed below.
6.2.1 Future intervention studies
Research should continue to focus on the use of parasites as novel
therapeutic agents in the treatment of asthma and allergic disease. As the
studies presented here have established that infection is safe, further
intervention studies can now proceed, but these should be designed to mimic
natural infection more closely and, in doing so, to aim to induce more of an
effect on the immune system. This is likely to involve administration of either
repeated low-dose infection or a higher single dose of infection, though the
former may be more appropriate as this would be likely to reduce the
undesirable adverse effects experienced with the higher doses and to imitate
naturally acquired infection more closely. One to five larvae could be
administered on a weekly, fortnightly or monthly basis for between three and
six months (depending on the tolerance of any adverse effects). In such a
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study, allergic symptoms should be monitored for a longer period of time (for
example, three years) than in the studies presented in this thesis. This could
be important as the immune modulatory effect of chronic infection may differ
from that of acute infection 314 and thus a beneficial effect, if one exists, may
only be seen after a longer period of time than has been measured previously.
In addition, allowing a longer period between infection with hookworm and
assessment of allergic symptoms is more likely to represent the circumstances
observed in cross-sectional studies, where acquisition of infection may have
occurred several years before the study took place.
The choice of population in which these further intervention studies should be
carried out needs careful consideration. It would seem sensible to conduct
such studies in countries where helminth infection is uncommon and
participants are parasite-naïve, and then to focus on different populations
according to disease severity. The caveat to this approach is the possibility
that the effects of parasite infection on the immune system - specifically, with
regard to allergy - may be different in helminth-endemic populations compared
with populations where infection is uncommon. Logistically, however, it would
be challenging to undertake an intervention study of experimental hookworm
infection in a country where parasite infection is endemic, because of the
likelihood of naturally acquired infection. One option therefore would be to
undertake a large study in a country such as the UK, of people with mild to
moderate asthma, using a different dosing regime from the intervention
studies reported in this thesis (which have already shown no effect of a single
dose of ten larvae in such a population). Alternatively, a study could be
performed in a cohort of people with poorly controlled or severe asthma in
whom conventional treatment is often ineffective. There are two main reasons
why current available treatments fail in up to 10% of asthmatics. The first
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reason is that in a small proportion of asthmatics, the disease is driven by non-
eosinophilic inflammation which does not respond to usual asthma treatments.
Asthma research is increasingly using phenotyping of disease to characterise
the underlying pathology occurring at a cellular level in patients with difficult
disease. A study of patients with difficult disease would require detailed
assessment of asthma phenotype (using techniques such as sputum sample
cell typing); and the heterogeneous nature of their disease would require a
very large sample size to observe a treatment effect, if one existed. The
second reason for failure of current treatment lies in psychosocial reasons
such as non-compliance and problems associated with social deprivation. An
intervention study in this particular group of patients might, however, prove
particularly difficult at a logistical level. So whilst a trial of the efficacy of
intentional hookworm infection in people with severe asthma is possible, it is
likely to be challenging and may not be worthwhile.
If a trial was to be carried out to determine the efficacy of hookworm in
treatment of allergic rhinoconjunctivitis, the design should include a number of
measures, in line with guidelines, that were not carried out in the safety trial in
people with allergic rhinoconjunctivitis reported in this thesis 315. Specifically,
the outcome measures should include a composite daily symptom score
based on nasal symptoms, possibly ocular symptoms, and use of anti-allergen
medication. More objective measures of disease activity such as nasal nitric
oxide or rhinometry could also be used 316. In addition, when designing a trial
to evaluate the efficacy of hookworm as an immune modulatory agent, it
should be considered comparable to a trial of immunotherapy. For example,
trials of immunotherapy usually start several months prior to the onset of
symptoms and last a minimum of six to 12 months. In contrast, trials of
pharmacological agents usually enrol participants when allergen exposure is
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sufficient to cause significant symptoms and are relatively short as was the
case in the study presented here 315.
In addition to using hookworm infection in people with established disease,
studies should also be designed to investigate the effects of hookworm
infection on development of allergic disease. Such a study should be carried
out in a population of young children whose immune systems are still
developing in order to maximise the possible immunomodulatory effect of the
infection. A significant proportion of young children will go on to develop
allergic disease (as described in chapter 1) and therefore conducting a study
in a population such as this will provide the greatest chance of seeing an
effect, if one does exist, using a reasonable sample size. In contrast, a
prevention study carried out in adults who do not have allergic disease is not
likely to be feasible, first because their immune system is already mature and
second, because relatively few of these individuals will go on to develop
asthma, and so the sample size would need to be extremely large for an effect
to be seen. Clearly the ethical considerations of giving intentional hookworm
infection to children under the age of five are huge and without stronger
evidence of advantageous effect, the potential risks of infection are likely to
outweigh the benefits at this point in time.
6.2.2 Studies of the immunomodulatory effects of infection
Future intervention studies should seek to identify the likely key helminth
molecules involved in immune modulation, which appears to involve T-
regulatory cells. This may be particularly useful in increasing our
understanding of how the immune system can be manipulated so as to
develop future new treatments, or preventative strategies for allergic disease.
The information from this could be used in two ways: either helminth products
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could be manufactured and administered in controlled conditions to modify the
immune system, which is likely to be more acceptable than infecting people
with larvae; or novel pharmaceutical products mimicking these effects could be
designed. In doing this research, it would also be important to elucidate
whether the immune modulation that occurs varies between different helminth
infections and/or between different populations. Any findings to that effect may
explain some of the variation in observational study results.
6.2.3 Future observational studies
Epidemiological studies should continue with the aim of establishing the
relative importance of parasite infection in the aetiology of allergic disease
and, in turn, the magnitude of its role in relation to changes observed in the
prevalence of allergic disease worldwide. Further observational studies to
address this would be of most use if they were large birth cohort studies,
carried out in areas where both parasite infection and allergic disease are
common. They should be designed to include collection of data on both
symptoms of allergic disease (using well validated questionnaires and
objective measures of disease) and immune function. Such longitudinal
studies would also help to address the issue of reverse causation, that is, the
question of whether infection reduces the chance of developing allergy or
whether allergic individuals are protected against parasite infection. A
longitudinal study, designed to investigate the aetiology of allergic disease
(and in particular the role of geohelminth infection and acetaminophen use), is
currently in progress in Ethiopia 100. In 2005/6 a population-based cohort was
established in the rural town of Butajira comprising 1065 pregnant women, to
whom 1006 live singleton babies were born. At ages one and three, data were
collected using questionnaires on wheeze, eczema, childs use of
acetaminophen and various potential confounders, along with a stool sample
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for geohelminth analysis. Data on those children without wheeze (n=756) or
eczema (n=780) at age one were analysed to determine the independent
effects of geohelminth infection and acetaminophen use in the first year of life
on the incidence of wheeze and eczema by age three. The results showed
that the incidence of wheeze and eczema between the ages of one and three
was reported in 7.7% (58/756) and 7.3% (57/780) of children respectively, but
the prevalence of geohelminth infection was insufficient (<4%) to compute
estimates of effect on allergic symptoms 100. As the cohort matures, and the
prevalence of geohelminth infection increases, this study should provide
additional useful data on the role of infection on allergic disease.
6.2.4 Studies of the effects of parasite eradication programmes
Studies should also be performed to try to predict the effect of parasite
eradication campaigns and hookworm vaccination programmes on prevalence
of allergic disease. To date, no eradication studies have had a convincing
effect on asthma symptoms, allergic rhinoconjunctivitis or eczema.
Conversely, some studies have identified a 243;245-7 increase in atopy after anti-
helminth therapy, but the clinical relevance of this may be less important.
Current evidence thus suggests a minimal impact of such parasite eradication
programmes on prevalence of allergic disease. However, hookworm
eradication programmes are now in place in some areas of the world and
provide the ideal setting in which to conduct studies to ascertain whether the
prevalence of allergy and atopy has increased in these areas and whether
these effects have been sustained. Such studies should be of high priority for
public health departments: if a potential side effect of eradication programmes
is a surge in allergy prevalence, then such programmes may need to be
reconsidered.
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6.3 Intervention studies of parasite infection in other
immune-mediated disease
The intervention studies presented in this thesis were the first intervention
studies of hookworm infection in people with allergic disease. The results
provide safety data and information about adverse effects of infection and can
be used to inform trials of other diseases. In addition to the interest in the use
of parasite infection in treatment of allergic diseases, parallel studies are in
progress to investigate the use of helminths to treat other immune-mediated
diseases and a small number of trials have been carried out in inflammatory
bowel disease with a number more in progress. At the time of submission of
this thesis, three other intervention studies of parasite infection have been
published. The first two are trials of the effects of Trichuris suis (pig whipworm)
on inflammatory bowel disease 317;318. In the first, a feasibility study, 29
patients with active Crohns disease were given 2500 T. suis ova orally on
eight occasions over 24 weeks. Multiple doses were required to ensure
ongoing infection, as humans are not a fully permissive host. Over two-thirds
of patients reported an improvement in symptoms of Crohns disease at the
end of the study period, but results should be interpreted with caution as there
was no control group for comparison 317. In the second study, 54 patients with
active ulcerative colitis were randomised, double-blind, to receive 2500 T. suis
ova or placebo every two weeks for 12 weeks. At the end of the study, 43% of
those with ova reported clinical improvement, compared with 17% of those
with placebo (p=0.04). Perhaps surprisingly, both studies stated that there
were no adverse or side effects of infection. The third study, published recently
by a Danish group, is a randomised double-blind placebo controlled trial of the
effects of T. suis on allergic rhinitis 278 and is described in more detail in
section 3.5.3.
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Reports from observational studies of the effect of parasites on other
autoimmune diseases such multiple sclerosis are also emerging in the
literature 319. Following on from this, further trials by other research groups in
rheumatoid arthritis 320, multiple sclerosis and Coeliac disease have been
proposed, or are registered on the International Clinical Trials Register, but
results are not yet available.
6.4 Potential hazards of using infection to treat allergy
There are, of course, potential problems and obstacles associated with the
use of helminth infections in the treatment of asthma and other allergic
disease. The first relates to the psychological and social acceptability of
infecting individuals with whole parasites: the intervention studies reported
here suggest this may not be a major issue, although the volunteers for these
studies may not be representative of the general population. One obvious way
of overcoming this objection in the future is the possibility of using specific
parasite products identified to be important, rather than whole organisms. The
second problem is that, as with all forms of immunosuppression, there is in
theory an increased risk of opportunistic infections which can cause significant
morbidity. Third, whilst we are aware of the effects of chronic infection
acquired naturally, there are no long-term data of side effects of intentional
infection which, depending on doses and frequency of infection used, may
differ. As a result of immune modulation, there may be negative effects on
other parts of the immune system, such as a reduction in TH1 responses (with
a resultant increase in autoimmune disease) or reduced response to vaccines,
the impact of which should not be underestimated. Fourth, there is a
theoretical risk of anaphylaxis and an increase in allergic reactions, if given in
high doses to already atopic individuals. Fifth, experimental hookworm
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infection causes gastrointestinal effects as demonstrated in the intervention
studies. The long-term impact on development of bowel pathology from
chronic infection is again unknown: whilst there is no evidence of an increase
in bowel disease from countries where infection is endemic, there are large
differences in population demographics and environmental exposures, which
will be important contributory factors. There is also the fact that life expectancy
is often shorter in these countries, and so the risks of long-term infections -
particularly in the eighth and ninth decades of life - may not be realised.
Irrespective of the evidence of its efficacy, it is important to exercise caution
before embarking on the use of helminths (or their products) as a treatment
modality in allergic disease, bearing in mind the importance in medical ethics
of the principle of non-maleficence. Focusing on the use of antigen-specific
products as immune regulators may enable avoidance of potentially harmful
adverse effects.
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6.5 Conclusions
The findings reported in this thesis have direct relevance to the improvement
of human health. Whilst further elucidation is required of the environmental
factors which are responsible for the rapid change in prevalence of asthma
and allergic disease that occurs as subsistence populations become more
urbanised and affluent, parasite infection is likely to provide a partial
explanation of the observations. In addition to the existence of an inverse
association between hookworm infection and asthma, there is now
confirmation of a similar relation between parasite infection and atopy.
Hookworm infection as a treatment modality has now been established as
feasible, acceptable and well tolerated. The lack of positive effect on asthma in
these studies could be attributable to a number of factors already discussed,
but further larger studies of asthma and other allergic disease, incorporating
revised dosing regimens, are required. At this stage, it is too early to exclude
the possibility that cultured hookworm or hookworm products may have a role
to play in the management of asthma, allergic rhinoconjunctivitis and other
allergic diseases. The adverse effects of chronic hookworm infection are,
however, unquestionable. Moreover, whilst the results of eradication studies
do not, to date, suggest that an increase in allergic disease is inevitable;
clinicians must be mindful of the potential impact of an international hookworm
eradication programme on allergic disease prevalence wherever such a
programme is introduced.
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Patient Information Sheet
Placebo-controlled study of hookworm infection in non-asthmatic
people with allergies
Investigators: Dr J Feary, Professor D Pritchard & Professor J Britton
You are invited to take part in a research study. Before you decide whether to take part, it
is important for you to understand why the research is being done and what it will
involve. Please take time to read the following information carefully and discuss it with a
friend or relatives if you wish. Ask us if there is anything that is not clear or if you would
like more information. Take time to decide whether or not you wish to take part. You can
keep this information sheet. If you take part in the study, you will be given a copy of the
signed consent form to keep.
Thank you for taking time to read this.
Why are you doing this study?
Asthma and hayfever have become increasingly common in more affluent societies over
the last few years but the reason for this increase is uncertain. One possible explanation is
that as we live in an increasingly clean environment, and are therefore exposed to fewer
infections, our immune systems start to respond to normally harmless things like pollen.
It is this inappropriate immune response that causes hayfever.
One infection that is now rare in more affluent societies is hookworm. This is a small
worm which has evolved alongside humans and lives in the bowel. Millions of people in
the developing world have hookworm and studies in Ethiopia suggest that infection with
hookworm is associated with a lower risk of asthma and allergic disease. This raises the
intriguing possibility that deliberate hookworm infection may be of benefit in the
treatment of asthma and allergy. To investigate this properly we need to do a clinical
study in a similar way to how a new drug would be tested. This study will look at the
possible benefits and side-effects of hookworm infection in people with hayfever.
We recently completed a pilot study of hookworm infection in people without hayfever or
asthma. Ten people (including the investigators for this study) received 10, 25, 50 or 100
hookworm larvae to work out which was the lowest dose that stimulated an immune
response but caused a minimum of side effects. Both the 10 and 25 doses were well
tolerated but we have chosen 10 larvae because this dose stimulated a good immune
response and we want to use the lowest possible dose.
Why have I been chosen?
You have allergies but not asthma and have expressed an interest in assisting with
research in Nottingham.
Do I have to take part?
No, you don't. It is up to you whether or not to take part. If you do decide to take part, you
will be given a copy of this information sheet to keep and asked to sign a consent form.
Also, if you decide to take part, you will be free to withdraw at any time, without giving a
reason if you don't want to. This will not affect the standard of any medical care you may
be receiving.
University of Nottingham Division of Respiratory Medicine
Study 2
Version 4
April 2006
What will happen to me if I take part?
The study will involve visits to the Division of Respiratory Medicine at City Hospital
over 16 weeks. These will be weekly at first and then fortnightly towards the end of the
study. The first visit will take around 2 hours, however each subsequent visit last about an
hour. We realise this is a considerable time commitment but we would like to keep a
close eye on you.
At the first visit, we will take about 20ml of blood to make sure you are not anaemic and
have no evidence of having had hookworm infection in the past. Female volunteers will
also be asked to give a blood sample for a pregnancy test. We will also do skin tests for
allergy to cat, dust and grass extract: this involves a small scratch on the skin and a drop
of each extract to see if this causes an itchy reaction. If you do have some itchiness from
this test it should settle in about 20 minutes. We will then measure your sensitivity to an
inhaled aerosol called adenosine monophosphate. This involves inhaling adenosine
monophosphate given by us through an inhaler device and then doing a simple lung
function test. We will then repeat the inhalation at stronger doses until the lung function
test shows that you are responding. This is the end of the test and you can take a reliever
inhaler (salbutamol, Ventolin) if you wish. At all times during the tests, you can stop
whenever you wish.
At the second visit, we will put a gauze pad on your arm under a plaster. This will either
contain a placebo solution containing histamine or a solution containing 10 hookworm
larvae. In both cases, there may be some skin itching and redness where the solution is
applied. The larvae then find their way through the skin, via the lungs to the intestine,
where they stay until eradicated. You should keep the plaster on for 24 hours after which
time you can remove it and put it in a special container which we will provide.
At each of the visits over the next 12 weeks, we will ask you to complete a questionnaire
about your allergic symptoms, we will take about 30ml of blood to measure your blood
count, inflammatory and allergic responses and repeat the lung function tests with
adenosine monophosphate. We will also need a stool sample to look for hookworm eggs.
Between visits we will ask you to complete a diary of your allergic symptoms, any side
effects you experience and a record of your peak flow (we will show you how to do this).
After 12 weeks, or if you choose to withdraw from the study, we will treat the hookworm
infection with mebendazole tablets (100mg twice each day for three days). These are very
effective at treating hookworm infection but are only effective once hookworm is in the
bowel (about 4 weeks from the start). If you decide to withdraw from the study before
this point we will give you tablets with clear instructions about when to start them to
ensure they work. Female volunteers will have another blood test to ensure they are not
pregnant before taking the tablets.
We would like to see you again two and four weeks after treatment to make sure you are
well and the infection has cleared. This will involve a final blood test and stool sample,
skin prick tests and lung function tests with adenosine monophosphate. All information
gained during the study will be confidential. We will reimburse reasonable travel
expenses incurred during the study.
What is the drug or procedure being tested?
We are assessing the effects of hookworm infection in people with allergies.
University of Nottingham Division of Respiratory Medicine
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Version 4
April 2006
What are the possible disadvantages and risks of taking part?
There is likely to be some itching and redness of the skin where we give the histamine
placebo or hookworm larvae. This should settle within a week but may return 7-14 days
later before settling completely. The larvae pass through the lungs on their way to the
bowel and so in theory this could cause breathlessness, cough or wheezing. When the
hookworm arrives in the bowel, some ‘stomach upset’ may occur but we expect this to be
mild if it occurs. The side effects which are possible are abdominal cramps, nausea,
diarrhoea and flatulence. If you experience these symptoms and find them unacceptable,
you are free to finish the study at any point. Hookworm infection is very common in
many parts of the world and other than in people who are badly nourished, or in very
young children, in whom it can cause anaemia or weight loss, no other major common
adverse effects are known to occur. One extremely rare complication of some long-term
worm infection is called endomyocardial fibrosis. Here, inflammation of the heart muscle
occurs and can cause scarring which can, in turn, lead to heart failure. However this
condition usually occurs with worms which are very different from the one that we are
using and only in people who have very long term infections. We are eradicating the
worm infection after 3 months and therefore we do not expect it to be a problem in this
study.
If there is a chance you may be pregnant (or become pregnant in the next four months),
you should not take part in the study. If you are a blood donor, you should not donate
during the study. Before donating again after the study you should inform the blood
transfusion service that you have taken part in this study so they can give you up to date
advice about when you can start to donate again. Hookworm infection is not contagious
in developed countries with normal standards of hygiene and sanitation. Therefore, if you
wash your hands carefully after going to the toilet, you will not be contagious to others.
Mebendazole can cause abdominal pain, diarrhoea or rashes and should not be taken in
pregnancy. Its effects can also be increased by an anti-acid drug, cimetidine: we will ask
you to change this if you are on it.
We suggest that you inform your private health insurance company (if you have one) that
you are taking part in this study.
What are the possible benefits of taking part?
The information we get from the studies may help to improve treatment of allergies and
asthma in the future.
What will happen to the results of the research study?
We will send you a summary of the final results.
Who is funding the research?
The Wellcome Trust are funding the research
For more information contact:
Dr Johanna Feary
Clinical Research Fellow
University of Nottingham
Clinical Sciences Building
City Hospital
Nottingham NG5 1PB
Telephone 0115 8231936
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Version 2
March 2005
CONSENT FORM
Feasibility studies of hookworm infection in the treatment of allergies and
asthma
Division of Respiratory Medicine, City Hospital, Nottingham
Investigators: Dr J Feary, Professor D Pritchard & Professor J Britton
The patient should complete the whole of this sheet himself/herself.
Please cross out as necessary
Have you read & understood the patient information sheet YES/NO
Have you had opportunity to ask questions & discuss the study YES/NO
Have all the questions been answered satisfactorily YES/NO
Have you received enough information about the study YES/NO
Who have you spoken to Dr ………………………..
Do you understand that you are free to withdraw from the study:
at any time YES/NO
without having to give a reason YES/NO
without affecting your future medical care YES/NO
Do you agree to take part in the study YES/NO
Signature (Patient) Date
Name (In block capitals)
I have explained the study to the above patient and he/she has indicated his/her
willingness to take part.
Signature (Doctor) Date
Name (In block capitals)
Appendix D:
Dilution Schemes for the AMP dosing schedules
Volume of AMP solution Add 0.9% saline Obtain final dilution
(mg/ml)
2 mls of 400 mg/ml 2 ml 200 mg/ml
1 mls of 200 mg/ml 3 ml 50 mg/ml
1 ml of 50 mg/ml 3 ml 12.5 mg/ml
1ml of 12.5 mg/ml 3 ml 3.125 mg/ml
Appendix E:
Protocol for AMP Challenge with Mefar dosimeter
AMP bronchial challenge v1
Placebo-controlled study of hookworm infection in asthma
October 2006
AMP CHALLENGE WITH MEFAR
Initals/ID …………………….. Visit ……………………………
Date …………………….............. Time ……….……………………
Last caffeine …………………………
Last cigarette ………………………… No. per day ………………
Last bronchodilator ………………………… Last ICS/LABA ………….
Last antihistamine .……………..................
FEV1 …………. Predicted ………… % Predicted …………..
FVC …………. Predicted ………… % Predicted …………..
AMP CHALLENGE *
DOSE DOSE IN PUFFS AMP IN ȝmol FEV1 % fall in FEV1
0 3 x saline
1 1 x 3.12 mg/ml 0.115
2 1 x 3.12 mg/ml 0.230
3 2 x 3.12 mg/ml 0.460
4 4 x 3.12 mg/ml 0.92
5 2 x 12.5 mg/ml 1.84
6 4 x 12.5 mg/ml 3.69
7 2 x 50 mg/ml 7.37
8 4 x 50 mg/ml 14.7
9 2 x 200 mg/ml 29.5
10 4 x 200 mg/ml 59.0
11 4 x 400 mg/ml 118.0
12 8 x 400 mg/ml 236.0
13 16 x 400 mg/ml 472.0
14 32 x 400 mg/ml 944.0
FEV1 for saline – 20% = ………………….
PD20AMP = ………………….
*Do NOT perform if baseline FEV1 < 40% predicted or < 1.0 litres or if subject is pregnant or
breastfeeding
Appendix F:
Juniper Allergic Rhinoconjunctivitis Quality of Life Questionnaire





Appendix G:
Daily diary for Allergic Rhinoconjunctivitis study
5  Daily diary Hookworm and rhinitis 2 
6 526 University of Nottingham Johanna Feary 0115 823 1946 Out of hours 0115 823 1947 (1) 0 1 
 
Daily Diary         Next Appointment______________ 
Initials     ID       Week  
Record the best of THREE peak flows measurements for Morning and Evening 
 Date Day of the 
week 
Morning peak flow Evening peak flow 
Day 1   
aaa aaa 
Day 2   
aaa aaa 
Day 3   
aaa aaa 
Day 4   
aaa aaa 
Day 5   
aaa aaa 
Day 6   
aaa aaa 
Day 7   
aaa aaa 
Day 8   
aaa aaa 
Day 9   
aaa aaa 
 
 
 
5  Daily diary Hookworm and rhinitis 2 
6 526 University of Nottingham Johanna Feary 0115 823 1946 Out of hours 0115 823 1947 (2) 0 2 
Symptoms (graded from 1(very mild) to 10 (very severe) 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 
Date          
Day of the week          
Antihistamines 
(tick if used) 
! ! ! ! ! ! ! ! ! 
Nasal steroids 
(tick if used) 
! ! ! ! ! ! ! ! ! 
Skin itching 
aa aa aa aa aa aa aa aa aa
Skin redness 
aa aa aa aa aa aa aa aa aa
Nausea or sickness 
aa aa aa aa aa aa aa aa aa
Diarrhoea 
aa aa aa aa aa aa aa aa aa
Abdominal pain 
aa aa aa aa aa aa aa aa aa
Flatulence or wind 
aa aa aa aa aa aa aa aa aa
Indigestion 
aa aa aa aa aa aa aa aa aa
Loss of appetite 
aa aa aa aa aa aa aa aa aa
Wheeze 
aa aa aa aa aa aa aa aa aa
Cough 
aa aa aa aa aa aa aa aa aa
Breathlessness 
aa aa aa aa aa aa aa aa aa
Tiredness 
aa aa aa aa aa aa aa aa aa
5  Daily diary Hookworm and rhinitis 2 
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USEFUL INFORMATION
For 12 hours prior to the study visit:
x No strenuous exercise
x No caffeine containing food and drink (tea/coffee/cola/chocolate)
For 24 hours prior to the study visit:
x No antihistamines
x No nasal sprays
SYMPTOM SCALE
Use this to help you when you are filling in the daily diary. You need to grade
each of your symptoms on a scale of 1 to 10.
For example, indigestion which is mild would score 2 out of 10.
None Mild Moderate Severe
Ļ                    
0 1 2 3 4 5 6 7 8 9 10
CONTACT TELEPHONE NUMBERS
x Dr Johanna Feary 0115 8231936
x 24 hour contact number 0115 8231937
(Leave a message and telephone number including area code)
PLEASE WRITE ANY OTHER SYMPTOMS YOU MIGHT EXPERIENCE
HERE WITH THE DATE AND DAY AND YOUR SYMPTOM SCORE
(OUT OF 10) NEXT TO THEM
Appendix H:
Extended hookworm infection information sheet
Placebo-controlled study of hookworm infection in people with asthma
Extended Hookworm Infection
May 2007
Version 1
Extended Hookworm Infection
For subjects in hookworm treatment group who decide not to take mebendazole
As you are now aware, you received 10 hookworm larvae at the beginning of the study looking at
the effects of hookworm infection on asthma. At this point, and in accordance with the study
protocol, now that the experimental period is over, we advise you to take a course of mebendazole
tablets to eradicate the infection. However, you have expressed a desire not to take these tablets
so that you keep the hookworm infection.
We would not expect you to have any serious adverse effects with a dose of 10 hookworm larvae
and they will die naturally within a period of approximately 5 years. However there is a chance of
developing complications due to long-term hookworm infection and some other issues which you
should be aware of and which are listed below. We would therefore ask you to read this document
carefully and sign where indicated at the bottom of the page. Please ask if you are uncertain of
anything.
Possible adverse effects of long-term infection are:
x Anaemia (low blood haemoglobin) due to the hookworm removing small amounts of blood
from your gut – this may cause you to feel tired or breathless and sometimes needs
treatment with iron tablets. For someone who is otherwise well nourished however, and has
no other cause of anaemia, anaemia is unlikely to occur.
x Endomyocardial fibrosis, which is an extremely rare complication of some long-term worm
infections. Inflammation of the heart muscle occurs in this condition, which can cause
scarring and in turn lead to heart failure. However this condition usually occurs with worms
of a completely different species to the one that we are using, and generally, only in longer
term infections. This complication is therefore extremely unlikely.
Further advice:
x If you are a blood donor, you should inform the blood transfusion service that you have
hookworm infection, so they can give you up-to-date advice about when you can start to
donate again.
x Females should be aware that mebendazole tablets should not be taken during pregnancy
or whilst breastfeeding.
Placebo-controlled study of hookworm infection in people with asthma
Extended Hookworm Infection
May 2007
Version 1
Please read the following and initial on the dotted line to show you have read and understand each
statement:
o I am aware that I have been infected with hookworm as part of the asthma study……….
o I am aware of the long term risks of having hookworm infection outlined above…………..
o I have been provided with a course of mebendazole tablets to eradicate the
hookworm infection but at this point in time, I have decided not to take them……………...
Signed ……………………….. Witness signature………………………
Name/ID……………………… Witness name ………………………….
Date…………………………… Date………………………………………
Appendix I:
New hookworm infection for those receiving placebo in trial
Hookworm Infection
As you are aware, you received placebo at the beginning of the study looking at the effects of
hookworm infection on hay fever. The results of our study showed no strong evidence that giving
people hookworm had a beneficial effect on their hay fever although a few individuals did report an
improvement. The study also showed that there were no negative effects on breathing and so we
are in the process of performing a study looking at the effects of hookworm infection on asthma
symptoms. We will send you the full results of both these studies when they are published.
You have now expressed an interest in receiving a dose of 10 hookworm larvae to see if it
improves your hay fever symptoms. It is important that you are aware that this will be outside the
context of a study.
We would not expect you to have any serious adverse effects with a dose of 10 hookworm larvae
and they will die naturally within a period of approximately 5 years. However there are some
symptoms which can occur as a result of having hookworm infection and some other issues which
you should be aware of and which are listed below. We would therefore ask you to read this
document carefully and sign where indicated at the bottom of the page. Please ask if you are
uncertain of anything. If you wish to eradicate the hookworm at any time in the future, you will need
to take a 3 day course of a tablet called mebendazole which you can obtain on prescription from
your GP. Your GP will be sent a copy of this document.
Short term adverse effects of hookworm infection:
x There is likely to be an itchy red skin rash which lasts up to a week but can return 7-14
days later before settling completely.
x About half of people given hookworm larvae in our studies, will experience some ‘stomach
upset’ such as abdominal cramps, diarrhoea or indigestion. These vary from person to
person and can last from a couple of days to a few weeks.
Possible adverse effects of long-term hookworm infection:
x Anaemia (low blood haemoglobin) due to the hookworm removing small amounts of blood
from your gut – this may cause you to feel tired or breathless and sometimes needs
treatment with iron tablets. For someone who is otherwise well nourished however, and has
no other cause of anaemia, anaemia is unlikely to occur.
x Endomyocardial fibrosis, which is an extremely rare complication of some long-term worm
infections. Inflammation of the heart muscle occurs in this condition, which can cause
scarring and in turn lead to heart failure. However this condition usually occurs with worms
of a completely different species to the one that we are using, and generally, only in longer
term infections. This complication is therefore extremely unlikely.
Further advice:
x If you are a blood donor, you should inform the blood transfusion service that you have
hookworm infection, so they can give you up-to-date advice about when you can start to
donate again.
x Females should be aware that mebendazole tablets to eradicate the hookworm should not
be taken during pregnancy or whilst breastfeeding.
Please read the following and initial on the dotted line to show you have read and understand each
statement:
o I have requested infection with hookworm ……………………………………………….……….
o I am aware of the adverse effects of having hookworm infection outlined above…………..
Signed ……………………….. Witness signature………………………
Name…….…………………… Witness name ………………………….
Date…………………………… Date………………………………………
If you have any questions in the future regarding the hookworm, then you can contact the following
doctors/researchers who are based in the Division of Epidemiology and Public Health, Clinical
Sciences Building, City Hospital, Nottingham:
Dr Johanna Feary
0115 823 1936
johanna.feary@nottingham.ac.uk
Dr Andrea Venn
0115 8231721
andrea.venn@nottingham.ac.uk
Professor John Britton
0115 8231054
j.britton@virgin.net
Appendix J:
Patient Information Sheet (Asthma study)
University of Nottingham Division of Respiratory Medicine
Placebo-controlled study of hookworm infection in asthma
PIS Version 3
December 2006
Patient Information Sheet
Placebo-controlled study of hookworm infection in people with asthma
Investigators: Dr Johanna Feary, Dr Andrea Venn, Professor D Pritchard &
Professor J Britton
You are invited to take part in a research study. Before you decide whether to take
part, it is important for you to understand why the research is being done and what it
will involve. Please take time to read the following information carefully and discuss it
with a friend or relatives if you wish. Ask us if there is anything that is not clear or if
you would like more information. Take time to decide whether or not you wish to take
part. You can keep this information sheet. If you take part in the study, you will be
given a copy of the signed consent form to keep.
Thank you for taking time to read this.
Why are you doing this study?
Asthma and hay fever have become increasingly common in more affluent societies
over the last few years but the reason for this increase is uncertain. One possible
explanation is that we live in an increasingly clean environment, and are therefore
exposed to fewer infections; our immune systems start to respond to normally
harmless things like dust. It is this inappropriate immune response that may
contribute to asthma.
One infection that is now rare in more affluent societies is hookworm. This is a small
worm which has evolved alongside humans and lives in the bowel. Millions of people
in the developing world have hookworm and studies in Ethiopia suggest that infection
with hookworm is associated with a lower risk of asthma and allergic disease. This
raises the intriguing possibility that deliberate hookworm infection may be of benefit
in the treatment of asthma and allergy. To investigate this properly we need to do a
clinical study in a similar way to how new drugs are tested. This study will look at the
possible benefits and side-effects of hookworm infection in people with asthma.
We recently completed a pilot study of hookworm infection in people without hay
fever or asthma. Ten people (including the investigators for this study) received 10,
25, 50 or 100 hookworm larvae to work out which was the lowest dose that
stimulated an immune response but caused a minimum of side effects. Both the 10
and 25 doses were well tolerated but we have chosen 10 larvae because this dose
stimulated a good immune response and we want to use the lowest possible dose.
We have also completed a study looking at hookworm infection in people with hay
fever where people were given either 10 hookworm larvae or placebo and found the
hookworms were well tolerated.
Why have I been chosen?
You have asthma and have expressed an interest in assisting with research in
Nottingham.
Do I have to take part?
No, you don't. It is up to you whether or not to take part. If you do decide to take part,
you will be given a copy of this information sheet to keep and asked to sign a consent
form. Also, if you decide to take part, you will be free to withdraw at any time, without
giving a reason if you don't want to. This will not affect the standard of any medical
care you may be receiving.
University of Nottingham Division of Respiratory Medicine
Placebo-controlled study of hookworm infection in asthma
PIS Version 3
December 2006
What will happen to me if I take part?
The study will involve visits to the Division of Respiratory Medicine at Nottingham
City Hospital over 18 weeks. These will be on a fortnightly basis at first and then
every 4 weeks towards the end of the study. There will also be one week when we
will ask you to attend for an extra blood test. The first visit will take around 1½ hours,
however each subsequent visit lasts about 40 minutes. We realise this is a
considerable time commitment but we would like to keep a close eye on you.
At the first visit, we will take about 20ml of blood to make sure you are not anaemic
and have no evidence of having had hookworm infection in the past. Female
volunteers will be asked to give a urine sample for a pregnancy test. We will also do
skin tests for allergy to cat, dust and grass extracts: this involves a small scratch on
the skin and a drop of each extract to see if this causes an itchy reaction. If you do
have some itchiness from this test it should settle in about 20 minutes. We will repeat
this skin prick test at the end of the study to look for any change in your skin reaction.
We will then measure your sensitivity to an inhaled aerosol called adenosine
monophosphate. This involves inhaling adenosine monophosphate given by us
through an inhaler device and then doing a simple lung function test. We will then
repeat the inhalation at stronger doses until the lung function test shows that you are
responding. This is the end of the test and you can take a reliever inhaler
(salbutamol, Ventolin) if you wish. At all times during the tests, you can stop
whenever you wish.
At the second visit, we will put a gauze pad on your arm under a plaster. This will
either contain a placebo solution containing histamine or a solution containing 10
hookworm larvae. In both cases, there may be some skin itching and redness where
the solution is applied. The larvae then find their way through the skin, via the lungs
to the intestine, where they stay until eradicated. You should keep the plaster on for
24 hours after which time you can remove it and put it in a special container which
we will provide.
At each of the visits over the next 16 weeks, we will ask you to complete a
questionnaire about your asthma symptoms, we will take about 20ml of blood to
measure your blood count, inflammatory and allergic responses and repeat the lung
function tests with adenosine monophosphate. We will also need a stool sample to
look for hookworm eggs. Between visits we will ask you to complete a diary of your
asthma symptoms, any side effects you experience, a record of your peak flow (we
will show you how to do this) and a record of which inhalers you have used.
After 16 weeks, or if you choose to withdraw from the study, we will tell you whether
you have received the hookworm or placebo. If you are received hookworm, we will
then eradicate the infection with mebendazole tablets (100mg twice each day for
three days). These are very effective at treating hookworm infection but are only
effective once hookworm is in the bowel (about 4 weeks from the start). If you decide
to withdraw from the study before this point we will give you tablets with clear
instructions about when to start them to ensure they work. Female volunteers will
have another urine test to ensure they are not pregnant before taking the tablets.
We would like to see you again two and four weeks after treatment to perform a
blood test and to collect a stool sample. This is to make sure the infection has
cleared and that you are well. All information gained during the study will be
confidential. We will reimburse reasonable travel expenses incurred during the study.
What is the drug or procedure being tested?
We are assessing the effects of hookworm infection in people with asthma.
University of Nottingham Division of Respiratory Medicine
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What are the possible disadvantages and risks of taking part?
There is likely to be some itching and redness of the skin where we give the
histamine placebo or hookworm larvae. This should settle within a week but may
return 7-14 days later before settling completely.
Some worm infections, but not hookworm, have been shown to cause an increase in
airway responsiveness when the larvae pass through the lungs on their way to the
bowel. This may lead to symptoms of cough, wheeze or breathlessness. Therefore,
before giving hookworm to people with asthma, we wanted to check that there would
be no negative effect on airway responsiveness with hookworm and so we performed
a safety study where we gave 30 people with hay fever either hookworm or placebo
and measured their airway responsiveness. Our results confirmed that having
hookworm infection did not increase airway responsiveness when compared with the
placebo and so we would not expect participants to have any increase in asthma
symptoms during the study.
When the hookworm arrives in the bowel, some ‘stomach upset’ may occur. The side
effects which are possible are abdominal cramps, nausea, diarrhoea and flatulence.
If you experience these symptoms and find them unacceptable, you are free to finish
the study at any point and we can give you tablets to get rid of the infection.
Hookworm infection is very common in many parts of the world and other than in
people who are badly nourished, or in very young children, in whom it can cause
anaemia or weight loss; no other major common adverse effects are known to occur.
One extremely rare complication of some long-term worm infections is called
endomyocardial fibrosis. Here, inflammation of the heart muscle occurs and can
cause scarring which can, in turn, lead to heart failure. This condition usually occurs
with completely different species of worms from the one that we are using, and only
in people who have very long term infections. In view of this, and the fact that we are
eradicating the worm infection after 4 months, we do not expect it to be a problem in
this study.
If there is a chance you may be pregnant (or become pregnant in the next four
months), you should not take part in the study. If you are a blood donor, you should
not donate during the study. Before donating again after the study you should inform
the blood transfusion service that you have taken part in this study so they can give
you up to date advice about when you can start to donate again. Hookworm infection
is not contagious in developed countries with normal standards of hygiene and
sanitation. Therefore, if you wash your hands carefully after going to the toilet, you
will not be contagious to others.
Mebendazole can cause abdominal pain, diarrhoea or rashes and should not be
taken in pregnancy. Its effects can also be increased by an anti-acid drug, cimetidine:
we will ask you to change this if you are on it.
We suggest that you inform your private health insurance company (if you have one)
that you are taking part in this study.
What are the possible benefits of taking part?
The information we get from the studies may help to improve treatment of allergies
and asthma in the future.
What will happen to the results of the research study?
We will send you a summary of the final results.
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Who is funding the research?
The Wellcome Trust are funding the research
For more information contact:
Dr Johanna Feary
Clinical Research Fellow
Clinical Sciences Building
City Hospital
Nottingham NG5 1PB
Telephone: 0115 8231936
Email: johanna.feary@nottingham.ac.uk
Dr Andrea Venn
Telephone: 0115 8231721
Email: andrea.venn@nottingham.ac.uk
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Appendix L:
Daily diary for asthma study
5 Hookworm and Asthma 2
9 529 Johanna Feary 0115 823 1936, Out of hours phone 0115 823 1937 (1) 0 1
Initials aa ID Number aaa Week!!
Record the best of THREE peak flows measurements for Morning and Evening
Morning
Please complete this section when you
wake up in the morning
Evening
Please complete this section before you go
to bed
Date Day of
the
week
Morning
peak flow
Night time
symptoms
score
Number of puffs
of reliever inhaler
during the night
Evening
peak flow
Daytime
symptoms
score
Number of puffs
of reliever inhaler
during the day
aaa a aa aaa a aa
aaa a aa aaa a aa
aaa a aa aaa a aa
aaa a aa aaa a aa
aaa a aa aaa a aa
aaa a aa aaa a aa
aaa a aa aaa a aa
aaa a aa aaa a aa
aaa a aa aaa a aa
5 Hookworm and Asthma 2
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Other Symptoms (graded from 0(none) to 10 (very severe))
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9
Date
Day of the week
Skin itching at
plaster site aa aa aa aa aa aa aa aa aa
Skin redness at
plaster site aa aa aa aa aa aa aa aa aa
Nausea or sickness
aa aa aa aa aa aa aa aa aa
Diarrhoea
aa aa aa aa aa aa aa aa aa
Abdominal pain
aa aa aa aa aa aa aa aa aa
Flatulence or wind
aa aa aa aa aa aa aa aa aa
Indigestion
aa aa aa aa aa aa aa aa aa
Loss of appetite
aa aa aa aa aa aa aa aa aa
Wheeze
aa aa aa aa aa aa aa aa aa
Cough
aa aa aa aa aa aa aa aa aa
Breathlessness
aa aa aa aa aa aa aa aa aa
Tiredness
aa aa aa aa aa aa aa aa aa
5 Hookworm and Asthma 2
9 529 Johanna Feary 0115 823 1936, Out of hours phone 0115 823 1937 (3) 0 3
Night time symptoms
Assess each morning on waking (symptoms such as chest tightness, wheezing, breathlessness
and cough)
0=No symptoms during the night
1=Symptoms on waking but not causing you to wake early
2=Symptoms causing you to wake up once or to wake early
3=Symptoms causing you to wake twice or more (including waking early)
4=Symptoms causing you to be awake most of the night
5=Symptoms so severe that you did not sleep at all
Daytime symptoms
Assess each evening, just before going to bed (symptoms such as chest tightness, wheezing,
breathlessness and cough)
0=No symptoms during the day
1=Symptoms for one short period during the day
2=Symptoms for two or more short periods during the day
3=Symptoms for most of the day which did not interfere with usual activities
4=Symptoms for most of the day which did interfere with usual daytime activities
5=Symptoms so severe that you could not perform your usual daytime activities
Other Symptoms Scale
Use this to help you when you are filling in the daily diary. You need to grade each of your
symptoms on a scale of 0 to 10. e.g. indigestion which is mild would score 2 out of 10.
None Mild Moderate Severe
Ļ
0 1 2 3 4 5 6 7 8 9 10
Please write any other symptoms you might experience here with the date and day and
your symptom score (out of 10) next to them
5 Hookworm and Asthma 2
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USEFUL INFORMATION
For 4 hours prior to the study visit:
x No salbutamol (ventolin)
For 12 hours prior to the study visit:
x No strenuous exercise
x No caffeine containing food and drink (tea/coffee/cola/chocolate)
x No salmeterol (serevent), symbicort or seretide
For 24 hours prior to the study visit:
x No antihistamines
x No nasal sprays
CONTACT DETAILS
x Dr Johanna Feary 0115 8231936
x 24 hour contact number 0115 8231937
(Leave a message and telephone number including area code)
Appendix M:
Data extraction form and Newcastle-Ottawa quality assessment
scale
DATA EXTRACTION FORM Reviewer: Study ID:
Blank data extraction form (version 1.1).doc (version 1.1) 1 19/07/11
DESCRIPTION OF STUDY
Study design Cohort ฀ Case-control ฀ Cross-sectional ฀ RCT ฀
Timing of study Prospective ฀ Retrospective ฀ N/A ฀
Measurement of Parasite exposure Stool ฀ Perianal tape ฀ Urine ฀ IgE ฀
Specific parasites Ascaris ฀ Trichuris ฀ Hookworm ฀ Enterobius ฀
Schistosoma ฀ Giardia ฀ Other ฀ Combined ฀
Measurement of Atopy Skin prick test ฀ RAST ฀ Both ฀ Other ฀
Aeroallergen D. pteronyssinus ฀ House dust ฀ Grass ฀ Cockroach ฀
Cat fur ฀ Dust allergens ฀ Mite ฀ Other ฀ Combined ฀
Setting (e.g. country, number of
centres)
PARTICIPANTS
Inclusion criteria
Exclusion criteria
Number of participants studied
Number lost to follow up
Final number of participants
evaluated
METHODOLOGICAL QUALITY OF STUDIES
Newcastle –
Ottawa Scale
Case-control/cross-sectional
studies *
Cohort studies
*
1. Selection a) Case definition
b) Representativeness of cases
c) Selection of control
d) Definition of controls
a) Representativeness of exposed cohort
b) Selection of non exposed cohort
c) Ascertainment of exposure
d) Outcome occurred
2. Comparability a) Matching / adjustment for age
b) Matching / adjustment for other
factors
Factors=……………………………
a) Matching / adjustment for age
b) Matching / adjustment for other factors
Factors=…………………………………….
3. Ascertainment a) Ascertainment of exposure
b) Same method of ascertainment
for cases and controls
c) Non response rate
a) Ascertainment of outcome
b) Was follow up long enough for
outcomes to occur
c) Adequacy of follow up of cohort
Note: if retrospective cohort study, then no * to be given for Ascertainment b) and c)
DATA EXTRACTION FORM Reviewer: Study ID:
Blank data extraction form (version 1.1).doc (version 1.1) 2 19/07/11
RESULTS
Primary Outcomes Group= N= Group= N=
Comments:
